var title_f30_2_30752="Diagram of prepuce";
var content_f30_2_30752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Diagram of prepuce",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 381px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF9AgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK8y+IOr60vxP8G+HtM1u50mw1O3vZLl7eGB3JiRWQ5ljcAZznjoa4/Q/jZqsGlWFncaO+vazcXd/BBPbJKkd3FbHiRRFFKxZs4wq7QRklRQB77RXk0HxX1a88R22k2fgm83/2dDqV79qvFt5LONiQ4eN1ydpHbk+grHtvjlf3Glw3i+FLcefok2uRIdVP+qhdlkRj5HDfKSMZB4zjsAe40V45b/FO/muddu9K0PVtXEWn6ZewafE6MFFym44CQmQbRyxzJnsqiu/8AeJ4/F3h5dUi+yDMrwsttLLIqspwQfNiicN6goPxoA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAx/FXiTSvCul/2jrty1taeakIdYXlJdjhVCopYkn2pvhzxRpHiNrtNJuneezcJc280EkE0JIyN8ciq657ZHPasL4weFdR8YeE4tO0d7RLuK9t7ofapGRGEb7iNyqxBP0rifFnwr8S+Kj4l1W61Ow0zV9UW2gjs7SV5LcwQnPlyyNGC2/PP7vAx91gaAPbaK+frb4FT3U2hW+rpbHRLbULy7vbIakzhlmiVdsPlW0AjG5clAAMdDyRVofBS8Gvi+I0Zk/wCEpbVSWLs509k2tASU5J7oTtPc0Ae23F/DBf2lm6XJlud5jaO2keNdoyd8iqUT23EZ6DJq1XhGnfCHxBZ2vhyF7nTpIdKbWR5UV5LARFdx7IkjcREptJOTj5eoDdK6z4MeBdT8ER6rDfjSktJ/JW1jtEjaYKikEzTpBD5pJOQWQkc8nJoA9Lor58ufg94suvFtxrD3Ph23M0WpwSmzQW4nS4hdItyJbhiQzBmLySeo54L4PgnrtpYXVvpeo6bpr3fhSHR55LZ5F829SVWMjYUZRkUpu+9gn5aAPYNH8V2Oq+LfEHh23iuVvdEFubh5FURv5yF12EEk4A5yB+NdBXmPwm8A3/hHxL4m1G6tNGsLPU4bKOCy0yVnSIwxsrk5jT7xO7pnJOfU8ZN8INdsfEOsa5NdjUZGmvLqG5iuxHcOksZAheP7KzyDsE84L6Be4B7zqF3HYWUt1Os7xRDcywQPM5/3UQFmPsAaxfGPi6w8J6Fb6rqMN3JbTTw26rDGN4aRgFJVyuBzznkeleCeEPhD4j1PwSZPs2naDNd+HP7LNsxlSW5mMm4S3S+WNpUDAGHPv2rd8Q/BnX9R1O7nD6HdtNLp0kN7dTSCezS3UCSGMeU3yMcnIZc9x6AH0BRXgcPwa12LxZqOqTahFdvPdXU0N79tEMuyZCojlQWrO6jONvnBcchR3m0T4GLp2neCYXh0yaWwuftGtiaaWaO7/dGMBFdSCMYG0hRigD3G8uEtLSa4lWVo4kMjCKJpXIAydqKCzH2AJPYUWs6XVrDcRiRUlQSKJY2jcAjI3KwDKfUEAjuK+f8ARPglr+m6NpsC3Wjrepomp6XezRySfvzPv+zgny8siBlBz93HANaEfwk16PX/AAxfxHRt+m2un2txNeSi8QpBGofyYJLbMTFhwyTL0yQCeAD3WiiigDJ1zw1oXiBoW17RdM1NoQREb21jmKA4zt3A4zgdPSjUfDWhanYQWOpaLpl3ZW/+pt57SOSOPt8qkED8K1qKAMqy8PaLppaTT9G0+2f7P9mzBaohMI5EfAHy5/h6VnaDpHhbV9A0zUNO0PTBp93p4W3U2Ua4tZl3mLbjhW3ZKdDk5rpq5T4U/L8O9Ch7W9uLYc9PLJTj2+Xp2oAvXHg/wzcwtDc+HdGmiZIo2SSxiZSsY2xggr0UEhR2HTFaemafZaVZR2emWdtZWkfCQW8Sxov0VQAKtV5f461fW2+K2geHdO1+40bTrvTbm6mkght3bfGRtJMsb4A7gYoA9QorwbTvjXqNn4Ftb++srDVdTC3jskcs0T3UMDkeeiRwSqEIByzMiAg846X9T+L+s6it3a+E/DHnsNEh1dr2XUEiFqksJcMyFDuKnHAzn2FAHtVFeKeGfilrq+FvB8V/plnqWvaxp8195z332eJooYwzOxEOBIeR5aqQOpbFWofjQ1wmhXaeHpbLRtUhhcalqUk0UCyu5TylaOCRdwIPLlARzwOaAPYaK4nx/wCNrnwxrfh3SrHSotQudZa5WMy3ZgSMxR7+SI3Jz06ce9cNb/Hdn0aDUpvDYjiutFn1e2Vb/cWMLlHjf92NvIOGG7IxkDoAD2+ivI5vi/ePc6lbaX4TutTubXTrG/SO1nMjSC4CkgqsZbagbkqGJx92pdJ+LU2uaho2l6Fpem3uq6itxId2ozQ28Kwnayl3thIZM/weUMDnOKAPV6K8Dl+Jd94T8b+MIb6C81Sa51exsLKzE8skNuz225gu2N2C5BOEjLMf4a9b8B+ILrxN4dh1HUNGvdFui7xyWd2jqylTgMNyqxUjBBKj6UAdDRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN5E09pPDHI0TyIyrIpwVJGMj3FTUUAc/8AD7UZdW8C+H7+6YvdXFhC85JyfM2Dfk9/mzXQVyfwy/deHLiyOd1jqV9bYPZRcyFP/HCldZQAUUUUAFFFFABXKfDPKeHLq3Od1vqupRc/3ReTbf8Ax0rXV1yngH93P4ptv+eGtTcZ6b0jl6dv9Zn8c96AOrrH1zwxoGvyxSa7oel6nJECsb3lpHMUB6gFgcCtiigDH1Lwt4f1SO1j1PQtKvI7VDHbrcWccghUjBVAQdowBwKLXTdB0vUIorSw020vbi28hFigSN3giAGwYGSihlGOgyK2K5XWv+Sj+F/+vK//AJ29AFpvBPhV9OXT38M6G1gspmW2NhEYhIRguF243EADPXipZPCXhuTUYdQk8P6Q1/AEEVy1lGZYwowoVtuRgAAY6Vt0UAVLzTLC9urW5vbG1uLm1LG3llhV3hLDDbCRlcjg46iqUHhfw/AkKQaHpUaQwvbRKlpGAkTkl41AHCtk5UcHPNbFFAHNjwH4QEDwDwpoAhfaGj/s6Ha23O3I24OMnHpmrFz4Q8NXWm22nXPh7R5tPtiWgtZLKJooiepVCuF/AVzPgnxLqF/8QviLp+qXqtpmjzWotVZEQQI8Jd8sACRkZyxOK5NPjuofUw+hwzx2+lTapbXFpdzGC5ET7WQPLbx98/Ogde2aAPVZvC3h+eC5gn0LSpILooZ43s4yspQbU3DGG2jgZ6DgVc0jSdO0WyFno9haafaAlhBawrEgJ6naoAya8g1H44Xmm2uqXF34Xh8vTYLG7n8vUyxMF1tClcwjLqXGVOB1w3rZl+Kd5YeLtQ0eHT5dQlk19NHgF1eRxRxbot4YbINwXPZi5757UAex0V4zJ8bgfCtpqcGj2x1KRrtJNLe8mebNv94x+VbyblwDlnEajuepHR6/8TItM+D0Pj2DTHuI5YLeYWTz+WR5romN+09N/pzjtmgD0OivG9X+M17ptzd6d/wiy3etW+t2+i/Z7fUh5UjTxu6MkrRrzlMFWC4z1qS9+Ml1YT3n2/wx5EOmT2Vnqa/bw08M9woO2KMRkShCcbty7sZUEUAewUV47Y/GiSbULRLnw/HFZXWpXmlxSR3++XzbcE7jGYgAh45DEjPQ8ZraV8V9X1ux8I6pdaBdaHp2sapDawPHqMEq3CMshcsDEWCqUHHyMc9RjkA9rory3wZ8Wo/EfjW20EadB9nvLea4tdRtJ5pIZRG21gDLBEG6HlC4zxmvUqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOT8H/AOj+J/GllwANRiukHosltDn/AMfSQ/jXWVydqfs3xU1FP4b7R7eQD/ahmmVj+UyfkPx6ygAooooAKKKKACuU8KfuvF/jaHn5763ucf71pDHn/wAhfp711dcnpGIvib4li4Hm6dp9x16kvdIePYRrz7igDrKKKKACuV1r/ko/hf8A68r/APnb11VcrrX/ACUfwv8A9eV//O3oA6qiiigAooooAwrrwf4Zu9W/tS68O6NPqe9ZPtkljE029cbW3ld2RgYOeMCs+y8N+Ck1e/0yz8OaIl2lqr3Sx6dEoMUzOArHbg7jE2V9hnqK62uS8GD7V4j8YakcFX1BLOI452QwRgg/9tGmoA1J/C3h+4jnjn0LSpY7iOOKZXs42EiR48tWBHIXA2g9MDFSN4c0Rrz7W2jaabvzxdecbVN/nAYEm7Gd+ON3XFatFAGDP4O8MXEEUNx4c0WWGKR5Y43sYmVHc5ZgCvBJAye9VvF3gnSPE3gqbwrMj2GkyCNQlgEiMYjdXUINpUDKjjHSunooAxrbwr4etba3trXQdJht7e4F3DFHZxqsU46SqAMBx/eHPvUlz4c0S71iHVrrRtNm1SHHl3klqjTJjptcjcMexrVooA47wj8OPDfhea9ubOwiub66uJrh7y6hieceactGHCg7OT8vuetb0egaPFa2NtFpOnpbWEgltIltkCW7jPzRjGEPJ5GOprTooAxdM8J+HNKvvtul6BpFlefN+/trKOOT5vvfMqg89/WtqiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooJA6kUAFFJuX1H50uR60AFFFFABRRSM6oMswA9zQAtFVRqNkTgXluT6eav+NTrNE33ZEP0YUBYfRTDNGOsiD6sKrT6nYW6kz3ttGB/elUf1oHa5corGPijRfMSMajCzucKEy2fyFWhrNgf+XlfyP+FLmXcfJLsX6KpDVbE/8ALzH+dL/adl/z9Rf99UXQuV9i5RVT+07L/n6h/wC+xS/2jZf8/cH/AH2KLoOVnO67i2+IvhW56faLe9sD7lhFMPy8hvzPrXWVxXj6/tI5fDF8t1D/AKHrUBJDjgSrJb+v/TeupOp2X/P1D/31RdBysuUVRbVrEf8ALyh+mTTDrNiB/rmP0jb/AAo5kPll2NGisttdswOPNb6If61GfEFsOsNxj1wv+NLmQ/Zy7GxXKf6r4q9/9J0X/wBFT/8A27/OKsz+KIEOEjQn0eUA/kAa5fUb/U7rxvpOpWdq3kRWF3ayuiY2mSS3ZeXwD/qmxxxk1LqwW7H7KR6VTZHSNcuyqPVjiuMml1SfO6Q4Pdpiv/jqjH61TeznDbpru1QnuIMH8y39KyeKgtilR7s7dtSsVODeWwPoZV/xrldZ1CyPxF8MsLu3KizvwT5q4HNv71TFsD/zE5/+ALHj/wBBNZN7ozzeJNLv11VxDaw3Eb7ygfLmPG0bMY+Q5z7Y71P1uPYfso9z02O/s5DiO6gc+iyA1Z61wIs5HX91qBk/30Rh+mKdHbX1vzDNAf8ArmGh/UE0LFw6g6K6M7yiuPi1TVbYDerSgduJAP8A0FjV608UQudlxEySei9frhsH+dbRrQlsyHSkjoSQoJJAA5JNcp8KwZPA2n3r536k02pkkcn7RK8wz+EgH0ApfHeuRQeA9fubGYG6WylWFejeaylU46/eK10OlWUem6XZ2MH+qtYUgTjHCqAP5VqZ7FqiiigAr5s1/wAAeK9Y+I/xJv8ASJrnTbG8ENrceZE6i+tTAC4t22kNIGjCemHYex+k6y/FGsweHvD99qt0rPHbR7hGn3pXPCRr/tMxVR7kUAeAaHqXj7wr4N0HT9P0/WobceFZ/Khi0lp2i1ISMUDjy2ZDtxgNhT6V1/hXW/GVzrljH4sn1/ToDZae9sllpAkiu5niUzi5kEDmHEmVI/d7Rk54zXq2hDUP7Fsf7ZMR1MwobnyRhBJj5gvsDkVeoA8C0nxL8Tnmg+0rqKXL2l8dTjutFY22nyqSLb7OY4984J25CtLxz7Ull4r8fJ4XmF5Y+Lpr8X0FuL6G2iRHQo2+QRtp/mrFnqDA7ZCgN1z79RQBxPwc1LxHqngO0n8aQzRa0ssscvnW5gZ1VyFYptXGRjkKAeuK7aiigAooooAKKKKACiiigAooooAQsB3pDIB2b/vk07FNNADDNj/lm5/L/Go2uWHSL82xTnNV5DUtlJCSX0o6RoPqxP8AQVVl1K6U/KIfxQ/406SqsoqW2aKKGTategfK6KfZf8azp9V1I9Lph9FUf0qzKlVZI89qzbZrGMexRmv9SY83s/4Nj+VUpZr1yd15cn/tq3+Najwj0qMwCodzVW7GM8cz/emlb6uTUTWrN1Zj9TW59nGelL5A9KVirnPNZnsTUL28i9HcfQ10bwj0qE24J6UhpmAIJif9bL/30alS2m/57S/99mt1LUelTLbD+7QkDkjDW1lPWSQ/8CNK9nkfNk/XmugFuAPu1FLGOwp2Juc3LaD0qMWHPTiugeFURnkIVFGSScACucvLptQkZLdjFZocNJ03+w/z/hUTkoq7LTK8jp5nlWiCWTuew/H/AD7Zp32RBg3U/wA3op2j/H8qc7R28DNuFvbryzMcE+5J/wD11Da3NreKXtJY5R3KnP51CpVaurfKvxMJ17fCi5bx6cs0RIbcHXk7yetdGpsOzTD6NJXJPcQQzwpLNGrl1wpYA9a1heW3aeL/AL+CtFgeqkzF4hm2PsfaS5H/AAKSjFr2muv++pKyFnRvuyxn6OKsRlz05/Gn9Ut9ph7dmiEtz0nuvzf/AApdlv3upl/3pMfzqmvmjt+tToZfQ0vqr6TY/bstLaRyDInmdfaTNOFineW4/wC/hqtht25o+fXHNSJLIh+V2Hs3zD/Gs5YaqvhlcarX3JhYx95J/wDv63+NOFhD3Mx/7bN/jSw3AcgONrdvQ/Q1aFckpTi7SbNL31uVhp9t3Rj9ZGP9acthaA/8e8RPuoNWKWp5n3C42ONI+ERVHsMUu9nYrCu9h1J4UfU0iIZ2IBIjU4JH8R9BSXl9bWERDEAIPurgBR79hXRTo82siG23Zbkott2PNkZvUL8o/wAf1pxFvbLk+VEPU4Fef6348wzR2IMp/wCmZwv/AH11P4YrlbjWtavZSyyLDn/nmuSfxOTXSko7Fqi38TPZjqNmP+XmI/Rgf5UDULM/8vMI/wB5gK8eittfnAPm6gw9V3Y/SrKWevKMmTUPxDGncv2Ee560q2lzyogl9xg0G0T+B5I/91v6HIryV7rVrcjzZA+O0sYP9M1etPFV/b4WeKTA7xOQP++TkUnyvcX1d/ZZ6W0My/6t0cejjBP4j/CoZ1V02XdsWX/d3r+n9QK5vTvGUUmBJIhPpKPLb8+ldHbavaTKCz+V/v8AAP49KzdGD2IlTqQ3RyPjezjng0axtJ2H27VLdAu7euIiZ298YhOcEcV10Orajp4xcAvGP4jl1/P7w/HIFZ2raTJqHi3Q7wRqbKzhuJHlVgD5rBEjAxz91pTn2961zDNH/q281f7r8H86pe0p/C7mfMn8RrWGu2tyqmRhCW6EsCjfRun54rWHTiuHktYJHOzdazsSeBtLH3HRv1pba8vtLYA5MI7qC0f4r1X6jitqeJT0loxOknrE7euN1cnxB48sNKRgdP0UJqV6Ou+dsi3jP0w8p9CsZ71oXfi3TrDRbvUr9jDDbQtM2Pm3gDOEPcnoB1JpngDSrjTtDNzqabdY1OVr+/Gc7ZXxiPPcRoEjHsgrpTuYtNaM6WiiimIKKKKACiiigAooooAKKKKACiiigAooooADTGNONRuaQ0Ruarualc1A5qWWiGQ1XkNTuarSGpZoiF6gYVOxqI1DLRCVpvl5qbGakVaVh3IREAOlMkTFW9vFQyiiw0ymU5pyxZqdUzU6R0rD5iukOamEQA6VZSPApHGBTsTcpy9MCohFu5q35e41z3jDUXgWPTbIj7VcD5m/55p6/wA/8kVMmoq7LWuhjazf/wBqTtbWzlbCE/vZAcbz6D/Pv6VGkYKrhAkajCIP4R/jS28CJGI4+IYu5P3j3JqZyiqDKWVT91B95vr6VnRhzP2s/kZzbm+SJl69po1PSZ7TfsLgEN6EHNc/4d8PzaBFdXM06yv5ZwiZ28c/0rrxLatn9yQP7wwcfkc0k0I8vch8yIjkdeP611Jpu4pQqQhyrY8b1W4u7i/kPmOMN1Bxk+tPt31Jcbbq4H/bQ12s3hYPeI8EqmN2A+Y4OCfoc1pjwcRx5qD/AIF/9jXpRqU97nlyhPscIt5qqj/j5kP1walj1PU16yKfrGv+Fdyvg0HrOB+P/wBarEXgiJj811/47n+oqvbQ/m/MXspdjh4tf1OM4BT8AR/I1saX4l1WSdEJlIJwWVyce+DmuwtvBWnKf3jO59gB/PNbdnoGm2wG2AOR/fOf06VDr01vqUqU/Qy/D2o6ld3Sxsomhz88hXbtH1HH4V1RiPY0JtRQqKFUdABgU8H3rkqTU5XirHRCLirN3I2jBBVgCDSwOQfLc5b+En+If41LwerCmuiOMFsdwR1Brlr0VVjbqawlyslBpJMkBVOGY7QfSokk+bY5G/sR0Ye1OZgrxuxwqtkn26f1rylDlnyyN91dE14xt7ULD8uSEB9K8v8AEMGs6rqEkAtJ0s42wiAcN/tE9816xIiyIUcBlPUGoBZQd0J9ixI/nXpCp1FE870PweS6m86/884zk/iegrtrDRIbVAI1jh9ol5/Fj1rSllhtYwWIRegUDk+wAqu1xKecLEvoeW/wH60Jdiuec9h4sIO/mE+vmMP5Gg2Fue0n/f1/8aoS3L5/18h/If0pguZNuRNKPxBquVj9jPuX305CCFklA9Dhh+orMu/DkExyYLd891BiP6ZzVtLuYKCJQ2f76j+mKkj1CQffjVx6o2D+R/xosxctSOxx+peEUG4xtJH6eYuV/wC+l6fiKxn0vVNL/eWzt5fXMR3ofw/+tXqMd9A5wzeW3o4x+vQ0TWUMpLBdjn+JOD/9f8ahwRccRKOkjzzTPEk9pxKrR+pi5Q/VT/Mc12Gm+Ibe6jBcj3dDlfxHUVDqnh2K4JYxhyf4kwj/AOB/SuVutBubORpbJ2Yr12Aq6/Ve9L3l5ml6VbfRnpBEVxF/BJG3PqDUJhkiP7pt6f3XPI+h/wAfzrgNN8Q3FlLif5QTy6DIP+8v9RXVL4osYdMmvdQlSG3gjaV5gcptUZJ9unQ/rSajPcxnQnT1WqOc8RWq674qsdGssRQ223UtRRgdrFW/cRsv+06lyfSLvmu103Wp7GVbe8Rih6KWz/3w3f6HB+lYXgnTJG0ubVdUgaHVdWlN7MpPzwggCOLP+xGEUjpnce9bdzHiNkukEsB/ix0+o/qP0pXnS+HVGSalpI6u0uYruESQNuXp7g+hFTVwsb3OlyCe1kaWDHJ+8wH+0P4h+o9+tdZpWpQ6hDuQhZAMsmc/iD3HvXXSqxqLQznDl1WxeooorUzCiiigAooooAKKKKACiiigAooooAaaikNSNUMhpMaIXNQOakc1A5qGaIic1XY5NSSGoWPFSy0MNNpTSDrUljlWpAMUiilJxQIa5qE/MadIe1CDNAxyLVhFpijmphxQIU8VE3JpzNTQeaBojuZ4rK0luZjiONSx/wAK85t5Zb2ea+lz9oumIT/YT29v/rVvePboyi00uJsGY75MdlHT+v4gVmW6hQXjAz/q4x2H+f5CueovaTVPpuypPlj5sdIViTIA2Jwq/wB5vT8Kx57ljcEElmbqfWrV7OpfCE7EG1ff1P41RhDTSRuRgBjXQ3c6aNNQiLHFJECQRljk1dikKHIJx/Eo71Gw3yDHQZFPiILEKeBSNJK6JUjzdQGNtqtIp9R161vG1Y/8tgP+2f8A9esK14njT+7IpH0J/wD110YYjuKtM45wV9iH7HL2nX/vg/404Wsw/wCW6f8AfJ/xqbzfaniRe4qiOSPYiS3mX/ltGf8AgJ/xqVY5h/y0jP4Gnhoz608GP1/MUXD2cexGEm/vRH86cFm9Y/8Avo/4VINnqKfhRzkUrh7OPYiCz/8ATL/vo/4U4JP/AHUP0f8A+tTiQPSm+aOyk07h7OPYGjmYYaJT/wADP+FIPtacCNHX/afn88U8S/7JpwYkdKynTjU+JDjFR2GxvcoPlAjH90vkD9KcXuJP9Zc7B6RqAfzp2WIxSBMHuKI0oxHZEKov2ssFOI1HLHJJPck89P51HLIWkwQTnv6VO3E0gJ6qDVZuh7YqmbwWhWlyXAPAFJEJFX5vwpy8uxPJpXYhgcA0jUeWZkGBgg1XBc8jO7PQdqkkc7MqCAeDTosleOp70CJY5STiQZU+tTx5QD7PI0YHQKePy6VnCUnepGMdSKfDLjIDfTNAnFM147504uI9w/vJ/hVgi2vF/hcr3H3l/qKyIpHIO/HtTm25DDIYdGXgilymEqC6EWr6BHcAsF3n+8oAcfXs3864rVtElgiljZPMtWIMikEo2CCA69u3WvRYb2WPiceav95RhvxHQ/pU7R298m9D8w43rww9j/gahxJjUnS0lschoniN42WKX5D08pz8p/3T2+ldlZ3sN2hMTfMPvI3DL9R/WuW1jw4hBZVSMnuB8h+o/h/UVkRSXelTqkwkwn3SD8y/Q9x7f/qqbtbmkoU62sdGd/JblDvtsL6xn7p/wNZzK9rN9qsdyMhzJCByvuB/Md/rS6Rrcd0iLMwDMcCQDCsfQ+h9v/1VqTQLKQSSrr0deoqXDXmjucz5qb5ZGxo+pR6jbCRCu8AbgDkc9CPUGr9cRbn+xNSieJmMEpLMD65y/wCed2PUH1rt67YS5kYzjbYKKKKsgKKKKACiiigAooooAKDRQaAI3qCQ1M/Sq8lSykQOaryGppDVaVqhmqIXNROacxqFm5qS0gzTlqLdzT1NIqxLkAU12wKazVBJJzSuFh+cmpVqsjZNTqaEBYSnM+BUQbio5HpisPZ+aA9VS9Utcuza6RdyhtpCEA56E8ZpXKSucpNctqGr316ORuEMJ/L+m0/nVyY+RCSnHlgIn+8e/wCA/rVTSoPKht1YbSqmRx6Mf/1n8qffNlY0bj5TI2fVun5DNY4fVOp3KS56luiM+RgyjaMf4VJHHsxg1HbMkm9PTjNWY0KgF+cHitjsK75EwxkZGabaBkce7GrFyrNPgD5dlVoHUPnPQ0hrVGhbtm4iI6lh+jD/ABroMt7Vz9uc3UBxxvHH4iuhIH/PP9K0Ry1PiAZ7tTwKjwv9zFO2rj/69MzJetOGKh2+hb86eoP95qB2JMc/dFP/AAFRgN/ep43+1IYvPpTweOlMBYdRUgDEfdNAhpfHbFJ5lP2t6Um1qAASemakRs+maYA3vT1Yj1piG3AIKycYHB+lVZcBq0eGUgjIPY1nyoVYo3OOhPcUma030IQfmwR1qN/lHoM8E1MxCjn86gWTL4OME1JsFv5o3eZyp6cVZIJX5cBqiaUBhkUnnfvOOmOlAhs67QNpGT2FII/lD9PalcMJh8uV7e1PdCY85IPagYseUAU96b5oRgCcfWnqCI/nPIqMR7z84HHQ0ASCRy/XgVKJNp8wFkYfxLUSLg7sU4jnbg49aCWkzTt74NhLkKAejj7p+vpUWoaXHLEQiB06+Xnkf7p7fTpWYZvLKocDPAHrV+0unhxwzRf3D1X6f4VLRzypOOsDmbvT5LJ2mtmLQnhgw/Rh/WtXS9eZUVJGV8D7kjbWH0PRq3ZoI7tPNgYBzxns3swrk9Y0v5JHgjKsPvRY5X3HqKhq2qLjONVcszdjdtdvYoIFUCPLNhwxUEYy2OBwTj1/Cu8UBVAHQcVxnwqs0g8PSzjBkuJ2JPsOAP5n8a7SumkvducVaylyrZBRRRWhkFFFFABRRRQAUUUUAFIaWkagCJzxVaQ1YkqrJUsuJXkNVJTVmU1UkPJrNmsSGQ1AzVJIarseahmqFDVIDxVbPNKHpXHYkkfFVmfJ60SScVDvyaTZSRajNTq1VI2qwpoTEyxu4qCV+KC3FQSnmgSQ7fzWH4tk32tta9p5gGHqo61rg81z2vN5uuWMXaNGkP6j/Cs6srQbKS1CJdxl/wBtljH07/zNUtQk33TkD5SSPy4/pWjbHZBHIegV5v8AP51kSxM7xZbGOvvWkI8lOMR4dXbkQQxqkgKnlmBq3NK6MBgYzWcrHzd3aNunrVXxjqTWGk+dEcSyEIv+z6mmdiV2bs7/ADhhzxVVIVRcj+I5rP8ACt3JfeHUnuGLSglNx6n/ADmtiCPcAD0FG4aIms/+Pi3/AN8fzFdGSQelc/Z4+1Qem8fzFdExB6LmtInJV+Ibu9QaeuG9aZsPcLTgppmZKAMU4cU1VPqakVPc0hoMmjNG0UEe9Aw59P1p2WHQY/GmhR604Aev6UABd/ak3se4pcH2/KkH4UCFz6tTh/vGkA98U8H3FADlYZ6VHcp5igqPnXp7+op4Gew/CnAfWmC0MyX5owVGee9UWVmLNH9/sMVrXkOAzZwjfex296qJEYtwXJJ71B0RldEcbMfvL27+tIyEyNgfN7UpJWNtwxjripISpAKHPHWgoELKQD261JIScEHFRruWU5wc05xt7cUCFJ3DIo/hJOcU1VYMTn5T0FKxkZWG3pQBF5pRsZ+X0qVpsAYBzVJlLyfOMMDwBU8e5GGe3WgZKqgkMeSDn6U9WZJMkdRTHkAIKjIPWneagAZuM9KBFyCVopN0XOfvIeh/+vV2aOO9hEkRAkH3WPY+hrHZwDnOMjirFpctG3mAHafvqO49R70mjCrTv70dzR8P3yadI9rMgjiZ8kf3GPf6H1/+vjrK5G+txcRCWHDOBkY6Ovp/hWn4a1AXEH2eRiZIxlSerL/iOn5VpTl0ZyTXMuZG3RRRWpiFFFFABRRRQAUUUUAFNanU1qAIZKqSmrMhqpKahmkStKaqSGrEpqpIazZtEglNV3apZTVZzUM0SELc00vxTGNMLVJdgkemI2TTXOaENSXYtIasK3FVUNTA/LVEMkLcVC55oLUxjQAorm79i2v3TA/6qDA9s4NdGK5lvn1fVG9kT+YrGv8ABYOjLtxiO2lQdFRFH4nB/lWVOSyBo/vdq1L7mM+7qv5An+tU32pES3AFdcty8MrQKawoYiSPmY5NZ3iPR21e0hhiZVdGz83QjvWzaxHzHLHK9qmX5pWAHA4qLXOlSsZthZLp2n29pFyEPJx1J6mr/CoxHrSMypId3TpTim/I6A0xN9yXT9rTwMpBG4c/8CFdIy89f1rm9OjEUkajkKyD/wAeromdR3q4nJU+IXb9PzpwGOwqDcSeM/lThu9T+dMgmyacufWogD3P604AUiiUE+vFG73FMCg9h+tO2emKADcf9k07c3otIE/Gg/Q0DF3H+6PwNKD6jH1NR/8AATTgfrQKxIAPalK0wf7ppwP+yaAFC+xqRVHqRTV+hp4FAhGHoM1QkQxvgg7T9wn+VaGCPQfjSTKkkRQsBnoR2PrRYcZcrMmUAD0JFQKcSKCO1WJ9xwCB1IbHY1XaZIwqFSWbvjpUnSieIjDEcNTVLMSXxx2p2MDI6Uuznd2oEKxwN2OOlRyM2CfwAFPOTHhV5HTNQHe2NvD56UDFhyPcnvQN6zbSAamT7wyKUZwzDGc0AUpFLFVJ2kfrQSRs8xScHgYqVEy/mPySc4zTmz9oBkTII4NAEkjBlXaOvXFOiGwbmOSKUIQcgZB9e1NfgNuzgUAaemThW8on5H5T2Pcf1/OkuGfT9Riu4gdpbJA7n+IfiM/iKy7Nto8tW+cHehJ7it2dRe6ednV1DLns3UfrUvR3OOrHklfozq1YOoZSCpGQR3FLWR4WuftGkxjPMR8v8Oo/QiteulO6ucclZ2CiiimIKKKKACiiigApjU+mNQBXl71TlNW5apSmoZrEqymqkpqxKapzNWTN4orymqztUszVVdqhmqQ12qNmNDNURaoZokOJOaVTUW6gNSHYto9TbuKpI3NTB+KaJaJd1BNRbhSF6YrE2a5yDnUNTP8A00T+ZreD1hwDF/qw/wB1v/QqxrP3fmhSWjLV6Pl/7a/+yVnyjdlDznnFad6MoxH8Lqx/EMP8KoSDa4fHauuW5eG+BDl6EAYNJby7jINuCD+dPi+duaGQCQgdDSNhk8SPjPY5pVDZ46YpZuD7YpkEu+LIHTt60C6Fu0UbkY/xSg/kQP6Vunb2FZCJs8heuGUfXkVqmrRyy1FBXuD+dLlewqPNGM9/1pkolBHsBUisPb86rhR9akAFIZNuX2/CnZHr+lQqf96nAj/aoAfkUbh/+sUm4dgaUP7fpQO4ZX0pwI9T+VJu9v0pc59aAHAj1peP71M4o/CgCUbfU08Y9ahVz3Q/lTvkI6FfwoES7Qe5/OgouMHNRhV/hlxS7XHSSmIpahHtJMfyl1z+I/8A1j8qoRMC2GAPvWjfZBQsxOFY/wAqz4gJIwwfFS9zop/CMnLAY7ZpIpy6MFOGU96WUZYhTlupFHk7cc5Y9R6UiywC/lguRk9xTlHXHU96avyrsYZFMSXL4BB5I47UAPBI4OBTVcBh6e1DEMNpU09UCpz26UACopJxUE8gVlL5x2qwoxhs8VEyBnwBkd8igAWYuieXzng57Us4baR6jHHemhBuKITx3FPUFiAx5X170CGQxKZo5VByvqa3tN4gZc8K5/Xn+tZC5wNta2mAhJs95P8A2VaT2MMR8JZ8Hny5r+D+FWBH5sP6CulrmPCWWv8AUXH3c9f+BNXT1tT+E4qvxBRRRVmYUUUUAFFFFABUbVJUbUDRWm71RmNXZe9UJ6zZrEpymqUxq1MaozGsmdEStMaqSHmppmqrI1Zs2ihjGo2NDtURNQaIlzxTSxpm/AppekNFhGOanDcVSjkqcPmmmDRODSM1Rh6azUybEoasyBc6zfx/89IlI/z+NXd4qkjBPEER7SwlfxHP9KyrawYpLQ0D++tnAHLx7x/wHB/qazzyefu4rRtz5ccbEcRMVP8AugkH9Kqzw+TLInZeB9O1dl+ZKRlhpaOJXjXEy46YNNQEMQeeSajEhQrk8nIq5EAOCcmkdT0K4B8xhIQV7CpNPgw4AHAO4/0/WgoGk3AE5OMDv7VqQQeTEQcFzyxppGc5WViGUEtGAcHzF/mKvGNvc/jVRv8AWRc8+Yv8xWiw/wBqqRhIhAI6p+tSDPZBTWOP4m/Ko/OQdZAPqRQIsgt/cFOBY/w1VWdD0kU/iKljmB/vH/dUmmJlhQ3pTwD/AHahE2OqyfihH9KUXCe/8v50CuTgDulLgehqD7Qn+ZE/xo89f8sv9DQF0S5A7U4Eev6VX80noo/X+gpfNYfwD8n/APiaQ7lj8vypfyquJm/uD8n/APiaXz37Rfo39RQFyfHvSgH3qo106/eCr+K/1YUn2qQ/dkiI/wB0k/oTQPcu7OOc01tiqWJwo6mqYmlPUs3PYbFP8z/Ko55zkBzuI6KBgClctQbHSEyF3ORu6AnoKrfcG4LuB7elT7VOck5PUZqnMSQojOGzyDSNkraD0A+f5e+M04hXwUJLA1DDI6uyMuBmrMG08gYbvQMUhxGCeCKreSZB8uVIOTU0zhiytnb3p4GFIBAHXNAEYYrliePzqO4ndDmNQw7gml80NbtkjA69qpysCxkj5yMYzxQBfjmUwhiD8w/KnwkOmQOhqjDI/lgOfcCtC3YGLKqAfSgGRzDy/njXLd6nBVuvUVXDYU8/OT0pkEhErbgcMe/agReiAMmAa0IJBBYSTvyMs4HrzgD8eKz7dchmQHex2L9TVi7V7m5g0616AgEn1xxn2A5P4Un2Oetq1E2fBtsYdOeVuTK/B9QOP55rfqO3hS3t44YhhEUKB7CpK6IqyscMpczbCiiimSFFFFABRRRQAVG1SVG1A0VJulUJzWhN0rOn71nI1gUJz1rPnPWrtwetZ0561jI6YlaY1UkNTStVaRqzZvEiY0wn3pHNRlqg0SHk8UwmkLCmFqQ0SqTUqtVUNUitTTBotocikc1EjUM1Mmw7dVS9YRXNnOeAkgBPoDx/jUxaq9+gls5VYcYzSeqsDWhtRcSyr7hvwP8A9cGiaDzowo5mQYA/vr/iP89arafcGe2tZm6sNj/73Q/qD+daBUMMMP8A61bYZ81JJ9NDznJ0p3MRoD90DcQfyqeGJ5JMKpLDjA/r6VplSx+dYpPeSPJ/Ohi5XYSFT+6g2iteQ6HilYigjS25wJZh6H5V/H1qC4uJCM7wF9QMD8O5/CnzuqKQR8g4CjjcfT6etZbzNO5YN83r/QegobtoKnGVT3nsKHd7iIF2271yScd/TmtlbeGQZDxt696wkwZo885den1rZigaEccBvfmpudHs4kotYAM/uwP90/406MwglUlXPoM/41AeejZPcU5LfBaZiBkcCi4eziWlRX/jz/wEVG6xg46n02r/AIURDYd5FLKocnbxjnIOKA5IroJ+6U4IYH6Cno46ZkH0c/0okVAmDjJ7mlWLaAVNAcqEMmH2nzR7+Yf8alB+UHdJ/wB9mo5cEM2c47VWnlOVxkY7UD5UWmYliBkjHUsaHCBeVGffpUEcrCIHgipoj5kZ3LzQFkO8tCudiH8KjdI1LYii45+6Kk8s4GGxioblQT975j0oBIjiusOQUCr7CrCsZHwHxjsO9QLD5ihnwAvTFPiU/fGT9aB6E7Ab1JY5x09ajTY7ljnrxmnsQSGJxxVdnYYYjIBoAsOY1cMRyeKqTEPIyx8MvI561PhZFAORnmmrEyltyrjsQOaAGzFI1AAUtxkmpAuwKeOvahoFZMhSWJyPapFiEaDzmC56Anr+FArkEhI3BckfnTt6yJnAGeORTpbi2tYi0pVFPeVggP8AX9KyZvE2nRcJIj+0cTN+pwKVwvfY1ZNkaFfLBUj061VjhBx8u1c8gVm/8Jbanol3+ESD+tC+KoCfuXf/AHwlK6Gk+xqttLhVG1Rx0qxGm1wQQV9ax08TwE/dm/4FCP6NV2216zcYOwZ9cr/T+tO6B37FqZQz4XORzU0VuZCBjLep7VD/AGjYbd3yn6SL/U1bshc6sm2wiAticGQHIP1PT8s/0prUzlPlQNOIyBbgFgNsZHOCf4sfoPXntXS+HNL+xQmedT9pkHOeSo64+p6n/wCtS6NoqWJEsxWS46g9l+mep9/5VsVpGFndnBUqc2iCiiitDEKKKKACiiigAooooAKY1PprUAVJxwazbitSYcVm3IrORtAyrisyc9a07nvWVcVjI6oFOU8VUkNWJaqSGsmdESJ2qInmklPeoi3NQaomJphNM3UhNADg3NSq1Vs81IjUgZZVqeTUCtzT81QhSaAexphNJu5pAO0TIN3aE/dIdCf8+wP41uwt5kat6jkehrm2k+y6hb3GcITsf6H/ACD+FdFAdsrp2PzD+v8An3p0JclVx6M4MTDW5NimS5Awv3icD61Liq90dquwPKrgexbgH+ddz0OWEeaSRk38hLbYeQcqpJ7ev49aqQJ5OOd2OM1KWDSnHXoBTFceXlhg5rE9aKsrBbn/AEmIZBxIvT610DCVjkjIzx7Vxl/qK6ZLDhHeRm8xVUgAAHqSQe4P5VMPFN44+S0x9ZD/AEApXKtfY66ODBJIIb2FSNHI6+hHSuOPiDU2+5DGv1Ln+tRtq+qyHnyR/wAAz/OjmDlZ28asE2yYxjvTd6LwZIwPdhXEifV5eVI/4DCv+FSbddbpJcge0eP6UuYOQ7NngK4MsZ+jUqSxr/Fn6KTXGC31xv8AlteD8SKX7HrPe6ux/wBtiP60cwcnmdi8iMhXLDP/AEzb/ComjjflnfPtG3+FckbHVW+9d3B+tx/9ekGm35+9cyfjP/8AXo5g5fM61II1LESSnPbyzxVhXUKAfNOO+zFcWNKvD1nJ+sw/xp39h3DdZFP/AG0o5mHL5nZq6qpBWRvqB/jUZEeclZcjp0/xrkP+EelPVk/77pf+EclP9w/if8KOZi5V3OtaSHbgiX81/wAaaJ7dV2ky492T/GuVHhiQ9k/X/Cnf8IvJ/sfk3+FF2HKu51LXdpjBLcerp/jUYurQjAYED1lX/Gub/wCEXk9U/wC+W/woPheT++g/4A3+FF2Fl3OibULFDkzW4P8AtXCiq8viPT4utxbjH91mk/kKwz4XkP8Ay0X/AL9v/hSf8IrMOjqf+2bf4U7sLIu3XjGAJtt0llb/AGVEa/mcmsifxBqdxuEIS2Dd0GXP1Y1Ybw9cQ9Wh/E7f5igaReIP9TkeqsD/AFqW2UlExWtZp5DJO7yOerMcmrMVio7VqLYXa/8ALvJ+VTR2N2f+Xdx9RikaXRnpaKO1TpaJ6VfXT7gffVIx/tOBVuDS2ON7s2e0a5H5niiwnKKMtLWP0q7FpnQyDy1PTcOT9B1NbFvZJGRtCp7j5m/PtWja2u45gQHPWV/8e9Uo9zKdZIx7bSY3liTyCwc4zI+3sT0Hbj1rbt1n0dY0tpVSNmOEUnGepODkU25vbXTI2cyK0nQyucAe36dBWLoXiWyu9dKalBObcjEchUtuPoVA4X2H40JpO1zkk5VNbaHplhO1xZQTSLteRAxA9xViq1vf2twwWGZSx6KeCfwNWa6kcL3CiiimIKKKKACiiigAooooAKRqWg0AVpRxWdcr1rUkHFULpeKhmkWYlyOTWTc8ZrauhWPdDrWMjqgzLmPNU5DVufrVKSsmdESCSoGNTP0qu9QzVDt1ITTM0oNAwJpyNUZoB5pDLKmnhqgQ1IKYrElNNL1700ikMSeMTW7xkZJHFael3DTafFKcmWE7W9Tjr+Y5rPj4qTTJPsuqNEeIrgZHs4/xGfyFZ1L25lujGtC8TpF5FVL/AISTH+xn/wAeqa1OAYj1Tp9O3+FF2m5XUDll49yOQP516CkpxUkefT92ephRbWfccggZpJRhdqjknrUzALnA4bpimTDlSBnIxUnpFOS1gnlgWeJZMMApLldoJGR7itiLTbJGCLHCrehLNWbtXzYATwWX+dbFtA28gkbcdamyGOWztgRhYR7rEB/PNTeVHGPvuB7AD+QqMRHzSoLFRSliQVccA807IRIqxHJy/HrI3P601VjIJ8lSPcZ/nSeUA4cdB0zT97ICvr0oAgaSIsyRwRBlGeVHNPRyFG6JA3stPjQBgzjnHpSFw0uHyOKYEzTLHFuOAfYU8Ss6ko4z/Ks9+FDZyPSkilADBuCx45ouFi+Z2L7VkGV+8KhkvJXIjjba/Ukim24VWMnXPWm4EshJwDnFAWHrdTZIZ+B3qzDOXXk8iq8rorKnA/rUioFKlcHsaAshGmkIwrfNTI7icHaxBI70rLvfIJGPenOAMrjB9TQGhHdSzlcxvtNRs9zMi+XIV2/eOaGRiwG4AjpmnjeVCxrxySaAshPtEoIJYt7Cp5JSSpLEewNQQs+NmwHt9KewwwVs4HTAoAmSZvKznPqKjwpTc1tCWz3QUxYzGc+vAGaezuBt7npQKxEtxA+QtpHuBwQBT8rjm0hz7rmn28JDAkc+tTQ2zTtlF3npu6KPxpCbUdWJHt2Hyo442/2FAqRIXueFUt6nOB+dXUsoYk33TggdR0X/AOvVDV/ENtp8e0EJx8qgZdvovb6mk5GPtXJ2gi4LeC1UG4bzH/hjA4/Lv+NYGueKUV2gth50nTYh+Uf7zf0FYFxf6jrDtGgMEDfeCn5mH+03/wCqtXQ/DvmBWRR5feVh8v8AwEfxfXpWTk3sWqSj79VmVHbXepTpLdEu54RFHA9lX/P1rrtM8PtEMyv5IPVY8Fz9W7fQfnWzY2ENmp8oEufvO3LH/wCt7UTXXzFIAGYcFj90f4mk+WCvIynXctIaIpXdn9ijEsEkhjUjerMSRzwynqCK6/S52ubCGWT75GGPqQcZ/SuLu5Li4uY7SNjJvwzrgccjaB9SPyBruLKAW1rFCDnYuM+p7mujDy51zLY56t7K+5NRRRXQYBRRRQAUUUUAFFFFABQaKKAGOKp3C8GrxqvMuRSZSZhXadaxrtOtdFdJ1rGu4+tYyR0wZz9ytUZBWvcx9azZUwaxZ1xZScVA61bdaiYVDNUVMUoqVlpNtIZGQabirATIpClAxiZqVRTQuKlQUCFC0pWpFXNP2cUCIFFNu4mlhzGcSIdykdiKmKGnIMGlYb2NG1uFnt4bpOBj5h6eo/D+laEi714OD1BHauf05/sd80Df6mc7k9m7j/Pp71t2zbQYj/Dyv09Pw/wqsNLkk6T+R5teHK7ooXUZBLY2jPP+yfT6elVQCQAwIrblQMcg4bGMj+VUJrVhkrgDtg5H5Hp+ddTia08QmrSMvj7VECOPMH866GNfQkAjvWOltILqE7f+Wi87R6/WuhG5R7+8Y/8AiqlJmzrQ7lEJIk5IY7ccD0qcKTknvTpJ3Q/dB+nH9DUZuZSeMj6kH+gp8rIeIh3JJA5X5VJA7VXkjmk2/u2AHPAqxG8r/eYfqP5Gp1gDDmWT8G/xp8rF9ZgVIoZtpyvIP8VIbeR5t8pCgdDmtBbSI/e+b6gf4VKtpAOiY+jEUcpP1qPYxGtQuBHNF1z8zVKLFZCD5iluo281rvEn1+rE0zyYz1RP++RRyE/W/IoLaiLO4tg/7BoVI1yN5P4YrQEMY6Ko/AU8IO1PkF9afYzikTDHH/fSj+tPCIFwNv1Mi/41f2e1GzHYUcovrT7FHYuMAx/9/BTWjU9TGf8AtoK0QAPSmySIvB5b+6o5pNJK7YLEyeyM8pFkFgCR/tqf603dEpY+aFz/AHjgD8avEOx4CoPfk/8A1v1prIgOJHdmPbdyfwFcssVTWkdTSNWfVFVYSFDR/P7jmkWCTuhPNWk02NjuitEiYn73+rJ/Ec1Zj05cDzZZW9lkYD+ef1qoVXLeNinXSM/ymMgD4HcDv+AqzHZu5BEe0D+J/wDCr5NvZrj5Uz2HJP8AU1j6v4ltbAYd1Vz/AAn5n/75H9SK0ciPaznpFGmtnDEhadg4HUvwo/DpVTU9ctbFMGRFOON39B1NcXfeI73UJdtmjIp6O43P+A6D8Kis9FmuLjM5eSZuSAdzn6+n1NZuV9i44dv3pssah4gvNQk8uyEijPDsMt+A6LSaboktzKXkWSaUn5uc4P8AtN2/nXUab4dWFf3+ET/nnGeW/wB5uv4D863USK2hCoqRRKOgGAKXLfccq8KelNGXp2hwwKDcBZD/AHAMIPw7/U1qySpEBvbHoO5+gqvJdM4xAMD++w/kKqyyRwAyTPyeNzck+w/wFZTxEY6R1ZztSqO8mTSSyTHvGnoDyfqapyzkt5FoN0mduVGQnt7n2qW3trzVGK26NFD3YnBP1Pb8Mn6V0+l6Tb6eqlQGkAxuxgD2A7UU8NOq+aoOUowVit4f0gWSmacZnbn5uSPcn1/l0FbVFFenGKirI5ZScndhRRRTEFFFFABRRRQAUUUUAFFFFAAaikHFS01ulAGdcpWRdR9a3p1yKyrpOtZyRvBnP3MVZc8YzW9crWVcDrWEkdcGZUiVEy0C/tppQkUhO77rbSFb/dbGD+FMaePzNgYFsE8H0Iz/ADFZtM3UhCtM2003duZkh86MyuCVXcMkDrSiWN13I6suM5BzxU2K5h4A9KXb7VRTVLN1hZLhWEzFUI5yRx/h+Y9avB19aBcyE20o4NIXX1ppkAosPmLMZz2qwq5FZ6TgGrkU6kdaaJbHOnFRDg0+WUYqq0oz1oY0ye4iE8OFJDr8yMOoIq5YXJu4A/C3EZww9/8AA/55FZ8c49aQym3uBcQjOeHUfxD/AB/z3rOpFtXjujOpDmR0KOJEDD8Qe3tSP0qvFKHUTwHejdQO/wD9eptwdcqciuuhWVWPmebOPKyBuJIyezr/ADrRMinvWbMOU/31/mKstj3rckmKq1RtEB0FIsgFPMuaBEYVuwNTR7x6/nQr571KhHHWgBys/wDk08F/UUKFp52YoAjL+pFIJAO4pWVM96QIv900AIZsdxSidu1KFX+6KCyIMsVUepNAC+Y5pRvPU0gkBxsVnz6Dj86dsZ/9ZgD+6vT8fWuepiadPrdlxptjFLSH5DhO7+v0/wAakVQpCRpl27evuT/Wn9B7VZsUxCJD9+Qbj7DsK89OWJn7z0NtILQalpkAzOSe6qcD/Gp44kjGI0VR7CoNQvEsrdpHIGAW5OAAOpPsK821PxpeXkjx6fCdnTzJhnP0Xp+ea64wjDZBGEqh6RNfwRglW8zHUrjA+p6Vy2reNrOAtHDL58v9y25A+rnj8q457HVdVG7ULiV4uuHbag/DpW7pHhZcKUgaYnndjan59/wp83Y6I4eMVeRQl1fV9UJSEfZkbqIslyPdjz/KptN8O75SGDyy9SqfMR9T0H4129joMUIHnsG/6Zxjav8Aia1kSG2i2oqRRr2ACgUWvuKWIhHSCuYOm+HViT98wjH9yLr+LH+n51u28ENrHshRY16nH8zUUl32hXcf7x4H/wBeq8pype4kyo5OeFH4f41lOvCGi1MZOdT4mWJLsHiAB/8Aa/hH+P4VXk5/eTvnbzzwq/hUH2h5nEdlE0rHkNg4/Dufw/OtOx8OyTkSanITzny//rdB+p96hQq1/JBaMNzLWea6kEVhEXZujkcfgO/14HvW1p3h1Q/nag7SSnooPQemf6DH41u29vDbJtgjVB3wOT9fWpa7aWFhT9TKVZvSOg2NEiQJGoVB0AGAKdRRXSYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKAIZFyDWZdrwa2CuRVeS0WT7zn8AKTVyoyscpecZrl/EchNvHApK/aJViYg4IU8t+YBH416PNolvL96WcfQr/AIVm3/gvT76IxzT3YGQwKuoIIOQQdvWsnBm8asUeb61PFBbRyuVRIZEIPZRnB/QmuXmvWnup4VgnQSmRVZ1C43oGBxnPVTXq2p/DKwuLObZe3811tPkmeVdqt24C4HPfGasyfDXSJJ/Oe4vjJxzvXtnH8P8AtGo9lI09vE8M0WUwfvXJyn2eUE9gxdX/AFZ60LfW1mNmrSp++eWKQAAHjO38Mfzr1/8A4VfonlsnnXmxgVI3JyDk4+77mmt8KvD7hgzXR3KFPKcgdB92h0pMarwXU8JS9EagF03JcCDhh94CL5voTGfzq6dXnMOrQC5JuGk8uD5uQW4G32AwfbmvaG+FOgFQA92AF2DmPp6fc6UxfhTo0ePIuLqPAwMBOP8Ax2k6UhqvDueZW+t28tvEzTIrtgFCwyG9MeuatG7969AHwq0wSGQXlxvP8WxM/nipl+GGm/xX16fptH9Kn2Mi1iafc82N371JFf4I5r0j/hWGk97zUP8AvpP/AImm/wDCr9K/hvr8fVk/+Jo9jMPrNM4YXe5aqy3JU138vw0jUf6Nqki+0kQb+RFZtz8OdS6Q3Vm49WLKf5Gh05dhxr0+5yMd383Wriz7hWwPhtrOc+fYD6yP/wDE1K3gLW4F+U2s3tHIQf8Ax4CkoS7FOtB9TLsL420vGWjb7yZ6+49/5/z3YmiuF82B+vcfyIrPPhHXOQdPb/v7H/8AFVPB4W8QRMGSzZW/vCaMHHvzz+NYzoSb5o6MznyS6ondJWeMfI2XXnJHcfWtA2kp6mMfmarxaJ4j8+LfaoIw4LHcmQAf9/8ApW0NI1M9VZfxT/Gi2K7mHLT8jN+xP/z1T/vj/wCvSiyYdZR+Cf8A160/7E1I/wDLRh9WT/4ml/4R/UT/AMvQH/Ax/wDEUezxT6hamZosz3mb8AKcLb/ptL/47/hWiPDl8fvXn5P/APYU8eGrk/evWH4n/AUexxL+0F6ZmiA/89ZP0/wo8j/prJ+n+Fag8LOfvX8n/j3/AMVSjwt630h/77/+Lo+r4j+b8Q5qZleT/wBNJPzH+FL5A7vIfxrWHhWLvcyH8W/+Kpw8K2/eZz+f+NH1av8Az/iHPTMgW6f7f/fZ/wAacsUaHKooPqBWsPCll3Zj+Ap3/CK2Hv8A98r/AIUngqkt5B7SCMncPUfnTgRjitM+FbHt/wCi1/wqOTwpBj91IqH18vH8iKn+z5dx+0h3KH1qzZSAxLGfvxgKR6+9UrywvtM+ZgZoc9c7h+DdQfrx70kU0dxzGxWROo6Mv1FZpTw0veWg2lJaFjVLD7bGAHVTtKkMu5WB6gisi08LRQsCHhjH/TKL5vwJJ/lWuJ5x3Rh7jB/P/wCtS/aJz08tfwJ/wrf6xTfUIyqQVosS20u0gYMI/MkHO+Q7iPp2H4Yq1LNHFw7gE9upP4VSlkbaWlmKoOuDtH5//XqoLuEA/Z0ab1MY4P8AwI8frUvEX0grk8jk7yZovdOw/dJt93/wH+NVZnRAJLmTOOhc9PoKS2g1C+P7pAqHugz/AOPHj8MGtWx8NIreZdylpP8AZOT/AN9H+gFNUK1X4nZDvCG5jLPLOwSzgZmPQuCPxA6n9PrWnaeHJZnWTUZSccheuPoOg/U+9dHbW0Nsm2CNUHfHU/U96mrqpYWFPXqZSrP7JBaWkFohWCMJnqepP1PU1PRRXUYt3CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARgGBVgCDwQe9YWpeHopn8y1xG44xkjH0I5H06VvUUpRUlZlRk46o446PqycI24f7W1v1yKemgalKf3txtHpvC/yGf1rrqKwWFpJ3sae2kc7D4Yh3K1zKZGHQhckfi2TWrBpdnCBiBXI5Bk+Y/rV2itlCMdkQ5ye7CiiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30752=[""].join("\n");
var outline_f30_2_30752=null;
var title_f30_2_30753="Dermatitis herpetiformis AGA";
var content_f30_2_30753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A skin blister on the elbow of a subject with dermatitis herpetiformis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Ciclitira PJ. Gastroenterology 2001; 120:1526.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30753=[""].join("\n");
var outline_f30_2_30753=null;
var title_f30_2_30754="MOST trial pacing mode intention to treat analysis";
var content_f30_2_30754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Relative risk for each event for intent-to-treat (ITT) and on-treatment (OT) analyses in the MOST trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HFH: heart failure hospitalization; AF: atrial fibrillation; HR (Cl): hazard ratio (95% confidence interval) for dual-chamber pacing (DDDR) versus ventricular pacing (VVIR).",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: Hellkamp AS, Lee KL, Sweeney MO, et al. Treatment Crossovers Did Not Affect Randomized Treatment Comparisons in the Mode Selection Trial (MOST). J Am Coll Cardiol 2006; 47:2260. Copyright &copy; 2006 with permission from The American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30754=[""].join("\n");
var outline_f30_2_30754=null;
var title_f30_2_30755="Albumin: Patient drug information";
var content_f30_2_30755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Albumin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/59/27574?source=see_link\">",
"     see \"Albumin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/40/20101?source=see_link\">",
"     see \"Albumin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Albuked&trade; 25;",
"     </li>",
"     <li>",
"      Albuked&trade; 5;",
"     </li>",
"     <li>",
"      Albuminar&reg;-25;",
"     </li>",
"     <li>",
"      Albuminar&reg;-5;",
"     </li>",
"     <li>",
"      AlbuRx&reg; 25;",
"     </li>",
"     <li>",
"      AlbuRx&reg; 5;",
"     </li>",
"     <li>",
"      Albutein&reg;;",
"     </li>",
"     <li>",
"      Buminate;",
"     </li>",
"     <li>",
"      Flexbumin 25%;",
"     </li>",
"     <li>",
"      Human Albumin Grifols&reg; 25%;",
"     </li>",
"     <li>",
"      Kedbumin&trade;;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-25;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-5",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alburex&reg; 25;",
"     </li>",
"     <li>",
"      Alburex&reg; 5;",
"     </li>",
"     <li>",
"      Albutein 25%;",
"     </li>",
"     <li>",
"      Albutein 5%;",
"     </li>",
"     <li>",
"      Buminate-25%;",
"     </li>",
"     <li>",
"      Buminate-5%;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-25;",
"     </li>",
"     <li>",
"      Plasbumin&reg;-5",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add back fluid after fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692065",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat shock.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3406052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help treat some patients with an illness of the hollow belly space.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to albumin, blood products, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703170",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia or a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11033 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30755=[""].join("\n");
var outline_f30_2_30755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130904\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012153\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012152\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012156\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012157\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012159\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012155\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012160\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012161\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/59/27574?source=related_link\">",
"      Albumin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/40/20101?source=related_link\">",
"      Albumin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30756="Clinical significance of residual stone fragments following stone removal";
var content_f30_2_30756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical significance of residual stone fragments following stone removal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30756/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/2/30756/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the advent of shock wave lithotripsy (SWL) and percutaneous nephrostolithotomy (PNL), patients underwent open surgical procedures for stone removal. A successful open surgical procedure was defined as complete removal of all stones without leaving any residual stone fragments. Patients with residual calculi were considered a treatment failure.",
"   </p>",
"   <p>",
"    However, the introduction of less invasive procedures for the management of nephrolithiasis has resulted in a change in treatment goals. With these modalities, minimal emphasis is often placed on the presence of residual stone material post-procedure. Instead, success, as currently defined by some investigators, is determined by fragmentation rates and the size of remaining stone fragments. As an example, small stone fragments, such as those less than 5 mm in size, are considered by some clinicians to be \"clinically insignificant.\"",
"   </p>",
"   <p>",
"    Several studies, however, have noted a dramatic increase in stone formation with the presence of residual calculi following SWL or PNL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As a result, it is not acceptable to use the term \"clinically insignificant stone fragments\" since residual fragments may act as a nidus for further stone formation.",
"   </p>",
"   <p>",
"    The clinical significance of residual fragments following stone removal will be reviewed here. Detailed discussions of the methods and indications for stone removal are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESIDUAL FRAGMENTS FOLLOWING STONE REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high incidence of stone growth has been found among patients with residual calculi after SWL or other treatment modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Based upon this observation, various algorithms and neural networks have been created to help predict the incidence of residual stones following lithotripsy treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual fragments following SWL or PNL lead to high rates of symptomatic episodes, as well as high rates of repeat intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. The incidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rates of recurrent disease vary with the type of stone, size of fragment, and procedure.",
"   </p>",
"   <p>",
"    The following studies illustrate the range of published findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent stone fragments are particularly important in patients with struvite (infection) stones. In one series with a mean follow-up of 27 months, 16 of 20 kidneys that were free of stones at three months after SWL remained without stones; in comparison, 14 of 18 kidneys with residual stone particles at three months showed disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40231?source=see_link\">",
"       \"Management of struvite or staghorn calculi\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a report of 160 patients with residual nonstruvite stone fragments smaller than 5 mm in size, the incidence of a symptomatic episode or the requirement for reintervention at two and five years was 43 and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, 42 patients with residual stone fragments (most of which were smaller than 5 mm) after PNL were followed for a median of 32 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients with fragments larger than 2 mm compared with patients whose fragments were 2 mm or less experienced significantly greater numbers of stone related events (71 versus 24 percent) and required significantly more repeat interventions (53 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that the presence of residual stone fragments after stone removal increases the risk for future clinical stone disease, all attempts to render a patient completely stone-free should be made. &nbsp;It is important to properly image patients two to three months following their stone removal procedures to diagnose the presence of residual stone fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moreover, adjunctive medical therapy with a selective alpha blocker (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ) to facilitate passage of residual fragments, a metabolic evaluation to guide selective medical therapy, and continued patient compliance with appropriate physician follow-up are mandatory to ensure effective prevention of clinical stone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A metabolic predisposition to stone formation (hypercalciuria, hyperuricosuria, or hypocitraturia) is found in the great majority of patients with calcium stone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) Since the metabolic defects underlying stone formation persist after the procedure, the likelihood of recurrent disease among patients with residual calculi after SWL is inextricably linked to the institution of medical therapy (eg, thiazide diuretic and low salt diet for hypercalciuria,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or potassium citrate for hyperuricosuria, and potassium citrate for hypocitraturia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .) Growth of existing stones",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    formation of new calculi due to supersaturation of stone-forming substances",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lack of stone-inhibitors may be inevitable without appropriate medical therapy.",
"   </p>",
"   <p>",
"    Reported benefits vary based upon study design, underlying disorder, compliance with effective therapy, and severity of residual disease. Most trials evaluated treatments that were not specific to abnormalities found in metabolic evaluations (eg, thiazide diuretics in patients with and without hypercalciuria). Nevertheless, findings suggest that comprehensive metabolic evaluation and aggressive medical management may control active stone formation and growth in patients with or without residual stone fragments after SWL and PNL, thereby moderating the need for routine second-look procedures.",
"   </p>",
"   <p>",
"    Several randomized trials of medical therapy after an initial surgical intervention have demonstrated efficacy in preventing the recurrence of clinical stone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 100 patients with calcium stones who had residual stone fragments after SWL, patients randomly allocated to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      were significantly less likely than those given placebo to have growth of residual stone fragments (18 percent versus 58 percent) or to require repeat SWL (18 percent versus 42 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second trial, 90 patients with calcium oxalate stones who underwent SWL (approximately one third of whom had residual stone fragments) were randomly assigned to potassium citrate or no therapy; potassium citrate significantly reduced future clinical stone episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/11\">",
"       11",
"      </a>",
"      ]. The incidence of recurrent clinical stones was also significantly lower among the subset of patients with residual stone fragments (65 versus 78 percent). Similar benefits of potassium citrate were noted in children with residual stone fragments after SWL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After SWL, 70 patients with residual fragments post-SWL (30 with sterile calcium and 40 with struvite stones) were randomly assigned to alkalinization therapy with citrate or to hygienic measures only (such as increased fluid intake and avoidance of excessive intake of dairy products) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/14\">",
"       14",
"      </a>",
"      ]. Antibiotics were administered to all patients with infected stones. At one year, alkalinization was associated with a greater likelihood of being stone-free in patients with calcium stones (74 versus 32 percent) and also in patients with struvite stones (86 versus 40 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefits with medical therapy have also been noted in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. One uncontrolled study examined the association of selective medical therapy with active stone formation after SWL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30756/abstract/5\">",
"     5",
"    </a>",
"    ]. A full metabolic evaluation was performed in 80 patients (31 who were stone-free after SWL and 49 who had residual stone fragments). Although initially prescribed to all patients, only 55 chose to remain on appropriate medical therapy to prevent stones for more than four months. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with residual stone fragments less than 5 mm in diameter, active stone growth was significantly greater among those who had discontinued their medical therapy (55 versus 16 percent).",
"     </li>",
"     <li>",
"      Among those with residual stone fragments, the decline in stone formation rate (SFR) was significantly greater in those continuing with medical therapy (from 1.17",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year pre-SWL to 0.00",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year post-SWL) compared with those who did not continue medical therapy (from 1.33",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year pre-SWL to 0.77",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year post-SWL).",
"     </li>",
"     <li>",
"      In fragment-free patients, medical therapy after shock wave lithotripsy was associated with a significantly reduced SFR from 0.67",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year pre-SWL to 0.00",
"      <span class=\"nowrap\">",
"       stones/patient",
"      </span>",
"      per year post-SWL. The change in those not taking medical therapy was not significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of residual calculi following shock wave lithotripsy (SWL) or percutaneous nephrolithotomy (PNL) is associated with an increased risk of stone formation or stone growth. As a result, it is not acceptable to use the term \"clinically insignificant stone fragments\" since residual fragments may act as a nidus for further stone growth. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of residual stone fragments after stone removal increases the risk for future clinical stone disease. Thus, all attempts to render a patient completely stone-free should be made. To limit morbidity resulting from undiagnosed residual stone fragments, it is important to properly image patients two to three months following their stone removal procedures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Residual fragments following stone removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Underlying metabolic predispositions to stone formation persist after surgical procedures to remove stones; thus, the likelihood of recurrent disease among patients with residual calculi after SWL or PNL is inextricably linked to whether appropriate medical therapy is initiated (eg, thiazide diuretic and low salt diet for hypercalciuria,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or potassium citrate for hyperuricosuria, and potassium citrate for hypocitraturia). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several cohort studies and randomized trials in patients who have undergone SWL or PNL have shown that medical therapy is associated with a lower risk of new clinical stone disease. Thus, in patients with or without residual stone fragments who have undergone stone removal procedures, it would be reasonable to perform a metabolic evaluation followed by targeted medical therapy to ameliorate risk factors for recurrent stones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\", section on 'The complete metabolic evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/1\">",
"      Beck EM, Riehle RA Jr. The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol 1991; 145:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/2\">",
"      Zanetti G, Seveso M, Montanari E, et al. Renal stone fragments following shock wave lithotripsy. J Urol 1997; 158:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/3\">",
"      Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol 1995; 153:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/4\">",
"      Osman MM, Alfano Y, Kamp S, et al. 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. Eur Urol 2005; 47:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/5\">",
"      Fine JK, Pak CY, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 1995; 153:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/6\">",
"      Streem SB, Yost A, Mascha E. Clinical implications of clinically insignificant store fragments after extracorporeal shock wave lithotripsy. J Urol 1996; 155:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/7\">",
"      Sumino Y, Mimata H, Tasaki Y, et al. Predictors of lower pole renal stone clearance after extracorporeal shock wave lithotripsy. J Urol 2002; 168:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/8\">",
"      Poulakis V, Dahm P, Witzsch U, et al. Prediction of lower pole stone clearance after shock wave lithotripsy using an artificial neural network. J Urol 2003; 169:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/9\">",
"      Raman JD, Bagrodia A, Gupta A, et al. Natural history of residual fragments following percutaneous nephrostolithotomy. J Urol 2009; 181:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/10\">",
"      Weizer AZ, Auge BK, Silverstein AD, et al. Routine postoperative imaging is important after ureteroscopic stone manipulation. J Urol 2002; 168:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/11\">",
"      Soyg&uuml;r T, Akbay A, K&uuml;peli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol 2002; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/12\">",
"      Arrabal-Mart&iacute;n M, Fern&aacute;ndez-Rodr&iacute;guez A, Arrabal-Polo MA, et al. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology 2006; 68:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/13\">",
"      Sarica K, Erturhan S, Yurtseven C, Yagci F. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. J Endourol 2006; 20:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/14\">",
"      Cicerello E, Merlo F, Gambaro G, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 1994; 151:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30756/abstract/15\">",
"      Kang DE, Maloney MM, Haleblian GE, et al. Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. J Urol 2007; 177:1785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7364 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30756=[""].join("\n");
var outline_f30_2_30756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESIDUAL FRAGMENTS FOLLOWING STONE REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40231?source=related_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30757="Ethambutol: An overview";
var content_f30_2_30757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ethambutol: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30757/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/2/30757/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also used as part of a combination regimen in the therapy of Mycobacterium avium complex (MAC) infections in patients with or without concomitant infection with human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS), Centers for Disease Control (CDC), and Infectious Disease Society of America (IDSA) statement on the treatment of tuberculosis, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     file://www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    is not completely known. There is evidence that the drug exerts its bacteriostatic activity by virtue of inhibition of arabinosyl transferase, an enzyme that polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organisms with minimal inhibitory concentrations (MICs) exceeding 5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are generally considered resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    . M. tuberculosis resistance to ethambutol is due to random spontaneous genetic mutations, occurring at a rate of approximately 1 in 10(7) organisms; mutations most commonly result in increased production of the enzyme arabinosyl transferase, which overwhelms the inhibitory effects of ethambutol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary (pretreatment) resistance rates of M. tuberculosis to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    vary widely. Although a report from New York City cited primary resistance as high as 14 percent, a global survey performed in 35 countries between 1994 and 1997 found a primary ethambutol resistance rate of 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimicrobial activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    is limited to mycobacteria. Most data regarding the clinical and in vitro activity of ethambutol derive from experience with the drug in patients with tuberculosis. Minimum inhibitory concentrations (MICs) for M. tuberculosis range between 1 and 5",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/5\">",
"     5",
"    </a>",
"    ]. Synergy of ethambutol against M. tuberculosis has been demonstrated in some in vitro models with other antimycobacterial drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and fluoroquinolones.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    has variable activity against nontuberculous mycobacteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. bovis and M. kansasii are usually inhibited by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      concentrations that are easily achievable in the blood",
"     </li>",
"     <li>",
"      Mycobacterium avium complex (MAC) is also generally susceptible, but may require higher concentrations (up to 10",
"      <span class=\"nowrap\">",
"       microgram/mL)",
"      </span>",
"     </li>",
"     <li>",
"      M. fortuitum and M. chelonae are often highly resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    dose is absorbed after oral administration; absorption is not significantly altered by food but is reduced by concomitant ingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    . Peak serum levels after repeated doses of 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    are approximately 4 to 5",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    and occur between two and four hours after administration.",
"   </p>",
"   <p>",
"    Because of its low degree of protein binding (6 to 30 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    undergoes wide distribution. However, cerebrospinal concentrations are low (1 to 2",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    in the absence of inflamed meninges. Ethambutol is partially metabolized in the liver, with 50 to 80 percent of the drug excreted unchanged in the urine and 20 percent in the feces. The serum half-life of 2.5 to 3.6 hours may be prolonged to up to 10 hours in patients with end-stage renal disease, requiring dose adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    tablets are available in strengths of 100 and 400 mg. The dose of ethambutol is dependent upon body weight, frequency of administration, and indication. For the treatment of tuberculosis, the recommended daily dose of ethambutol in children is 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose 1.0 g) or 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice weekly (maximum dose 2.5 g) in combination with other antimycobacterial agents. In order to use whole tablets, weight-based recommendations (based on lean body weight) have been established for adults (",
"    <a class=\"graphic graphic_table graphicRef51663 \" href=\"mobipreview.htm?32/26/33195\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    HIV-infected patients treated for MAC are usually given 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily. HIV-negative patients with MAC pulmonary infection are usually treated with 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for the first two months followed by 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternate antituberculosis regimens with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    include daily therapy for the first two weeks, then two or three times weekly. Ethambutol may be discontinued prior to eight weeks if the organism is susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , but rifampin monoresistant strains may require treatment with INH and ethambutol for 18 months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;No adjustment of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    dose is necessary in patients with hepatic failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with creatinine clearances between 30 and 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the dosing interval for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    should be extended from 24 to 36 hours. A small amount of ethambutol is removed by hemodialysis. Patients with creatinine clearance less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or requiring dialysis should receive a dose of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times weekly by directly-observed therapy. Those requiring hemodialysis should receive the dose after dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since visual acuity and color perception changes are difficult to assess in young patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    is usually avoided in children whose visual acuity cannot be accurately assessed, except in cases of drug resistance or in special situations where the disease is \"adult type\" (ie, upper lobe, cavitating lesions). However, the magnitude of risk posed by ethambutol in this setting is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    is a category B drug, and is generally considered safe during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29096?source=see_link\">",
"     \"Tuberculosis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients may be more susceptible to the side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , especially if they are receiving higher doses. Since renal function declines with age, careful attention should be paid to the need for potential dose adjustment based upon renal function in this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    frequently demonstrate low maximum serum concentrations (observed with a daily dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice weekly or 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    thrice weekly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    is generally well tolerated. Side effects are usually dose-related and are more common when doses exceed 15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Visual changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic",
"    neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    toxicity. The reported incidence of optic neuropathy when ethambutol is taken for more than 2 months is 18 percent in subjects receiving more than 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, 5 to 6 percent with 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, and less than 1 percent with 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/9\">",
"     9",
"    </a>",
"    ]. Optic neuritis is reversible in most patients.",
"   </p>",
"   <p>",
"    Intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    dosing may decrease the risk of ocular toxicity as illustrated in a study of 229 patients treated with ethambutol for pulmonary Mycobacterium avium complex disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of ocular toxicity, confirmed by an ophthalmologist, in those treated with daily ethambutol (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two months, then 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    day) compared to intermittent therapy (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three days a week) was 6 versus 0 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic (neutropenia, thrombocytopenia), gastrointestinal (nausea, vomiting, abdominal pain, hepatotoxicity), central nervous system (headache, dizziness, confusion), and cutaneous reactions occur infrequently, but may be more common in patients receiving concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    , when used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    for the treatment of latent tuberculosis in patients exposed to multidrug-resistant strains has been associated with a high incidence of hepatotoxicity or gastrointestinal intolerance leading to discontinuation of therapy (approximately 60 percent of treated subjects in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30757/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally recommended that patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. All patients should be advised of the side effects associated with ethambutol, most notably those associated with the development of optic neuritis. The need for routine periodic visual acuity testing during therapy is controversial, especially if a dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is chosen, but patients noting changes in their vision should be referred to an ophthalmologist for careful monitoring. In all patients receiving combination therapy for tuberculosis or MAC infections, baseline laboratory studies should be obtained, and repeated in the event of suspected drug-related toxicity.",
"   </p>",
"   <p>",
"    Although serum level monitoring of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    is not routinely performed, it may be useful in cases of severe renal insufficiency or suspected malabsorption (as demonstrated in some HIV-infected patients receiving antituberculous therapy). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'HIV-infected patients'",
"    </a>",
"    above.) If serum drug level monitoring is performed, the proposed therapeutic range two hours post-dose is 2 to 6",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     \"Ethambutol: Drug information\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564659\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis. It is also used as part of a combination regimen in the therapy of Mycobacterium avium complex (MAC) infections in patients with or without concomitant infection with human immunodeficiency virus (HIV). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of action of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      is not completely understood. There is evidence that ethambutol exerts its bacteriostatic activity through inhibition of arabinosyl transferase, an enzyme that plays an important role in mycobacterial cell wall formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organisms with a minimal inhibitory concentration exceeding 5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      are generally considered resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antimicrobial activity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      is limited to mycobacteria. Synergy of ethambutol with other antimycobacterial drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and fluoroquinolones, has been demonstrated in vitro against M. tuberculosis. Ethambutol has variable activity against nontuberculous mycobacteria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      is well absorbed after oral administration. Because of its low degree of protein binding, ethambutol undergoes wide distribution. However, cerebrospinal concentrations are low in the absence of inflamed meninges. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      is dependent upon body weight, frequency of administration, and indication. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No adjustment of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      dose is necessary in patients with hepatic failure. For patients with creatinine clearances between 30 and 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      the dosing interval for ethambutol should be extended from 24 to 36 hours. A small amount of ethambutol is removed by hemodialysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Special populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      is generally considered safe during pregnancy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      toxicity. The reported incidence of optic neuropathy when ethambutol is taken for more than two months increases with higher dosing of the drug. Optic neuritis is reversible in most patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Visual changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is generally recommended that patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lewis ML. Ethambutol. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams &amp; Wilkins, Baltimore 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/2\">",
"      Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/3\">",
"      Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996; 93:11919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/4\">",
"      Pablos-M&eacute;ndez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/5\">",
"      Karlson AG. The in vitro activity of ethambutol (dextro2,2[ethylenediimino]di-1-butanol) against tubercle bacilli and other microorganisms. Am Rev Resp Dis 1961; 83:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/6\">",
"      American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/7\">",
"      Tr&eacute;bucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/8\">",
"      Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/9\">",
"      Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/10\">",
"      Griffith DE, Brown-Elliott BA, Shepherd S, et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005; 172:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30757/abstract/11\">",
"      Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 478 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30757=[""].join("\n");
var outline_f30_2_30757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1564659\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Visual changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564659\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/26/33195\" title=\"table 1\">",
"      Ethambutol weight-based dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=related_link\">",
"      Ethambutol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30758="Bicalutamide: Drug information";
var content_f30_2_30758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bicalutamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/55/12149?source=see_link\">",
"    see \"Bicalutamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Casodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bicalutamide&reg;;",
"     </li>",
"     <li>",
"      Ava-Bicalutamide;",
"     </li>",
"     <li>",
"      Casodex&reg;;",
"     </li>",
"     <li>",
"      CO Bicalutamide;",
"     </li>",
"     <li>",
"      Dom-Bicalutamide;",
"     </li>",
"     <li>",
"      JAMP-Bicalutamide;",
"     </li>",
"     <li>",
"      Mylan-Bicalutamide;",
"     </li>",
"     <li>",
"      Novo-Bicalutamide;",
"     </li>",
"     <li>",
"      PHL-Bicalutamide;",
"     </li>",
"     <li>",
"      PMS-Bicalutamide;",
"     </li>",
"     <li>",
"      PRO-Bicalutamide;",
"     </li>",
"     <li>",
"      ratio-Bicalutamide;",
"     </li>",
"     <li>",
"      Sandoz-Bicalutamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, metastatic:",
"     </b>",
"     Oral: 50 mg once daily (in combination with an LHRH analogue)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, locally-advanced (unlabeled use):",
"     </b>",
"     Oral: 150 mg once daily (as monotherapy) (McLeod, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2649929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F141233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required for mild, moderate, or severe hepatic impairment; use caution with moderate-to-severe impairment. Discontinue if ALT &gt;2 times ULN or patient develops jaundice.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Casodex&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be taken at the same time each day with or without food. Treatment for metastatic cancer should be started concomitantly with an LHRH analogue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic prostate cancer (in combination with an LHRH agonist)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2874022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Monotherapy for locally-advanced prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7999083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Casodex&reg; may be confused with Kapidex [DSC]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Casodex [U.S., Canada, and multiple international markets] may be confused with Capadex brand name for propoxyphene/acetaminophen [Australia, New Zealand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse reaction percentages reported as part of combination regimen with an LHRH analogue unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Pain (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (53%), breast pain (6%; monotherapy [150 mg]: 39% to 85%), gynecomastia (9%; monotherapy [150 mg]: 38% to 73%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Constipation (22%), nausea (15%), diarrhea (12%), abdominal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (21%), hematuria (12%), nocturia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (25%), weakness (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (8%), hypertension (8%), angina pectoris (2% to &lt;5%), cardiac arrest (2% to &lt;5%), CHF (2% to &lt;5%), edema (2% to &lt;5%), MI (2% to &lt;5%), coronary artery disorder (2% to &lt;5%), syncope (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (10%), headache (7%), insomnia (7%), anxiety (5%), depression (4%), chills (2% to &lt;5%), confusion (2% to &lt;5%), fever (2% to &lt;5%), nervousness (2% to &lt;5%), somnolence (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (9%), alopecia (2% to &lt;5%), dry skin (2% to &lt;5%), pruritus (2% to &lt;5%), skin carcinoma (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (6%), dehydration (2% to &lt;5%), gout (2% to &lt;5%), hypercholesterolemia (2% to &lt;5%), libido decreased (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (7%), weight loss (7%), anorexia (6%), flatulence (6%), vomiting (6%), weight gain (5%), dysphagia (2% to &lt;5%), gastrointestinal carcinoma (2% to &lt;5%), melena (2% to &lt;5%), periodontal abscess (2% to &lt;5%), rectal hemorrhage (2% to &lt;5%), xerostomia (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (9%), impotence (7%), polyuria (6%), urinary retention (5%), urinary impairment (5%), urinary incontinence (4%), dysuria (2% to &lt;5%), urinary urgency (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs increased (7%), alkaline phosphatase increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (9%), paresthesia (8%), myasthenia (7%), arthritis (5%), pathological fracture (4%), hypertonia (2% to &lt;5%), leg cramps (2% to &lt;5%), myalgia (2% to &lt;5%), neck pain (2% to &lt;5%), neuropathy (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (2% to &lt;5%), creatinine increased (2% to &lt;5%), hydronephrosis (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (8%), pharyngitis (8%), bronchitis (6%), pneumonia (4%), rhinitis (4%), asthma (2% to &lt;5%), epistaxis (2% to &lt;5%), sinusitis (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (7%), diaphoresis (6%), cyst (2% to &lt;5%), hernia (2% to &lt;5%), herpes zoster (2% to &lt;5%), sepsis (2% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Bilirubin increased, glucose tolerance decreased, hemoglobin decreased, hepatitis, hepatotoxicity, hypersensitivity reactions (including angioneurotic edema and urticaria), interstitial pneumonitis, pulmonary fibrosis, WBC decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bicalutamide or any component of the formulation; use in women, especially women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecomastia: May cause gynecomastia or breast pain at higher (unlabeled) doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis: Rare cases of death or hospitalization due to hepatitis have been reported postmarketing; hepatotoxicity generally occurs within the first 3-4 months of use. Use with caution in moderate-to-severe hepatic dysfunction. Patients should be monitored for signs and symptoms of liver dysfunction; discontinue if patients have jaundice or ALT is &gt;2 times the upper limit of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spermatogenesis: May lead to spermatogenesis inhibition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: When used in combination with LHRH agonists, a loss of glycemic control and decrease in glucose tolerance has been reported in patients with diabetes; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bicalutamide may increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2874397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal studies have demonstrated teratogenicity. Bicalutamide use is contraindicated in women. Androgen receptor inhibition during pregnancy may affect fetal development.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2874023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bicalutamide is not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F141217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F141216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bicalutamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $556.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Casodex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $630.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F141205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodically monitor CBC, ECG, echocardiograms, serum testosterone, luteinizing hormone, and prostate specific antigen (PSA). Liver function tests should be obtained at baseline and repeated regularly during the first 4 months of treatment, and periodically thereafter; monitor for signs and symptoms of liver dysfunction (discontinue if jaundice is noted or ALT is &gt;2 times the upper limit of normal). Monitor blood glucose in patients with diabetes. If initiating bicalutamide in patients who are on warfarin, closely monitor prothrombin time.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bicadex (PH);",
"     </li>",
"     <li>",
"      Bicalan (EE);",
"     </li>",
"     <li>",
"      Bicalox (NZ);",
"     </li>",
"     <li>",
"      Bicalu (KP);",
"     </li>",
"     <li>",
"      Bicalude (KP);",
"     </li>",
"     <li>",
"      Bicaso (KP);",
"     </li>",
"     <li>",
"      Bicloc (EC);",
"     </li>",
"     <li>",
"      Bidrostat (AR);",
"     </li>",
"     <li>",
"      Biprosta (IN);",
"     </li>",
"     <li>",
"      Bypro (TH, TW);",
"     </li>",
"     <li>",
"      Calumid (MY, TH);",
"     </li>",
"     <li>",
"      Calumin (PH);",
"     </li>",
"     <li>",
"      Calutex (AU);",
"     </li>",
"     <li>",
"      Calutide-50 (IN);",
"     </li>",
"     <li>",
"      Calutol (EC);",
"     </li>",
"     <li>",
"      Casobit (KP);",
"     </li>",
"     <li>",
"      Casodex (AR, AT, BB, BD, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IT, JM, JP, KE, KP, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PR, PT, RU, SC, SD, SE, SG, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cosamide (AU);",
"     </li>",
"     <li>",
"      Cosudex (AU, NZ);",
"     </li>",
"     <li>",
"      Lutamidal (CN, PE, PY);",
"     </li>",
"     <li>",
"      Vicalud (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Androgen receptor inhibitor; pure nonsteroidal antiandrogen that binds to androgen receptors; specifically a competitive inhibitor for the binding of dihydrotestosterone and testosterone; prevents testosterone stimulation of cell growth in prostate cancer",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete; unaffected by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; glucuronidation and oxidation of the R (active) enantiomer to inactive metabolites; the S enantiomer is inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Active enantiomer:  ~6 days, ~10  days in severe liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Active enantiomer: ~31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (36%, as inactive metabolites); feces (42%, as unchanged drug and inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Iversen, P, Johansson JE, Lodding P, et al, &ldquo;Bicalutamide (150 mg) Versus Placebo as Immediate Therapy Alone or as Adjuvant to Therapy With Curative Intent for Early Nonmetastatic Prostate Cancer: 5.3 Year Median Followup from the Scandinavian Prostate Cancer Group Study Number 6,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2004, 172(5 Pt 1):1871-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loblaw DA, Virgo KS, Nam R, et al, &ldquo;Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(12):1596-605.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/17404365/pubmed\" id=\"17404365\" target=\"_blank\">",
"        17404365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLeod DG, Iversen P, See WA, et al, &ldquo;Bicalutamide 150 mg Plus Standard Care vs Standard Care Alone for Early Prostate Cancer,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2005, 97(2):247-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/16430622/pubmed\" id=\"16430622\" target=\"_blank\">",
"        16430622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLeod DG, See WA, Klimberg I, et al, &ldquo;The Bicalutamide 150 mg Early Prostate Cancer Program: Findings of the North American Trial at 7.7-Year Median Followup,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2006, 176(1):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/16753373/pubmed\" id=\"16753373\" target=\"_blank\">",
"        16753373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schellhammer P, Sharifi R, Block N, et al, &ldquo;A Controlled Trial of Bicalutamide Versus Flutamide, Each in Combination With Luteinizing Hormone-Releasing Hormone Analogue Therapy, in Patients With Advanced Prostate Cancer. Casodex Combination Study Group.&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 1995, 45(5):745-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/7538237/pubmed\" id=\"7538237\" target=\"_blank\">",
"        7538237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schellhammer PF, Sharifi R, Block NL, et al, &ldquo;Clinical Benefits of Bicalutamide Compared With Flutamide in Combined Androgen Blockade for Patients With Advanced Prostatic Carcinoma: Final Report of a Double-Blind, Randomized, Multicenter Trial. Casodex Combination Study Group,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 1997, 50(3):330-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/2/30758/abstract-text/9301693/pubmed\" id=\"9301693\" target=\"_blank\">",
"        9301693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9154 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30758=[""].join("\n");
var outline_f30_2_30758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141228\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141231\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141232\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649929\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141233\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141207\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141192\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141211\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141210\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874022\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141214\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141196\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298862\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218454\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141203\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874397\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141238\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874023\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141217\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141216\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141205\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141218\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141195\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141213\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/55/12149?source=related_link\">",
"      Bicalutamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30759="Fixed drug eruption histo 3";
var content_f30_2_30759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Intraepidermal CD8+ T cells in fixed drug eruption (FDE)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In situ activation of intraepidermal CD8+ T cells after clinical challenge with the causative drug (immunoperoxidase stain). Numerous intraepidermal CD8+ T cells are seen along the basal layer in the resting FDE lesion before challenge. Three hours after challenge, most of the CD8+ T cells are distributed in the lower half of the epidermis. At 24 hours, the density of CD8+ T cells declines because some undergo apoptosis at the site of extensive epidermal damage.",
"    <br/>",
"    (A) Before.",
"    <br/>",
"    (B) 3 hours.",
"    <br/>",
"    (C) 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30759=[""].join("\n");
var outline_f30_2_30759=null;
var title_f30_2_30760="MRI diabetic amyotrophy";
var content_f30_2_30760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    MRI findings in diabetic lumbar plexopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 569px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI5AfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5n0DRrnXL17azMYkWMyEyEgYBA7A+orem+HmsRIGaWywfSRv/AImqvw9uBba5I5ZVzAyjPf5l4r6q+D3gXwz4m8E3Wr+JILuWVbycO41K5hRUTGPlSQKABntQB8tHwJqwQsz2qgDOC7f/ABNYF9p0tnL5crIW6/Lk/wBK+yfhjoHwn+JlpqMmh6NrKLYyrHLHealdKxDAlWAE7fKcHrg8Hivn34n+HrTSfHWvWOmwOtnb3bwwRvIz7VAHG5iSevc0AeWsuGxkH3BpQhwT6Vdns5EuSroFJ5AXtVRo2BYd160AJ5Z3AAgk+lWG0+dbX7Q+1Y/c81CjnOQMtjuM4ro0gD6ErPl9x4Tpj3oAwFspGgE2V2E479aspo1y0e8GMDGeSf8ACr1tGAUhRDJH/Fnqpqe6ut1z5dtvMarhlA6fjQBh3Onz28CzyBfKY7QwPU1XeJkxuGMjNdR9juNdMNpYAsqfdQkA5rA1O1uLO8lguwPNjOGwc4oAk03RrzUlc2cauEGW+YDFa2neC9Sv4DMklrFGvUyuwx+SmsfSYJri8jht3dHkO35Tgn2rudSvLixmttMiYLGAA6Dkg+5oA6TQf2b/ABfrmmx31hqfh9oJOm64lB/9FVo/8Mr+Of8AoI+Hf/Amb/41X1P8J2iPgfThCysQgDsvQnFT+KPE8enl7a2ljS4A+Z352/QdzQB8o/8ADK/jn/oI+Hf/AAJm/wDjVeffET4Xa34Au44NduNPPmDKyQPIyH2yUFfoH4f1RdQ0e3uZHUMy/Mc8cd6+c/2xVa5tLGZZk8mIAqM/ePtQB8w6pod1p1rDcSmJ4ZRkNGScfXIrMCk9K7jw7cT6lpj6ddh5kcfKMcg9hS3fwt8Vx3DCPSLg2/BWVhhcH3oA4u2tzPPHEHRC7bQznAB96sappV1pl+9ndKBKuOV5Bz0xXs/hL9njxLd79Q1ea2stPgj85WR97ykc7QO1cF8QFuZ9cmW64uvlUKV2bQOBn3oA4pYnaTYo+b0oWJmYrwCPWrLQeXvVslgcbhyBVmGBRpbuGXzWyMDrj1oAzGTbjkZ9qlgtZJwTGV47E0sJLsqllAx/EK0TI1hBtiiyH5Dnn8qAMtoGBYZUkdcGp7PT5LqCWWOWEeXjcrE5x69KhRysgJ6ZyQK0UntoJVltwyAggkH+YoA09N8EahqNkLq2urExltoBd85+m2tT/hV2qBNz6poyH0adwf8A0CsLR9Yexu1TzP3TH53yeB7V0lj4lt4hKHUSw7jtQrlm/GgDM134eapo9vDNNeadPHKpYGCR2wB65UVzukaTPqrSrbNEpjAJ3kjOfTArpNU1176yuYTKsJI+WLccEelR/DrAmviccKnX6mgCi3g/UlHBgb6Mf8KP+EP1LaCHtzntvOf5V9J+GvDngTTvggvjbxhpWp3zJPOs5tL+dXYfbHhTaglRBgbR24HrXV+FPA3w38Ra5q+jnwrrmm6ppQha4gvNTnOFlXchDRXLqeO2c+1AHyCPCOoFtu+2z/vHj9KJ/CGoQxh3kttpOBhm/wDia9P1LT4dM8Sa1aWqkW8GpXlvBG7s52JcSIq7mJJwFAySTxVDVA4tQFiKHumckUAeV3elzWrlZWi3DsCf8KpBCW2gc10HiaTzJldWQheDgc5rEjzJcDGck0ASGxk5+ZD+JqSTTJ0VWJQhumCf8K0ZInaZYwQqjsfWrjshiYMSQpwCvY0Ac5LZyxSpG+A79Bmr02hXMKqZJYAW6Dcc/wAqsTgNqMakBjgbXzWrezxwnbIDNNgDB4AoA5O4tJIJSjYYjuvIqIpj+IVuvbKrqLnKxynAKHO2qN1HHbuVgIkB65GaAKjW7KwG5ST0xTGjIcLuX6g1NNLvG3b070sLHcEVgWJ6+lAEU0DxEZKkEZypoW3kZSwGFHUntVlQNxVxvc557VcljaWxX92VJ4B9aAMgxMHKgZPtTkt3fO3Bx1q2sDInmqx3ZwT6VGizxB3x14IPegCEW7f3k/Oj7M28rvTI+v8AhVvTQfOZjuB+nWpibcu/+sEp4C460AUhYymMyEoF9zQljIzqpaNd3QseK10Z7u2aBk2yA4B9RTLmGdjFGyjcvy7qAKT6PcKR80RB7huP5VE+mzpJsJQt7GteWNWVdpLFOH5+Wm27QGchS25egagDJ/s+beUym4e9Sf2VOY3YNEQvX5ulaIsyzmVpThjkmpoYw6tnKgDbz3oA59bdi2Nyj3OcVbTSZHHE9vn0LH/CnyLtLRPywOeBUDSMjgZZnzxg4wPSgAbTXVSxmgwPRif6VXlgMbEblbjOVzinkjeByMnnniprxQqoQpwVwOelAFCiiigDb8Jx+ZqUh37CkRYN6HctfWnw00nWvEn7O+s6R4euLWHUdQu7i38+6dkRY2ZQ5+VWOSu4DjvXyR4XaNdRYTAbTGRz65Fd14f8Q6lZM2n6V4g1m0h3l9lpfzwJk9TtVwP0oA+qPA/wsv8AwR8QLTU9I1VbzRZNKXT76O7CRzbowBEyLFGqsAFA+Y7uSSWrwH4oW7TfEbxT0Kf2i468qcCtKy1PW0hIuvEXiOR8Z3DWrsY/KSs+a0ZZZZnkllmmYyPNcTNK7MepLMSxP1NAHnWpWzbWkd0UqcI2MEfWuRvXZpyxxu9R3rvfFceyOSaRFKk4GO9eey/f+bOB60ACZCFx64zW9MR/Z9plirsPur1/KsW2jaaaOJejNXQuqm6SRhhkGMdaAHRQRCQAhw2M8d6jUbbhYQgVyCSc4H407JlnlkMhVlGOO4prBJVAzvl/vdKAJbeObT9Xt7nTmYOBkAj5Sa9A1H4eap4s0i21hoorG4kOGBG1ZB6gVxvkMbFZ3khjCrwN/U1o6Xr/AIn1O3MR1CdoLYDy4lbCge1AHfJ8KYdH0+HUFurUXCpub5uSfpXIagkFte+eYvNcn5ieMiqWreLbu1sRbsJH1INkuzHKj6VyV9dXs6h/ObLnc4duc+3tQB9ffD3xvp+neFI7fTCwdQGaI87fzrn/ABl4pg1jU1+ypvlA+c7sH/69eDaTrk9tbiKPb867cM3NamgySS3oWRyZX4DZ4AoA+gNN8UxaLolzb3FzGImQbE54avIfjFr8fiCwSW5mjcqAkSIPlBFR6nJFHZNZPcbp1O/eWzXm2rX0Qu3tbmUPAoO1h70AJ4X146TdtehS+wcIoB59fpXYXHxI1vxLYvaXGoTRRj/VrHwFPbNeX7VgnJjkVoiMZPp9Kt6TLClxhE56gk8ZFAHd+BPGHiS01iK3utWvXgilAKySEoB61a+JFxY6rqdxNqLyiechoJCAA2OuCK5ezRtTkldmEeAQcHANQalNLJZRWV+MTWmTEw5BBoAx1RUvZHAxF3y3X61JL5fneWhI3DOAMAe1S6NZy38N7bPtEoXeN1Rxwf6LIl4ZFaIcMBgj2oArQwBTKSqNHnkHrj2NSybyhCF1ix8oanQP5ttvlciFePrUCiedwyAeUh4Ge1AC3FpJBCJ3kx0AwvJpLoq1sjeWu8dTtxWm6i6tzAMeWOmT096xmZnYoZgVU8se+KAI4m4b7pbHAp8U8iQyhFypIJPpUT/KW8tfl9TUkOyNNz8k9waAGTMfMLMmCw711Pw4bFxeqQCGCA5+prlJZXkxvOcDA9q6PwFKI7q5JbA2rxnr1oA+rdC8JX3jb9l4+HtJltYby6urjy3uWZYxs1KRzkqpPRT2rsvh14Ev/D/jPV9blttI0XT7u1jtk0fR3Z4N6nJmYmOMb+o4ToetfO+iT6haaaiWGt67aW+5mW3t9UuIY1LMWYhFcAZYk8dzV86jrZj3DxD4oVf7x1m6/wDjlAFLX1LeL/ETOVKDWNQx6g/a5axNY8u2t2UyNvcfeJrVVYbaE/aGeSeV3kLSys7u7MWZmZskkkk5J71xHi3VA0RVVKkHHHb8aAOP1ZlkJYtyD8uO9VdPVWmG4HjuKhnk8w57/Wr2lja+8gZzgZ6UAXblcncjYI6tS2sjs4TqjHnjrTBFI7uVGJP7lW7SHP7xnEZHy4Pc0ARw2rSakH3jYn8APWrWoW/mTNID8wOOKdHE1tP5hB+b2rXPkx2MslwNqtgbj2NAHM3CF5clsA9AelVgyJcsZyFQj5WU8H61cu7dZW2xxsVJ6qetekfDHwbpzF7rxBYRi1iww+0H7x/woA8giSIuynfLIx6IMgCrCWk4bC2b7ezYxX2Do154Ht1SOPwzbtN0Bt0DJ/jXXS6F4b1Gzjng0KASn+Hy/wClAHxDpejagzkwabO2R3B/OtCPwzrEsbSpHtRT/FX1zq1vBpsDSQ2MNrgbQdoyR3rjdYjgu5f9HkgTIBWLbgg0AfPUfgrxDfwbrW2eSPPzFUPFdNp/wi8YX1h5r2Kx2xGVd/l/nXvljp19LDETqtpZxkAfvlC/jUmr2kY0qWK78b2jqDhUU5H86APmjWPh5remWZnlntiVOMbuRWEunT28iGcRkg5PljJr0XxLPaRyzQ/2pJcANwyjgCue0+8tvJlidN8hJ2Opwce9AGJqtk9nEk3Hz85UVnzo06De7bx029q3dWtLuWGJg3mRYyUDbitY1w0jRuq7VU8e60AV0DRRYAw7HlT3qIW7QnfIyqc5D46e1WoraWSIui/dHGepNQm1aSQvI24AfMOwNAFiFykJy4IPIOP5VGuFbluoydw6VHHCdoGC4I4A/hqKRxExwhDnj5uhoATUYzG8cquSjrjkVnHO9yoIHUHFbbwmXTyYAPMQ5YHqPpWVOS3lmI7iPlK+9AENvEZZOenrUl2rZOR8qjAI71MIZEVeqMDlgab5O6GdixxgsMmgDOooooAuaZL5Vzvxk7TxW94cZpdTRhksTjg85rmYXKFtvBIxXXeDUMV0J3BaL7pIxkGgD1bTGAg+yqPMZuzdQfrRfrcm1nNv5TlB/qyMY+hqzYvFFaicfPKBx8vJrE8Ua0bCxcW+5Z5shty9B9KAPO/FGoG6iwJCWU/MMdK5NyWbJPbvWpeS+aJsY4zk9KywNihwVPpnmgC3pMQlu1Lbgqc/L1zWnOAGa5DHJ4yBjH1pujRtDp8spXh/4u9WYcNGItoLS9RjOKAIrWL7SiMmWySMjgVZCCNtsLoSDlsCpPspihFvA4EigkHsKctowtgVXLjl2BxQBU1MvfzxW8O4wgDgL1+tehaDYxaJbRT2e5/k+dXHB/CuR8PC3u7iVxtHlkA+xrZ1XxE1qJRIQI9uxSOooAh1ua21q7lllggjkTjzUOPzFcvfaXNdTmTzYkycBh0IqaS7CxeYI/MV+QR6+9Z5uikqXM2XweMDAFAGvD4fuwbeUXML7uPl5/Ouv0XQriFtytulIwozkCuP0/Vkkuo4jG6g9MdK6vT9SMcZCFmkAOSQcD6UAXdX8OTxsRK4WXbk45/WuL1nw9DH+8MmV/ib39q6pNevZYzFNBLluQSMtVDW9O1q6gWS1tCikclxnmgDmLnT7GGJB9mdnPGV6VBc+TbhAkOMHkY6iqU9zqCTBZmcSI3zJ0rai1TTLm1VL12t5D12ruoAjbUPsqokduVjcg+pNS62rXVws2SQFALBcYrd0HWI7MCWziimWNSqjarEn15qoNZk1vz1v4VjnDYAVcAe5oA5qO5lg1KNox5p3De2K2dRkAkld3CxScbT0P0rJ1mJ7GSNpe7cMnAIqad21RLUFVWFOjEYP1oArW8BEk0DErHjO1h1NMghleV1ClUXjb0z71dlgMF8jyt5gXoD1IqBrr95Ikh8pNxZSvOD2FAFi0UC88iMgAdmH3vasjVbUwagyqVIbkhecexq5dTZkQz5WQ4IKirWsRxmzgltyiSHlmHX8aAOen/d7o8NgHio8lM7Tk46itDUFfy4mcK6diDz+NV0HB/d7s/eA9PagCMlVi+XkN14rT8IsI9R8wsFC4zxms1ExGdwBABwO9XfDWDdsOdxxgA4oA9v05I/Kh2uXLc89xV3fJLuRdoRenGQBVPQEENukcqrJLs4YHpT57wWxkjyFz1f0oA53xfqccWFQ87fvdj7V5XrV/8Aa5flxtHXHQ1q+Mr2R7xojv8AL3blcng/SuYYcZzQAg9TW+lqYrCN3IBYDGOorDhXzHAJPJrfneQW0SspZF6cd6AJF4VWfcpI4I71PbhghzllbnnpVdWV/klZvMPYHGKulGt4G2DOfxxQAkZa5iEchCsjZBHYVflkd7JIEQTFzjnpWZauC3XbKeMMOK25ljTT0liY+Yh/h7+tAHNa1FNpcigsUc87FNXdP8RXaRosklxJgZUbjiqGqJ/aN285uVLrzsY5P0qtHOI7gZYquOVA5zQB3Oj/ABB1XSpMQeWkmeCq9frW3B8Z/G8d7HHbXMIz/fjyB9a8pjka2MskhMjEZXPamNqU7QMrScsOq4A/GgD1HV/it4qvlzezWs+G+VCgwDXNyeLNfu5nlS7O7ow9B7VxiPcGHGQFPIzS20kizFWkVVbgkmgDppdXvpG2T6hLIvXcHJxWZd3lzLMWgvZnhxkgmqIYRNguSOgzxk0yUT7WGdqdQAetAFpLqS4iXY7Fhkbat6OHjm2u2EPDZrHgOJcK5UcZFX7XbJcSKXKsVx9KAOr0CBprpoEmLp/ezjI9Kr69pDWhkYTKmTnZjmoNBv5NMtZykPmFerk81D/ac+p3rzbcseAOwoArafI87O4Xew44NX7h47izJ8uOK4j4+Rev1qhbxC2vWckmbPY8DNSNP5UMkbLySS5P9DQBWuQYpkMLNyMsuMAGo1dnuF85iW/u4/pUsT7kZySyIMjeetNVct52VRgOFPcUAOs8kSZbO4427azJkHnSIowOobHf6VrC7x+9hAUr7VX12zPnpPE2EdQxI65oAy4S6y5ZySODzmrsaLHbXSRkMCjHBHTj1qmsRyjHJx1wOfxq8hKWs4z8rRt19cUAYVFFFAEkQJcAda6zw64jnijL8sfveh965zSYxLclWzgqc4rasH/eOuM4I2gdqAPYNLu4o7RzeyKQoATYOp9688+IN/K93KjkN5gG1geMVdTUBDzIy4x8wJ4Jrhdeu5Lq8YylmH8OT0HtQBVWJ9u52wmPrUMSiR1QZ5PX1q9abP3khO4IvQjjNWdOhQJvYANu4WgD0f4feDtE8ZeFZNL0vWHs/HMbu8dnekLb3cfZY27MB69+2ORydzpt/omsHTdTtJ7TUoDiWGVdrKf6g9iOD2qjexPask8Lskm7cCDtZSOQQR0+tet6J440vxppFnonxQEnnKvl2PiOED7RbHsJsfeX1P5j+KgDzUwgXYaT5VXq2ec003skKSLGB5T5BbGc13/iz4a6/o5aOO0/tO0MDXMOoWa74ZolGS+7txzg/hmvNGt5kRII+Wz0z1oA6nwLo6zQ+dKg8qQnK4yT710nifxVp+jRLp1noVneSMmA0ijIPrVfSra80bw4JrgFGaMtGF9K8tn1G7vJ7i7kcBxnHpQBZ/t6U3EkRtIIm3E5A6H2qDT7+G5kli1NnDE/KwA2j6isa2QyynDbWPfNRuSHKkk885HWgD2f4Y6Lbavq0Qs4lljQhS5GQD716H428OJpJjkSHyGTguqfK9Zv7Ntlapq9mpwhHztuPHTp9a+hfiHpAv8ATFKrGYwDnI6cdaAPnPw7bJfXiRxorTZ/iXg17jD8PLW80BFl/dSMhLFeCTXmfw1/d+O4rQQ+YqkgkcgivoTWtZstEtFmv5FigxjLHAoA+APizpC6LrjxqGEodlyfSuHjcKw3Ipz3Ne7ftB2tv4hvZNY0GOGSyB5ePru714PGAd24Z2jpQBLBcy2s3mQExsBjit+wvhptsXZ0kupeu4Z61iWavIXIPCjo1LOnmRE4UuD94UAdrrln9o8KRXFxjA5TyxyfrWBBJIdGIWJVZcBcHp7mr/hS+MumzaeMtK2cFzkAVl5a1nngC7ihwc9KACWNpUG52YoudpPOfrU0PkC0UoBIT8rF+x9qorGzu5lZsg4xV6AQR26WrjarktuHXP1oAgkJQiPb1HJPJ/CnGM3ZAR2wo4wMD8anaCcuEJQovRgcmp7eFltjJGy7kyQB0agChfxmKGMhlIYZZgOFx2rJcurLIpxk4JU1u30y3Gn7hH5cv3TGg6+9Yav8m3GDjhTQA6SPbG+wE59T2qz4bZY7mR2IG0DGfxqKFRNG75O/B+X8KfoUQl88YBbC7c9O9AHp+hawI7YtM2HUYCg/yrN1zX0kdUjfYzHDN1Jrlprk2J2Mx3PxuHSqFxc+ZqEBiG5VIBA7mgDY8TWTNYecg37SMsDkYrk50A2lejDOK7LX71lsBbR7kSQcjHGfeuOQFjhRhwetAFrTYf3qySIQuOD71qTMzOJFk2kdx0qtbiRrRiCvmf3T3q5HEiWwcjEg5KnpmgBY4EeRZCc5/jHrV8sFtXVmHJA96pKWd0DdV+YccVfstJudQnC26IZXb75OAooAbpOkPf6lFaRbi0h4Pt3rf8QW+j2UX2C0unLRcSt2LdxS2bW+lxzC3kMlzEpDyf3T7ViDRJ9TDyQQzyxA7snqSaAOf1lIraTbA2Mjkev41VtDubbICGAzmtHxRpR02+TzDkBQWQnkVYN3Zy6fLbxRYlcApIw5+lAHPySH7SfOY7SfTqKeWi3ExgMrHCg/wn1pkiyBmfCkDt1q1ZeS0nmSr8+Mjb/hQA69H2ZUS7jLP1BHApsOnySW73DjarHAzx+Vd3a6To+oaC93d65BHPBjZFtyzD0xXK39zbm6EsEjGNDhVI4P4UAUpbY/YgZFdpk/2eMfWq1rE13lVBWQDr610d1rN7qlkYVSC2KjGAu3cK5aZJoHMZLLjrjpQBagtZI3lDKSVOMngV0KaHDbaQNWu9QgLyHatrG2XPvXPF7i4t3dpCyRjCjpmmby9qGkDB0IxigDoNIIuUuIUAUtnap6mqNgPseoiKRMJyGPZateHbryWadkO4Y+bqRWnrdsl5GuqWp+VTtdAOT70AZt1azLLJuCRxhSQ471W0sFMLcksW52kZ/GtPUJ5NQ0tVTc7pgfd5/AVWtUE6FBkXCrtxnH50AR3U8EIkjTDSEZDEcGo7WH7W2H6RgFj1yPSiNUkneFWSTHyj60RTXFjOSQyJgqWA6UAWp/KRMwoAFPXg59qtRwR3KDdsTcvR1zk1RsstvMYf5fmLHBP5VqRXnlQi4klR0A7ryaAORMciXsse4sVJH400NJIJ1kxlI2Jx9Klvp0a5eeMbVLE4HrVZ22tI6jG9Dnb06UAUKKKKANDRZRDe7ihcbSDjt05rXnSOO5Pksw2ck1neG0Z7yYpjKxE8/7y/41v6mqyWoXco29WHFAGTdyzMvnEnYnBx1NZ06mRTPuXbnAWrE0oiRoTIzRsOGHSqsaYcl147YPWgD0Q/C661DwFbeJvCmoxa7AIw2p2VqpE9jJ1IKHllA749wCOa5OxEIQSACUjoG6ip/BPifVvCniAar4fvJLC4jGMLykg7q6nhlPp+VezafZeGfi451DRIbbw546wWn09+LXUD3aM/wufz9QfvUAeP8Az3GZExIuCAuPumprDKwOrFZG/hI7GrXiHTLrw/qN1Y6nbz2d1GcPDIMEH6dx6EcHtTNEgV4VMfzuxyF70AelfDX4xSfD7R5NJk0c6rYSytI5a8ZTHkAFVQgqBx0GMkmsXSdMsNc1yXUNNtpLbS1lMkUc7jcqZztyOuOlZVho8NvFPc6uREqHKRHlnPpj0q1o1zczXbO+Yoc4SIDCqtADfiXrU8sDpEjRlh5UQB4VBXlTSPHbeUwABOfrXp/iq/sprKZSmZA2xV68eorzqeP93g5IPTPWgBljDAYmmmDDZzw2M1Lp1k2oaiywrkdeau+F9HutcuVgtYZWTOGdUJCj3rsLjR4vD1kbdMNcMCWkxjPtQBp/CbU7qy8a2NsLlTbhwHwM49q+3L22TUdJMfQOmRxX5y+FL+e18QxGIr/rByxwc59a+49N8VzQeE4prq4EbrCBvlABJx29aAMLQ2s9B8bR21taRxgnbJMw+bJ/pVX9ou9gfwpNDbyOWyDvXkA15sdXRvFq3k15N5TvkuOT1rtvHWvL/wAIzKlkYpYWUs4nUFsY7GgDwP4aeOINJvpdM1uMXFhd/uyGGQhPGag+JPw9TQlXV9Hn+0aZK+7B6pk5xXD3It7nULkpG1uzOWUdcc16F4O1SLVbb+wtSnmERxjJzk0AeeXdzFJKjeSqDphOM+9OghkyY2yYpPuN2Fe26h8PNOvoSoEboi5R1bac/SuE8SeC5NEtYglyhi3ZJYElaAOV0eKew1ONlwrKw3Z6OtbPi5LaPUIHt8YmAZiOOa3YfCE+raev9nN9ouI04GcGsyTQrmxsBDq8MvngnYSPlB96AMzUIXWJJovuYyWB7fSqdgPKEblw6SMV+YZ4qzvjWyniMmHUZD+nsKr6VM/lMrxGQj7vrQBbvVEdysdpGxX7uc/nmtzSdOjDwxzIzo4Iyi8fnXPtF5t2zAGPC5wP610Oh67bWmkkvbkvDnDbyPmPTigDAvYRGbhSfLeEkgMMZGaxFaOVWYDax4Ab+I1d1m5ku7gzFy277wJ4FZef3pIYDHagCwjiEOdo8xlIJHPapfDkhjW72qDlQOe3WqrS5TbwSFOc8Gr/AIXt1uUvFYkEBSCPqaAILobI2ZTu7D1qpaTRxEvISzdlHb3rotasngjgkG0rLwT6VhahZC3fMbg+woAmvL1bi2jj3NsU9z3rPUDcBv2pn71aFlp5ulIzj5dxpIU3sAkJZVPNAGgsY2R+btwQNpUdadfbgVTIVF5we5psMcktwFEe1T0PYVpPDDaWwm2mbnkgcfrQAWMRnDPOfKjC5GB96rc+qmLT/sllF5ETn55C2WP+FZUchluo5ZiV4+QKePyrZKx3DKihTKxBwBzQArKp05Qi+Y5I6Dmu8n1GXwv4NiKfu5zFndtycnpx2rK0qyWO/s5JF5ByV24HHap/F14deuFCRrbW6DYwbgE0AeTagl9dxNdXO+R5mzvY81f0rRrpbUTysBDjqnJ/GutaztY3toVcsFHznGOat3kcNuHWIDy2+8qmgDzK5IS4O9doAIAJ61SDDYu35Oemea1fEMy3mrkQoFRPlAA6ke9UyDfMQUVGjGMCgCw12qKqsPMXHA6VWWVlcS/KMH0/pUMKN525FJ2HGKtSRS+WzRxEjPXFACaldGchppC7nnA420yzkIlVXYMW4weTVv8AslVjSR3GWHCj1plpZyx3W948gchhQBeljLSxW6hsH+IdKQWpjumM3KqP4ehrb0mA3l5CZwESM5+XpXT3Oh2Ulw2ZAUcZIB6fSgDm9BksRst5ZIRGxO4OuSPxrsLJ9OXSLmE2yyCP5nFuvAX6GueutAgB22cD+UeWlJyKr6fdz2CSqI2kOCGz0I9KAI9QEB2zaMHS3kbBVxhs/SshoZEvZVQnCnccj7341vTT217pxazkEZjxuBH3fpTJGaC3hhxHKzjcsn/16AMFIVieS4mUA9VjPGfpT0ZWY79uSOAx5z9KmuWaZnFw5cN6/wAH0qtAXeQtIxMYGNoHP50ASRKiymETKA4wwUcrVe32wNc2ruQxGAccGppSsQBgjOM/O38Q+tQ38iBhJF80rLwO1AGPeQtCwDrtxyfeoXINsTGpVTwcc5qzfzSSrGzxk4PJJ4qs7FYmRxnIzlRwKAKVFFFAGz4WIGpNuOF8s5HryOK3dSh/dSbsiM8BccYrldNJEshVipCdR9RXVRzl9KMQOS4AJf8AnQBjPpzNbeYi5ReOBVOeErZBkBC55zXRi5+zaV5THKk/LjvWDeSpMsUSDCF+StAE2nW5k015F27g+PmHSteyuPstsiq+JyQwlU7ShHTB7H3pgso0slX5gqnOF6mprG2Wd1URYQdS5wBQB7JoPiDT/HmiR6P8TYTJ9mTbZ+IkGJ4PaT++vqfzH8Vcp4y8H3/w7vbeWO3GoW1yN1pqcRzbSA8jBHRsdj+GawtWvAtotokkjxcYAbArd8CeO7vwnZvo2p20ereGbr/X6Xd8rg9TGT9xu/oT6HmgDGeze/fzmlMs7Dc+4ZI+ldfpWjhdO/0h0RHTZvbjb71t3nw/g1C2HiD4fX0uoaE+DNZP/wAfVmf7rDqwHr1/3hzWB4vnsorOKF52WOMcqDj9KAKvxC0bw/pPhu2/sm6S/nl+SSRMko3vTfgt8MpvE1wZdRB+x7sZxjNVPhxoM2vXV3PZwytp8ZzIXPAHrivXdC1mXRbn7Bo7K0SJuYgcD60Aeh2XhPR9L0q40uO3WNETKMi7WB9yOtfLvxu8jTbwWUE26XduIQfrmvQfFHxZn0bULq3mdL1pADGFbIPtXgOr6hJrmvz6hqLr8z8AHhR6CgDGtSI9QgMZBCsGzjmve9S15bnQLWFnd1EYJyehxXjGnxwx3wZXTcrbgreldb/a1ojHfJlD2z0+goAkurt43Ro5MDqR611kt7JqGmgTqwTy+Tjg15ne6rbLeh4t0ij+I8YrZ/4TO2W1jQ+YOwGaAOTvLMDXJHaQFFOcDqPrW74f0p7rU/PtN4kI+RsZG6sme6SS+nlNvL58o4YDium8Dav9huXEqFdvKH3oA6uxl1a1h+yXShbhfmDEHNYWsy6rJdtDeXWN2M7SP0rqrjW7jWXdIZ2mZRgqsYH61av/AAhLcaGtzaWMzXbjLhXyw/CgDzqexvLORI7m7kQykGOZSVYj0JFdZdQXJ0m2t7qSWeJkyJCucH3Ncrf/AGizDWd6swz/ABSnlfpXWfDDXLh7mLSdSt1uLRGLq+Mgj0NAHE+IdLs7Z4UtQdpH7wN1zVGVVjnhcEogGCuOVNd/8SNCtxr0cNk2DcZkEe4Hb6YrzWaCdJXt5I/3+/BLtz+FAFiKdmLvC+AuQxZcEe9UA2+JlciYHO7BxzV+WBXhjCuuEOCCcNn+tVG8rz2lgAAXgg9zQBQaYQ23lk5OeUJyRVNGgMi7lAOeO9Pu4kimLbuXOcGoUwWddgwPfmgCWRFR5WZRkghfQ1s+ACn26YSnCEKD79axpYvkU/w7CevQ1c8KStDcySDGFKk5/GgDvfFcEYsMRAFkIJ9vpXnM5bcQcE54BrrdW1RnDblBQjgDtXFyHZP5gBYZzQBqW2V3KrEK4xnFXIMrCUQjf64qpY3XnjGMIOoFWMsp/dd+c9TQBb00+WSzISehI/hqe/kjkK4OQBtZcYP1qpaXBjSUyFWyenpUgUyMGTcQ3QkUANskeabYqFkXoQOa6fS7QWhSacFWc/K+OVqloYZEaRmCLztY8c1pPPNBHGzMXj+85bnB9qAN2P7TCZbgZfahbOf1Fc3IHS3kuZbiQyM25UYf0rrfD99Z6rFHNqEjfZwMFQvzDFYGuLJLLPujBgJIiYfeA96AMuKYSQSXL/MI8YT/ABrD1a9aZZZI5liB+8u/JrVj0zzLd3M6quNuAfvGq/h3RI0mMmqRBY1b5Rnlj/hQBzWmw3moj/Q7GadwescZar0vh7WrMFpdJnjDdQyHJr6M+H+u21jZyRW0duuMfKiAY+tdfNO2sKksMUSytgBi3H5UAfH40nWcoUsSpbhRjkfWtVfDPiqfyYBbsN44AXGPrX0n4q0n7MUa2urRbgjLEYyD9K4bUZNSa4SQarbwEDDl8ZI+lAHks/grxGq8qS6t0xVyLwdrC2v76cjPLKeDiu51e8tZg8V14gCFVGzAxurA1rWgIAlrqTXE6KAFIAXHrQBgvomox3Ma2EvzYxhiMGr8lrrVs2y48tVjAwzDBPsBWZb3FyL0Ty8FujA459q3JtbvYWQXEguOCAJcE49KAL+m3N+lp5S281w0jffVCQB+FYeoadPClxNDcMXXgxSLgk+1ek/Dn4t6N4agkgvtEkkkCkM6uCoPtmuQ8d67Z668l/BcW8Ls5fy8YYL6YoA5LQLNprsws/lXknysvsfWptdt7nSw1uC7CJsHccqc+lN8HM1z4o0+W3BKPKoZweetd58bdI+zatEbaMN5i5Zc4yPpQB5/ewRQpG7AMWUE/Nx9KhEsMEfygJA4wy9Tn1FQWpKXCmaE72P3C3QVcvYiHdbZA7N0yvb60AZio0W1Cx2Md2WPao7mXz5XjVlSPGQCOlOkUxsY2j3MvHy8kfWrMCxYYMBtxwe9AGLdsfJKSJtXoG7motyCKRcHfs9c1PqRMkqonzxLzuHeoXZBHK0YyHXH0oAzqKKKAL2kyeVcs+FOE/i6dRWreXeTGFdQX5K461hWq75NpGQRV0pkuGDYQUAXbyb95DGu0so+72X6Vn3DCW6QKcgf3eOadcMdqvjgDbgd/wAagtCDeJtXgnGCaAOnZGXZKzAZGM9c/hU4uYt6xMrszLyoHaoLcxlnWXhR90jpmnyozS7yMqeBzigCwkfkQMVkzE3XdyRS2Fv9qlRZAWyw2nrmnXCiNFAzJJt4TG3Ht71teH7ULN9pAcTIM+WRwKAPQ/AN3caDdx3ljcSW7R/Jnsw7qR3Hsa7L4sX3gjxN4RvbXTbzSY/FSYu1iMZjM0gXDICR3GcDPXFcXKzLpwQZeR13OB2P1qr4A+HmpXuoTajLvSE8/vOCx7AUAdF4Qs00jwQbKxcRXtwm6fjAHsKxNaF3aWQW1YlmUruwRj6163r/AIcttH8LrLfyRw3KpvYn7w+nrXgetePZ44LuLdujJ2CfZzt+lAHB3+67ut1w4Vg+xdq/rmjT9A0+587zJ5xCjgOxwqj8aydc1WN5dtnj5hkn3qjp13NvbMjMW/hOdo9zQB6bdeEvDQjQx3qo3GHMmcinXHhvw3E0LT3sqR452HcW964K31K6Egi2bvm4HGDWncX83mEBYwhGNp4xQB1N3oXhO0vUlH2iaOVf3aqu7n39KgurPw/EkkC6eyup3b2xgVys17diBwrxiNjgKDyKZDa3F3bSvcTsYxjIHXPvQB0V9caelofI8sRDAGRkg1n6HqmmW8l1M8HnSZB4OPyp2naUnlxkWiyRA/M7PnH0FVvFM9pZy+TbIkZcggKvCn60AdX4R8e2S3NxC5SGNjlBKoUfia9APiewgtxdTanDsC7TFby/M4PavntIGkmK3SxYbAIjHP1zXWaTo506KW80+Vp1gAZxjfs+tAGt4v1K31W+zaqVjZcIr9vcnvXQ/BOyl1CTULLiSRYmLPjlV9hXmGo6rfa0mVkR2R/lONuPYYr1bwPbav4R0KHxo8QSPd5MiPwZAfX2oA4HxRczaN4xijuY3Y2uSpZ8EjtUt9Y2mvAX9hIVuEG6SMc7/cU3xleweIZLu5EKeZcMWVx1Q+n0rntLlNrYRmNQJUOGC5BHvQAy+iVZd6KSyn5hIMBfyqncOixlUYMrdcLyPfNb6XMgBby0licfMZBhal03wz/bV01vprILpoTIFlbaHA7Keh+lAHHXnlIsaH59wznNVv3hJCghgOPcVpa3pN9ptwiajYzW8p+6si7dwHcVFbW/mhWcrHGOSSc59sUAV0Y+URISJQp+XOARTNNuGgWbb0YDP4ZqWXbI0hVCBgkE1WtASkuCM4HWgDRa5a5SMA9uRVG4JK4Qgp6U8HEf7nBKj5jio5yZ2XAG/HIFAFvTECwSNJ0PGO9a9svl2TNkHJ6Hgis9AFjhjVSo7jPetR12xJEhyTyWagCOCJXX95HhexJ4NPjVW5eZlVeFxwPpQlvLFII1YHud3Sr9nFIpVlAmw2G44FAGrZo0toHZo3VDzt/h+taX2OS6MYhzhyFwAcGsWSb7PlUYoz9scE16b4L08zrYEyrvkYb2bjaPpQB1Xw28CQXtrJDdRkkf6yQdl9q858eTRaDfX9vYqPKVykcsq5P417nLeQeGYpBaTeZvYFSnRuOa+afjrqRu/EcaQMVD/vGABHPvQByc+oXEdu6wSIZHbJGcjHt6VlQajdrK3zMPTcc81oSXNtZxxwywkSsMs6Hr7YrK1C53Xg+znGBjpQBr6R4i1C2SR1uHBc4KqcA1e/4S3VyDHDeTJF1A3kY/GuahJtgBuTnrxQb0xLMiquCOnp9KANu58R6rMw33k0kIOPmbkfjVaa6a5LmS4Z957MeKw4GfdwScc4J4pwZoyURgSeWPpQBsGNZyZCCUQYBq5Y+TPGoG0uh6t6ViC4aJEEkrAdeO4ogVpEZ4o87Tklf60AdTdXaRtEVliBPBGOv+FQX0UewSrMAxHcZJ+lcqY5JZt3XB78VqvcTebGxYMI1xsOMNQBt+H7FdZmkgLqkaD5piMhT7isnV9Mmsb5oZysiHhZEHBqfwo0Z1Yz3j/ZLMHMgB4q74t1Sy1DU4ItMDLbRnliD89AHoHwJ0XS08QQS6qk3lhC8TlDs3duaf8Zvt0WtCS5imxglSOQRngiszTvFltoOgSGLf5xjZYl3YAPsK5fSvGdwkbnUXN6sh5EzZI9QPagDMl2yX/nxI8m9cMT2PtWza2t5FthmO5Dyv/wBenajY6dqMKT6HL5chOTb+ZxuPYVNZi6fT2NxK8Bgfa6SDLE0AZEkpV5la3itxnHPOfrV2TRLTU4GksrkRvFHu8kcg+vNQ3qqu5yoJPJB4yKoK4gvCvmCOHblecHPpQBjuHijkjVVCD73GD+FU5mMiMV2qirjA61108Fjq+nSBZxHeg4BYZLD0rlL8JBJJbqOVG0kjuPSgDNooooAsWI3SlSSMjGQcdxVsnEkohJKMQGYjJqla5LsNudy4+nvV6FG8pkiMiuDuJxxigCNx9oJEZb5R847DHepbFTCRcryo7moVinmn/dKxZz/dxurZ/sC/cQE2k8aOpMTbDtkAOCV/vAHjigCWzV8m4Y7IzztIyCfSr8eTJlo8rnOc4Iq9pek3qoLeYAjII3pgLS6/cyW7C2jhQY5Z8ct+PagCCBQY5biV9x3feYZx7V0eilkkg2vthcb5AxrnrJFuTGkrSLGeSvb8667TLK7u51srO3aUyqMOnYUAdj8MtKj13WZC8lzPp4kAldhgZ9BX0RbWkej5mkgAtYlxGOMj3rkPhnoMHh3QQs4w6nfJhcbmrn/ip4wnawkYTsiITtjjO0H6+tAHL/H34ghbKSC3YzCUjywB90dxnvXgdkx1qOae6Jjs1HCowGW9CKd4g1a3vLh2vZ52YHgg7gM9hXJ3Cbc/Y5S0BPUnB/GgBbuI298TMm1CSQFPaoIZDl0UHa/bNOZJj8yq7og+9jI9+adDNmJlGFfHX2oA0bGSOGGSVnO9F45/SqkepyjcX2nLZFU3Duu8A7TxxTD8nHU98igDXudRkeFCyhlPC4GDmpTdyx2IEDOJjwxzz+VYzsW2kklepAHAqa5kYpGgUEZyD3b60AdFZa61tZpE2x2Y7mIBySKq6hcDUrgvEMynseoJos9Ugg0i5gm0yOW7YYSVgRs+gqfwxYNc3CbFHmDkerH0oAzpHktmNu8w2R87sc5PrVvStcutL0e4itJGQXB2yuD98elJrtpdJdSNeW5jiZsAY2nPqRWPNE0CeWX3LwWx09qANTRJS1wIFkMCsNzMDxWsdYvbWW4snvpZ4ZV+VWlLKv0FcxE/kOF42FckDnd9fSiWX/SEdojHgZ56Ae1AG1p8xS5NrK5/erxIeAoq5Zu9lcvY3QTeP9XLnlge+e4rn7m4lYLnzGhK9wM/hU9vdzTRRRTbnjiHyPnlfx9KANmRjbJeWyTZjbn514z7VXsdev8ATvLhgmWLYDiVRzj29KjW6JhZbrLknKyY4rKvg8sMX7wuBnJ2YoA7KbxrP4m0m30vxGhZbcHyLtR8/wBG9a4q9bF2cNgAYyBgH04qRYSLQsS3+y+P6VVKSZG4nIIGD/MUASebJKCu88KSG9ahsYw4kJJ+XH9asQo8jyRMArBD8x71FpxCpOx6gDGOtAE6wOiEGQgnqe35VPplhukVwXJ7D1pttLJKoEQMrlgiRquWLHoAO9aOmeda3EklxGyOgKlWGCpzzkdiKAL66agkMksmGxnb2H401dgaTkiTGFb1qD7SJLp185mQDcVI4qvNckRqvRXPykDmgDQtVYyMXYlVGck9K2tCDsjkR4Vz971FYekRsu7fvkEp2he9eg+GNLSO3SS5ikUZIO88H6UAZC6XBdTRTTeZEm/AVhwa9XtEj0ZtPt2CBZE3EgciuOtJbc6nHNMFa2hbCAHhTnvXR6gLzUdag1Jgqoi/u0QfKQPU0AaWpeILeG9tIZCFhEmSm3rXgnxM1L+1PE97e25CIkmyNAvQCut1XxAJvEc9xfoFhgBLZ7H2ry/xBfW+oahcTpIdjNuVQMYoAzLiRpJxJJ988nFPVAZifNQsw7djTY42mmVdu5c5yBVq0t0jRpJoywXuDigCmwKgmdWLH7vNMBLADHP860ruS2uVjCQSRRqPvk5yazGDRscZ9qAHRKWk24JI7Zq1f28luY5CiKGAKhagh+QCRzjOcHPWtmObS2jH2mS53BMoMAgH0PtQBnxQq4Z51IUgEEn+VR2sz28pETfIx55q/q19az21t9njInAIdsfKR24rJjA3kgZXpn0zQBvtJbTwAPkz9mXpipjBbQ6c4QLNMWyGJwVrCTGYo485B5x3rX0W/iile3miDMx2qTQBm3LS4EcjYXrkjgGnwTMkkchdJMdGYcV1s1hBcWuWiTC9WHUtWFd6e9uwgMZQMMjAyB9aAKF1L9suMl9g9B0qTSofMMkEipu7HGM/jVuz0+zKTs1/AsqqMLzyajvLaSzlRoJ0nhZd37vrnuKAEsZmsvPEeXCNu3DtXWSX6eIdDdo5wl5a/PtzzKP8a424b96Nw+R1+hH1qvZXr21xHtcgKf8AvqgDqbeQXlmqzPsAzhm+8D/hVG5tgsBjkdJZPvBm4z+NW4rq2jZj87RS8724ZW/wqjfymWQqhMjEc4HAH1oAxhmCYAAocZ4NLeSxz7mcgSKh7+1S21tFN5zsC2OVweKgvbcKGfCA46enFAGXRRRQBe0lBJcMD12Ej3ORW/aQokD+bKyM57Dr7VzdgwSVi3Tb6+4q6JnSZSjsCM4XPFAHb+G5NLg1uwN6s89r5iieONgHMefmC+hxX21ZWfhfxl4Rt4tLFtNpaJ5du1uAGtiBjA7qw7g/jXwHoEgsba4vJHO8/LGT2NdJ8KvHmseBdel1LT5ybaUg3Vkx/dzj3HY+jDke44oA7L4m+Etb8CeIJH1Ym5024Yi1vI1IjYf3SP4X9u/UZrzpLwalfRoARGp+ZmGQ3tX3H4Y13w58WfBEkptPtOnXGYLq0uk5jcAEqfcZBDA+hFfMnx90iLT/AIt3lrYwrb2kltahI4kwqKE24AH+7QBieGdDMt/emaLzbcEGMA9PYYr2bwro7eH/AAtO7+W2tXsgSFRz5Mf9DXNeDdMXTFe4MUggjQHz/wD63c0/xL41H2CaK1Eonc4jcqOTQB2XxA8SrpOkafpml3JnnkAE7A52t3JNeD/GfWNiWUFvdO9zJzIc/d9q9o8BeEb/AFrTEu9UtlTeCxWQ7Cx7EV86fFLS5bfxJczXHmKQxAU9FA7UAca906GSJv3qvgkEYxUE7Rlx5abVH61J9nd9nlsWkbGFzyTXomi+B4BpVvqOrg7848sDkn6UAcjA1/e2sKXLFLSP7qKoAI/Cs+/iTzFhiQIw+97+9d5r8VtaQmOAoIxzIW4Kj0ArhdRkhikYWsT4bkSyHk/SgCkkpikOzJQcbTS2h3XSFlDKWG4Hpigqkir1Vz1Aok8vYojY8ckgUAdHqsWlzXdpHao1ta7R57Bt2T7CqPimLTl1CNdEkklttgG51wxbvxWVIhRoyHL7hnI7VLbs0s6jaHK8bgegoAntfNlVmbaJIxtVSSGP4Vf0q/ls77JKoXXIK8YP1rIulktbiTa27P8AGP8AGpoZHt7YFtpZ/u7j0FAHsmj6bZ+LPD26+uAbz7oVsNu/Ec1m698Jp7GxkubC/j2RgGQMDge1cr4J1iPQNQNxE0gOz5gX4/CvbbXxvZan4eWCQM8xXhwoKnP980AfPWoWwhugsEZklYbGccI3uKox28jziNladM4wpzj2rtvHGnzQMXtIvLjPLhOhz3zXE2t3LY6lvtrgow4DL6+lAD7mVbh4be2iMRjBVgTn8qoRvLG58pipAKkj0961rm2u4Gju5rVxFId3mMpVWPsapwQCa4kdmK7eQCM59hQBNYS3EyC3LnMfKrgc1aPNtJHNJuUHOBwR7ZrNhlETSOrZHTa3alZgTHJFlIxw2RnJoAv7s2BkhjHyAhQSAQP61Rtrd3VnZyAq7gOpqzMUdIwnySq2DgZUrWnthYSxIMy7Mq+MAUAZFq7fZ57iY8bNikcc471m2oHzEsAQQRz1rUksmaylkbcGUn5UPH1rMtFDB9wyOKAPav2YLjwnp3xAWfxQSuoOFGmSy48iOU5zu9H6bSeOvfFe/wDxr+Ddt4yhk1XQfLs9fUZYfdjux6P6N6N+ft8Vw3H2ZWZY9jr07k19EfBP45y6LZ22m+Nbpp9KdgkF4wJktfQP3ZPfqPcdADwzWbObStUudMvYpbK7t28uaKZdrKff29+9RQWvmRAhi7huFPGfpX3z4i8E+GPFV5Z63f6ZZ317BC32a4IDBldTjPZxzkZzjqK+HbC2Zr+O2WPYFOAw67hwRQBqaFYtLKk8Z2GLjYf4jXX65I+m2UEMdyrT43MmMkE+lS6dZiFoyIRsh5eQdS1UNXtHu70zGRY3dvkD8cfWgCrY2lzqsVrY5VYxJvZ8ckntxXrmkadbyWE8Ud2GkhQKwY42/hXlmk3Uuna0tqjD92C29eBn2rftJLcmd7u/ktQx3kA5Z/rQByvxhsToLMrWrGK5QBXPH1NeOWUAubjy1VQCeMt0rqviF4jl1O/e1gv5ru0U4HmHOPYVg6fbsgQjlm5II5oA11treDZCjr5y5Lj1FZ9zdJMCY4QCnQA8VDrUuwpGHG4/eI64rPtpXWNkjZVz1JoAaXeZyckn09Km8mQFEKHpnryafIiqiMj75MfMAOtWEnumKN9n6D5TzyKAKBBkwAvKdV7fnU8kZuQgQBSONqitK6tb5gkxtCGb/nmOce4qvGl7bSKVtWW4Gc8HIHuKAIrG0fexZcRrnJHJFMvogE3RKFwuDx196uJbapNEDHE8aO2MAfeNWY/DepSAyO4ZV4YL1oAxfJKwRBM+Y5yNp7VeuJ1jWNIFy6D94+evvmrdtoF1HMSyyDd0KnP5+lVXjuoBIHhEsCnBBFAF7TdRlkttgkKSZxnqGHpWtPA91F5TTCJwMkv3NczGyIY5YGWORTlVJ6fhWlHqnnxxrMCJg2dx/ioAydSjkgdYXRS47ocZ+tdHFoS3Ph6TUVmt7dI1wySS4Zm/2RUUlompxyN5X70jKuBjmuVlEyF45nOUJ4J4z7UAXjF5AjuS+5AdpQnOainQvNujULGPmHqDUSObiMRMys2Mrx0pu9wuWYMw4xQBI00xQiRmMX8WRzWjp80i2zC2RTGQQXbuPTFZsU7yr5argn75PpWhDKLfy5ThoyMbQetADbaAhZIun930NOv4oVgkZ3JmKHheQeKe90GaMhAh3FgB0ovds8czRqkf7pnK/h2NAHNUUUUAWbJQ8rAjJ28fXIqdlfzMSMuS30xUWnSrFOzMqt8uAD9RU0mwOZNx3scgn+GgC353m24hz8ufmNVLtjE6GNiAPQ8GhPMVZCMDjjNNgQp9/wCYnsOcUAdto/xB8XaTo8FppviG+tNPiyI7a3cKBk5PIGepJ611XhNNS1a9bWfEF9dT3ToBFJdMZG46DJ7CuB0axSZUJT5evsD616NYXEwijdw9xNEvyRrwuKAOm8Va9PZaTZ2cMhZuWYKMbvrS+GjYWU0Wp6qy+WuGjjb+JvbNcvfKVh+2agNk8nKpnmuf1TWpr66tZJwuIBtjTsKAPVvFPxK1yXVWXSl8m3RflhXDHHrmvBPGmqy311K1y8v2h3JYs2a6C81y6iRxG2XKkuUHUema4B2bUNTAO7532gHnFAG54LtpGu1vJVYpEwZOMhj/AIV2PiPxLNbqGlcrIOFRRhRVW2NnpllHE0jxQqPmPc/SuF1zUTqd8ViGy2U/IO5HqaAGS6hLdyTPLlyehJ/nVU7pI1J3CMnHPSrdpps7O2wsgPHTrW/B4djZInlLSoR9zoQfpQBz0LWkMyHzAVHDD/69STfY0cm2lBjJ6d1Fegw+GLFbHL22C3fHFXo/CGlS2wa6SAoq4UKMMPcmgDzAT2sJMYO6Juhpy3y2sMvlRoz5xuHGBXp1l4A0t5HlxGYmHyHPCe/PWtSDwZ4ftJBE+H43ZJ+8fWgDyFJjdQmC2tJTkZZsd6iNteyQlfs/zDjC4yBXr1zolgzrBHLlowdrngfTis270yLTrNpZTGitwrKM80AeWKwECRJIVlZsFXHT3rq/Cmuw6Qy2moJm0fgshzk+9Pe30q5dUnjO/dgEVg6nYmEuruCu7AUdPzoA9Ynnhez8tpIpNLnXKkcqvsa8q8V6Mum3bzROktq5yjxghQfSrXhjXzpSPYXyFrSXgBW+6fWt/VI1uLc2qujxOm6PByPzoA5ebxjrc2kQaVLeNJp0edkLKDs+hrG+0s8i73O3GBj1pt/BLbztFNjAPGOhpkLNhokUEsev+FAD52XeIiu1M5YnqTVpIY5r2CKBmKgDdnpVG5RkYCTORxgjmtjToXTTGlGETILSFc0AWGnjFwHgAKZ2NHjrTYpNzuCwQjoGGTj0FU4ZdlwSrF2zuUjpTlXMKspLzMxxg85oAe6yNbXDqcJg4Hc1l6cUHmBx1xiuibTrqa1lW1WVzDGfOUjG3jrXO6YFMx3420AaEE4YtJMuI14JNTNOrTW08GAI3DhSAwyDkZU8EexrOuJik+yE5QHJQc0JK0k4Cq25/wCEUAetRfGP4gXMhD+Jp1QDiOO3hTj8ErU8K6VtZby5jEsjfvMMOUJ5zXN+DtDto/IutTQpGeWBb5se1ehwSm+vY7LTImhR+FC8Ej3NAHTaZ4cTUUj8y7kjRn37FIBI9x6VxPxJv9P/ALdW0tzFGtsNqlDkt7mug8YeJrfwRoTW9ovn6zMPLHOSM9ea8BnvJ01Fw4Ju52zI7nOCe1AHo/huyN7cT6i8SPHF8qRuSC59jWR4imK21+7yLb3P8Eec8fWtXQTcL4duTI5KjGB2P0FcX4xuUkSS2iXe+0FiR0+hoA5DT4WkuPOwNoOWzzWjcXrfaMArhVwD6CqsDSRWT7yI0xtO0/Maq2oYzYbGwc4agB9jbSXV6QAMEnlq1odCuI490mzy3PyuSBVP7e0cpkhPyY4wMhauDUpL6SOMlvLAxjGM+9AHT6HoEKRlwqvMBgyAZ49K6ue0g07T8Yi3bQVjZefrXNeEZxbz4nPmoD8qqeD9a3NbWbU5ITaIVVCSxJzx6UAaelPZSWJeeNJGYdRwQaux2enx6ZJfbU+1HgRjuPeuStI5bq+gtIt7Qs2Cfu8fWtzVdOFuXjh8wCAgZVuH+tAF19Rs08qMwqqDDHcAQD7Yqlrmrwy5itUETKctkDkVz91ExvSZJyhOPk7D8akl0yeWYCOXzMjPswoA0rnFh4fuL+aAgvgIoAIPua4qLUYbqBzcLjJ4Uetdp4inA0JLSRlCFeR1Cn0rzuzCxJKp2kkcEdAKALd94eRgLlArZG44rmLuA2srMhdm74/gravJpEsUBuJFQt8p5BFYUksklxIwkJUnG7NAHQ6XqCXFiEDuskB3egNVNfiimAuERvNA+bHQ+5qjDIkWxraRpJAfmzwB/jWvNLDcoHk2qWHzAnvQByyFhIpK/e9OKsOMwsV4VGzgjqaiu4xHcERnIzxSAuWxyUU846UAa/hzSJNTlRVwwbpjqtLchkumsoUAaJiucZ/Oqlu09s5ewmfyc5+RsEVqaJp8t5qxWORyJBlHI5NAGaJZTdZJMpQYIAxg1ZuFmjtpmeQK8kbZVhztxXQX+ltEUS1VC44cZGc+9U7zTv8AiW3c0jqzrCxOD9046e9AHEUUUUATW+NzBm25U4NTeWFVXZuAeg71BbxGV2C9QM1ZlSTyFwBtzggd6AGq2VYhmZm6j0FaWlWJkIIIGeT3IqlDamUhhtjB4IPeup05reKyLW6HenDFxQB0On6fDpNspupvMEnO1DkkHtmug0S/coy28YhjTqT8xIrm7WNWgSa6l2Q43fMcH8KmutSW8tTFassMIXBT+Nh68UAQ+Mtca9nx5gEQGAR1OO1YmlTefOFCuXxkCqGuLtlhS12henPU1peHIpGnkkRQPLGCzNgYoAb4idhaqQwhbBACjr9azvB8aRSyXMqNJOchEHr60a8fMu0G4k54Gc1KkiWUEioArMueBQBQ1++uJZhEzj5T90dvrVC3VYZEByZOuaUys6NKqggHGe9RvNmL5QXz3/u0AdEuokxwoAC4XINa/h/VPtNz5c5AwMFi2MVxdlJ5XGAR1Jbmr1lqAivB5iMyk4BAoA9R1PXfLgggjfMbDYyLzuHrms6S/Mm23RHJbgAt1rGsbiCVAZcj5toJ6Zq9HapaTrK0ykKckk4xQBc1DULpLeG3fb5aH7obG361Tk1mY3hZATkYOOM+1ULvUYTdShyhZjkFegqncXKhm8qQKQQfmH8qANq31SaCTy3ViZDw3UJ7VD41uZLi0ijLjKLnI7U2G6tEfM0mXdcru/vVja5qG47nAJbglTzQBXtN8cKNuYy9QB3qHVLk/KGi5fk4PQ0yK5BhkLsdowBtqrdzoQriRgnTB5NAFYoJzGcHzGPODyBW7pU0qyRRuxhjibIYtnP1Fc4yoBuDkO3QdMVdtZpIvKWNtzMcOTzigDS1+xFzunibLjJPoa51T1YbQR0Brr447m5mEISQxlcA7cZrA1bTP7PmYPKp3rlQOT9KAGW8T3rFmAMiDIGclq1I70/2DLaiAEZ+Yk/MPwrKjZY5YXtcxuq5Lk85966rwtp9v4h1FYpY8XYQlpI+Ff6igDI8P6DNqkgVMxRNy0xOFFb8N1p2iagI9PgW9uVGA0h6N6gVPqOu2dhZvo6IsTW8h2yBfzBFc5FrCGfeqIjA5yBgn6UAa99rGpeVKquEaRWZmCDceOlcLbOEV2wCeOtbV3fTzh1k27MNjB56VV0CJGS7llUPHEoJX164oAiitXkDXKjy4uuWPX6Ve06ZLbM1qgEo6SMu40rW/m26zM+YgcFBxtqS3uVgjQWwyGbDCQZoA9M8OWdxc21tfX00cMI5kZ2Bb6AVf1TxnHp6m10FDCXOWuWwXA9PauJ0ma/1JhbxWsk7tkxw28ZZ2wCTwOTwDVMrLcsCSqJ/dC859zQBf1TWXu2aWVcSAZOTksfWuYsHFxrBmk5dQfmB6VNqch85ni27oxswRyTUXhjTDc3flTSCGVz8pJ6n0oA9MtoDD4MF40z7y23l8HFee6gwlnZww8snkHkmvR/iDbTQaXpdgiBMxDzcHBz9K8wnt/KkMKg8HGetAGVdzBom2D93nCnHU0yMKliJA+HB+43en3u4yGGVQEjPLVFfwGFUwRswMYoAkkkS5hLk7COqqPvGpbUYhLA7SOmapKUUxqC4UnLe9P8AM3uHfKqrcIBQBox313p08DpKVVjuKgdfau90LxTAtsomdPM3g+U/BI9q86eRZggljdSeQc4/SmLMJLhBGPlXqwXJFAHtuoeI7CFVuooljMZG1WIUn2rk9X8TyyXLXFtEYUY8oxzv+lcBe3Bkn8tZC4DAkt/FU895JJN5TFZEi+ZWJxgelAHU3esteSFY1BOOVYfd/GtK18VtY2KuoSXyhj3Arz17uWW8PkNgEYwDxiokkk/eqhAXGMGgDotZ106hF5kSyxknI5rJ+2hZQzPiXbwcZ5qraM81xHFHIBjnB4GfSq12W+0SMV2MD+tAGpLeXVzCqtuIHI3cYrPE7uhGBvc9cYBqd2kMQZ9qjbxk9aqwDzJSTt46KB1oAsRKjQMFATswNaNvGktooEybUPQ96z7e1mmj/dJIVbPQZIq5a6XMim5eI+WOMKCG/KgC1ewQy2p8rkrypJ/MCsZZFAaFOhOfxrWs4nhuTHNC6+aMojjFU9VtYrTUv3ZZk4PHBBoAksjEFIwsXHJHU11Oq340XTNOnslQXLLgEDkVzOnxzGSOWRQsbtxu53Cty/uItQsDEtoEeJuZF5CD6UAY/wDbV3PJ503lq+TkDjfWdfyyTwsZHkIB4XtTpbR/NXehAJyjHjIq4vlSaPdDJEiA8Hnt2oA5uiiigDQ0WMy3MgUZPlk8fUVe+x/ZZMoGkkbnb/dqLwsduou4XdtiJx68ityVPLd7pWyxONg6UAZsNuXkaVy3TJx2rd0W5trS3k8t0Z5B1Zc81km3aObKlgXXOO1XNJtg5WJowT3INADtRlllkIlJfHG1RTRI8cKkggtwABzivofwT8EtP8TfDW21Hz5rPWbl3mhmJLIY84VWT0OM5GDz36V45488La34T8QRabqFjJFcygiF1G6OUeqN0P8AMdwKAOHMM97q/k2qu4j6D3rqdJRtP0Se5uldCzeWysO9QXGNBu7eG02m7YbmdTyD6Gux1DUrPVfDlvb3YjiuyfnIGSx+lAHmtqJZbyaWQADqtVLyZRHINx8xjxk9K7fxR4ZutEsIJ0heSGQZ6YIzXnuoM0kpPkhWA27e496AKzvJHEMfLu649KjTesf8WH4wD1q55ZlsmyMtGBjFUFBOCByO9AFtGC5jjBbPBx0FOnBeNPKOQp/vYNV0RzFJIuAg68063KgbymFU8tQBcF1JCUjjlbacEoBmr13q8uxYguzewBPWsdGjNwTlj3Xtil3+bcFhwB2Pc0AX3uUZkT7pY/Pu9aZ9rRGkjQMz/wB4nIFUwzNKwkIDsOTjpTI5BGzF0O8jnJoAuXd4s9sFJIdcZI7UwN57qjjaqjORUFuyylomKgHkEipIP3E/z4ZH+U0AQb2SQq5O0nkdqlkKiNtgBRhgn3plyGDsB80YP504hijARsoz0UYoAZGv7o4BwR36H6VZhmKooVNrL/EOSKjggaSRYW+Yt7fdrstB8LJqIZY9ikDks1AGRbanfT2xLT/c44GMj0pb+3bULLeq4lXkKK6SDws7SOLmE4i4Cc/N70r6LLp9pNgeZH6KCHTNAHnVuGCsTzg8gnpXafDydbXX4JWmMY+6Sw4wa5qazMV95QUyO7gBAvatT7Wun6qbTbldwDAdj7UAJ4vtY7PxJfLuDxmQvkcjnmsMK5m2tgoSMY44rvvFum2kUkVxMX2NEGZQOp964J51fKxqwUHOT2FAF+VVhV8x7iUI3Ee1ReF42k+1BYzIuF3KPxp5lN5YSkLtZAenHGOtP8HOUe8+YKu1c5/GgDTmtWluSM7IAMEen1rP+xt3UttbgjgV0NvMYopGvGjaKTgo3HHqDUcCRPE8oP7g52x9z+NAHsf7JmhNdeLL7VZtxWwt9qhuzyHAx/wFW/OvYviL8I9G8ViS7slTTdVYlzLEuEmP/TRR3/2hz9a+cPh58Qta8F6NeQeHjZeVcSea73MBd9wGMA7hx/ia6ez+O3jZogZks2Y9NtuF/qaAPLvF/g3U/Ber3CeJ7SS1bcfs5Hzx3Huj9D9Oo7gVX8JadNqF28qR/u1O4HdyK6v4x/FLxLreiw6PqE9o9rcpvlj8mMkEHgg4ypHtWR8IGSSSS1llYK0ZYdzu/wAKANufUWvNXtINVURxLwZG+ZgvsKueOfhudRubebw3NI29NzDA6euKxNZurOHxXbpc75SUMa46V3vh/W1trjw5c6e7i6SUxup5VlHrQB896xoF/pd+9rqUbxTKctvGAw9ar8TwG1AberZBHINe/eNrzw14x8Szma7aO5dyksZA6jj5a8p13Ql0DxGdJs2M6yjcskgxtB6UAcc9rLFK0UqSB4xkKBnP+FRiMC0aTnf9eldNodvbWmsNHfar9nLEq2Uzx9au67YLI4i0yyVEUHMoYSGX3x2oA5S3iItxMJA7/wAKn+Gmx3ciksyp5bcFUHWmrbXN5cmFEAZOoUYApYIomndLyTYsQxlRnJoAbaAvO7lM9+nFDxGGQNgbOufX2qexsZpmcK7+Ug3bkGR+PpSNInyg4bPA/wAaAKiuyOwRtwPPHGKdC7iXzmXeB1z3FSQP5coSYEjfjgVfgsWEkkixEQZxv60AUnjEy+bbnG0jAzyPwp94pnxMqM2RyQOQfep47c5Y2rKUVsF1GM0zS4RNd3EEs00W7kKnO6gCukUbJ/rQGxgKRkZqzYWbzOn2bH3sM5GCKS9tBbsPJQleqd+asadPILuBBuRmOCp6E+9AHongqHT31aK1uF3x9CN23NeqXPgjTLu7S4s1SNAPmt5G4HuK8J0nWJ9I8QxxG3h80ONvG4OK9ng8dW0VwguPMJdQC2zlT6fSgCHXPAtmlsk9yiTZJCvGDuSvOPEnw31iG2N1YxR3hUF94Byq/T1r6e8P6XbeK/DCTQ3a5D8SRn7vsabrNrJpIit2heRQdqyKcqR/U0AfH/iW2bQfD2mQSyB76fMrc8ovp7VseCIzFp8kkrwtNNyFbnC+/aui+L/hy7WXW5lUulsyyIrJ8wU9eO1Znw+t4L/w5qlm0LR3RgzFInQ5HT60AcJ4g1GXVdUk8tkSGIlFwMflWWyyIjYYhCjdTndxTUBtWmWQMGjJXHf0q7BbutpIw2+X5DsCcZ+6aAMOiiigDX8MSCLUiWbaChHTryOK65vKSRVERGTnCjnFcl4XAOotuOMRkg4zg5FdUsrrOdxDsf41PSgCa8t8XCHd5qN90IMlR7in2lv9nveG2DH+sXnB+lJZLN9p3sS+7jHQ/hV1IkhlMjkhmGMNxg0AfU2ifF7wLp2nWmm29/cMlpAkW77I6jCgDPIqh4l+MHw91bRrmLUoLu/sl4YfZwCD6qSwIPuMGvmOd7VLN5FniN0TiQP0x7Vj3+qx3GjS20H7lo23FeMN75oA1FOh3vjOf/hGjqE+lSMPJOoBfNVu6kqSCB2PX1rU1q0aCeBBGFkMuGZiAMe1cj8OVkn1tGGAEbcx9K6/xuk93MV2kRiQBWB5P4UAdLHdTSaSrXm24t4JQjgnJxWT4/8AC9nd3cd1o8bCIoMnIyWPtT9M0bUJ7WKOWKVILi4ROTjgd6w/FtzeaX4xntjcNCnmiNEB4I9aAOKu9Lu7G/eLUkMOfunH3/wqC3tDcaiqNaSMn3f3Qxn613/xPtobFtEvDL5m5cbSMnd/hXIa3dBdVia3naJwASEbHNAFXU9LFhFseVSzdI1OWT6isrztkQjRt6DqGFara0st3m8hSc9PlGGb8auWVtpAuzJPLLEGQlFYbhu9KAOcVXnIjiXcVG4jHSlgLb2KRFnH3vat+bw7dyA3GlyLdLJ99YztZfwqvbxta2t59rt5jcKuFYjaB9aAM+dWk2HhTjqOpqOC3NwRkkyHg7qh3MFjLZ45we9WJGhESSwtI0obgY4FACQ2xeN04JH93qDT0U+X5cuW98fzrZ0+2kv7UKsKpdNnDA4zVfT4QZJbW7lTzFyMqc8+9AGfAst1bYigy4OPMzwKjfcrKjsduMH61cs/LtbyeDccPwrZ+XNN1SGSK5UXEAAYfeB4PvQBZ0+SONiuNroOHPOa7TwJe2y3hjedmD8gAdT9a5BY4tOhS4jkWR5FxhjwKteC7WWbVpyVCRBd28thVHtQB7VBeQyRqfNLkHGB1HtWpfaNI97DcPA/ksoJlU4I9iK8isJnWWa5spZkkRiUJO7dj2r6S+F+sReJ/BzXBYR3MSFZYjglyPUHpQB5n4p0SxW1Nzbwqbq1Hmh0xkj/AGq8Kvozb+JI5ix3St5oMi9Mmvpm9hhFxfyy2RigMbKQWxtOP1ryrx34fgOlaJqcYYSsjo3HXB44oAyfinFdWujaUJCGjuBvLbs544Arz+QkeUUwc8n6V6Z4yit5/hVpF06uC03lrvPKkZzivNYwsLiTcplHG0jORQBtaXpz3OnXTxudqoxY47YrP8LFALzdHvO1cAHnv0rQa+NpobRFsXEyHKLxtX3qh4Sx5tz8hLgKVPp1oA6CG3ZrEPMGK/3W5K1ctLMmxMkR2Rg52EdapxGSS4dFkIDj5sDOK2YrG782GztSxkmdUUf3iSAB+ZoApNHLHEpiiGwHKjPGao6xrx8oSNbmG6HyF0J4P0r2bxz8Hdf8NTLd2U39qaTgNI6JtaDjksg6jr8w/ECvD/Gs8EmopDZldo7D+I+tAGT4h1CTUEt2uCrzquNw64969J+EVgI9NlvpF2ucx5b6dq8mtYWe98oKpbk17X8NrOVvC9+SgYHJQqcEEe1AGPHYQXviKBYpJABIUaSQZIJr1Pwhp2iwa9b20GpR3NxaQurRtwTIR2rgfCGrxWH9r/u/M3Rks0i5KH1FcPPrctncpcWNwy3O/eHbrQBsW2g31p8RZA8ShYJGkck4IGc074naimr+LLW40+DIhiH2idF4OKzo/E8ryNd3jiSYn94Txv8AxqPxL4uhvYbW0022WzyMTOFxu/8ArUAcpcXRutUkuIYj5RyBx2qK3vrm1uy0U5hY9WU5xXQ6d4UvtQlSMXEaQOcs6jgCuzT4Qf6Iu64kDPypcAZHrQBx1j4lubecuiWtwJk2uZUHHvmrQtdH1iJZbuFtOkT700X3W+orsNK+FNm8ipeXkkcOcN5Y3bq9AsPgx4WvoEsbLXbqHUHBIZ1DImPUUAeACD7BaXgs9QD28gI4XbvrBs7CW6jVYyhBPUnAU/Wum+I+ijQtSuLBdTgvUt5jHuhxh8dwK5R2aBMRlwrc+xoA0ZkuBHJZStCsiEZZcHj61p+HBEjm1uJSyOcuQTgD1rnEuCqBmBfs2e9Xrl52s451kjG3hdpwQKALqy2tprskOmjMXJDud2/8KoX1/wCVqYuLZDDtGAuOvrUDJJaILhjGJX5Xac1qWGh/2vptxqJk8ryeZN3Q0AaV74cvbzQm1S3jkhSNfMcMeCPUVg2t0PsjIqhpV+bdnk1758PNKj8RfBW/h+3xxSw70IPVlHQCvnyKB0kkhWJj8xUtn0oA2vC1i+p6nbzCRkeNslS3JHtXR3XiXd4kMJVkt4xsWPAOcdc1w1m81lcu5kaMqOB/eresLmzbybqch7pjxzgL9aAPbvhf40XwB4jjh1qRv7H1YAxJGMLEx9Qa9R8SarYa34jit7O/cBBvMQXAU+oNfLnivWNO1ZNPtN7Rzwcvlfkz9TUvhjxtf2WpRPe3YNsvyrIB0/rQB7wijW9Y1+O4xm4smiVZRguVrzr4W6dcW3jC7ikhcWslo+YgmBvA969V+GWsaRrtxbG6MMlxFlhKGyT9R2qvp2iPrniDVbywguQ1hI4EwyBJnOAB3oA+Sb4OdUuzLHtmSZ1Mbnk896URpZWV1c3BQySRtBHCCcruHWuzbwZqNn4lu9Q8QxSWdoZXdpZl+VhXGeJL+1vLqQadHttYgVVv73vQBzlFFFAGz4VXdqTgFQfLPLdOorq0dbWXzFRXfo5x1rlfCys19NtGSIScfiK6wQlrbzpf3YH8HrQBa0u4aG7NwYiqdsjrW9ZRT6w0/wBi024umWNppEjTeY0GMv8AQZFZMbD+zwypwfmyx6V79+yppbSWes67Io2yMlnAfZfmf9WX8qAPmzxRYJb2C3QPysCAoHX3rjI5Cv7rcBG3YjJr7j+MvwUsfHFs91o040vWQMjj9xN7Oo+6f9ofiDXxz4x8J6t4S1kaZr9lLaXS8opXKyL/AHlbow9xQBvfC2BF1R0XaC6Y3kd66SC3S/8AE5ivnaGBvlMi88iqvw6VbNpby5jfY64UKuRVS9v4f+EpluIVcoeQijBz64oA17rxRe6d4gEkM0n2WzIRUPRwO5FUPEWt2+veIl1WO2UEdUZeM+prlEjl1HXXtFaZEZizSdcVC0U8dtdvDNl48jcTgAUAdZ4pTTxpNve392t5PnbFCP4fpXm4izcsUgmllZvlG09adLm9SPyHZpYxlyxwPwr0b4aWrarKkcio00fJf/D3oA4ceGdYliaRrN1ZcYGMYq5p/hXXp2RYbV5pD0A/h+te6/bbeBVijs9rJw2V+Yn3p2kzC6dmgT7rfMR8u2gDze28AeMrXTjPDpM3zHGYSC5+grivEUt7ZE208U6TbsSGYfNn0Ir6ITxo+h300q3RM9sjGONuQpxXzn4s1rUvEN5dahqDhzLM0jFR1OaAM+1ujagPJGrMD94gH8MU4XG+WR8hS5yOOB9Kz5SrRIxHzc5IPWpbKD7SSgyMchhQBrR6s1i5aLcQ64BYcqfaqFlKVlmmn3FZcg8YyasqVuIGEshTyfu8Zyaz7y4aWQfMMLx8vGfwoAna1uFnSbySYdwIOMjFeqfEXQjb+ANOvbWzdY5dsvm44UY5Ga4K81WODw3b2MAZHLbmccmu3vfH/wDaXwvj0WU5hhHl4YfNn29qAPLmdvsyq7LJnkiuh0LWDDpc8JjADrsVsfyrKtoojYyTwLHIU4dScHFURJI3EY2YO4KT0oA9A8A262+uwLfupjkbKAnlT7ite41uXwj441aWylkNlKCkioOOe49K8/s9SdLgEz/vm+U5H5c1BOuoR3Biy37whmBO4mgD3Lwz4ltdY0h7eZ5ZIpJAC0h5H1NddrPhdZPBRa5mWa0gmDQFT9zPqfSvmWx1S60u5dl86Iqfm2fd/LvX058LETxr4YTTL6+C20ib5WVupHRRQB5n8RLZrL4Zx2ktrGVS63QSIcjnvXn2m6TNNpZ1C6IhWNsb3Xj8K+t/i4nhPw94GsF1KwS4EbLGkAYbyO5xXyX8QtUju76OLTt9vorfNHEDx+PvQBz9wxne4uN5d2B96seEoRLLcZk2BdpPHuapXC/ZJVJT5WQhTn1Fbnw+tmuZb7a6qERS2e454oA6WNS90rWwURR/ex/F9K7b4VW1rffE3RTfTxwW1tI11K1w4RRsGVGT33bfyrkLq2B2tEzCNeSCcVR1a8e4lBkMRSLGETqfqaAPum78ZeGbT/j68QaTF/v3cY/rXz58YPDXws8S3E2p6F4u0HStdbl0Fwpt7g/7QXOw/wC0v4g14hdazbSh1d9pZcFpBkD6VxaNm6YQgyu7YAHegDYsNMnm1mO2iVCWk8tPL5HXGd3pXs9tbXeh6JNbRTW6mP5SjfezXB+DdG1xNQtm/s+SCFmDCRxgZHoTXefFqS2stCEr+VFqVwyxlSe/rQBxmhWep38OqT2sTfZ0JWVtvysT2rMtNJfSF1OfWlG/y/lQrnbnpXsVh4w0Lwl8NrewNurXIXzJQCCJXPc14+nimHWW1FdQj2PO/wApbnA9AKAMa+tEk8Mm+2Fo0k2rzgf/AF6xowt9ayT3QJdCFXbwMVf1rUVFudPtkby0bIGOKz5HWysjb7t7yYY4/hNAHpXwo1bSYHMWqXBiYArEzj5V9zXdwao1wJHjvBIqZG8D7w9hXzrpLP5zYXzFxzk9PcVo2Oq3dtd/6O8uUH97gfWgD6Q8PrLcWb3M+/5T8qR9SPWuP17xi+mPfscLEyFVb+M5rA0TxpJdRLGHeK6Vdm5Pu1i6xqUF1FJBdqkucgEDBJoA497YXtrJdK2XZySpOSKoywzJZRs6MIySASOK0IoZrAgq6qZGIIPK49Kg1A3BTZJIDGDwgOcUAM0tFBeaUgQrgHjNXrKcCWdl8t4wp27hkD8KtppX/FPGXOGbGwDnd9aybe3kgkMvlHpgAc0AVrzcXD7UCdAB0rYiu76Hw6Yoo5Vt5DtJ2/KxrMk3yyrGIWBJ+RF5ya7/AMRahFpngqx06ARrdv8APKVO4D/A0Ac94e1+/wBL0+5t1kJgxkJGeje9UNOu8zSfaoi0UgOWj4OazYBvmeRAxjHJHqadDI0ZnaFFGD90t0oAdODG2XkaRSce+PrUkbeWxjiVWJ4O+o5Vd7YSM4DMdzKRT9rzqHXaYc/MT1BoA2rfSDrFpE0AdpXcIQT8oNb1/wDDPXtP01r6GNfJhAMu1gWx6gelUvDGsxWISKZVhtM7t+ea9pj1rRoNOl8nUPOMsG5UR+enQmgDzD4PeLYdG8QmLUSxjuTtEyDgAdjX1Unxc8I22lmTTp1ln2kJaRKAzMPWviudIrfVHlZjHE0heN4juAOehp1jM/2y43SeXKrZSRTyaAOs8f8Ai/WNftryDWJnFlK7SQqV5T2rze0j83SbgkgBASPeun8QWmqaZe2Y8RWjQx3CeZDKW4dT3HauUvY5I3uI42DKpydvTbQBmUUUUAdD4JXdqdwN5Q/Zzgj/AHl4rshFIYTLhyq8hSelch4CbbrjdBmIjJ6Dla9T+xJdBpo5laQfex0x9KAOYlnh+wM9wGW4YkKqDO7612Pg/wCJ3iLw14Zi0vRbi1tbdJGfiBGILHJ5PU1wOr3Jg3h7hI5FY8YwK5+e4LWxlVsEn5VXv70Aeia78cfiKl60UXiOSOL1W0hXj/viuf1bx5rni+KG28V6zPqFqj740cKNrdM8AY61xEokkuUa/eTY38XXj2r0S0l0LRdKtLddLW91eZQ29gcRA9CR3NAHoVrCw8MW13prpCsEBWVduePWq3wh8N2Gvxap4h1aSP5AYoEZtvP97FZvj7xGbLwotgySWdxNAMkJtVgeled6L4mv20u30axYiRiULDuDQB2+uSaSNbnsNMliDQxsGkXq7Vw5I0zSr+CYq8s3Qt1C1S1GwTRdZmhmvSbhE3b0OQSe2fWsp2k1K5DMpCAYZmPGBQA7TlCQXDsMIy4Vjxn2qfQNXubG9V7Wdrds5DA1Ru5VlcQxMwgThBjOafF5FpIjEs5IywIxigDt7LxxeR3LfbCspcnexbk13+g+J7QacDBGktu65dDw26vCVltkuDJKrMSMqF7fWt3wsrG73mQ+UOWx2+tAHR+JpRqVtcfZ5zFIwJYNxx6Zrh9PuNlqYLlS0OSEIHQ1q6zLJHdsd7NEGyD6ip9K0PUNdZXs41URHLAnGRQBzV/JA0ccUMO1l6v61Z+zTQaQJUyFL/Mw7H0q34h0e8s7h0nXEaYyOpH5U661Jv7NS3miQquCpAwCPf3oAzLN32yq8gCeo7monVJpY1BG3dgsK0bObTZmC3IkUAfeAq7o1jpy6wTLLviRDIjheAe2RQBo+L9H03SNO0sRjN5LHuO05HPr6VyCO80ZRiq7eS9Xde1CbU9QLXMgkPAVlGABVRliigMZwzBugHJ+lAC200KRbmAVyCPl6n3pDn7SokBDbe/etW38M6s2hNqs9jOulxH/AF5iOM+max5JPNZhv+VRkECgCaH95KEjbCgZYuOleueBVt7y5WSyjgnfZtbzBnOPavJrVzdEbgiqmOOhatDT9Y1DSb5rmxnNr5PKZ5B9sUAetfF3S4ZfDNvdmCK2uYzgGMBSy+hHf615toOr3+gadNLp9xNbIzh1dH4B9xS3fjC61O2jhnnd5+WYsuRn09qy7aJ5luUVGW4ccKGzFQB0+oeJbm/iWbXZHvGJ3pM5zj2+lclqg8+IXQYNGJPlCHIArpPAusWOi6/GniO1S8swDG8e3K4P9RSeONCttIvHuNFuXuvDt9kxOoGUPXafpQBx11ePM53KuAu3BFdB8ObyGzurxpk3FggXrnOTUtppukx6Jc3Fy7SSmIiNEHIb1JrL8HXMttcXDRbQNo3MR0HNAHqfiEWz6Cb4IASMlT978q8z1e8ZmjcQFQ3O5Tzj6Vrya2zTLJMfNXG1FY8Yqt4Zsn8T/EDRtKtjj7fdRwtt/hUt835LmgDCvJI7jYX+WIcY6H8a1PBNg9zraww+U8A/eM0nBwPSvtj4k/Bbwr43U3Etotjqqx7Eurcbd2BgB1HDY456+9fInjrwPrfw1+0Q6zbus80hS1u4iTG6eqt6+xwR6UAbvhbU9U8W+Llhu7tra0tc7Y5FISNV7j3rA+KOrXN5qyWdw6XUYb93J93gcV0vwUludY1b+zJ4zNI6bo2I+fHfPtVbWfB1/qvxMi0qe0ZJZZfLQovAXNAHOaVZTiMar4lRjpcI2IM/6z2Fc1PqIkmuIbKFQJpMw46qOwr2T9pq2i8L6f4c8JWeAkMRnkxyWPTJrw3Tn8idHYck8Mf4fegC48J0q4JvG33YGQg/h+tV7W2nupSzIuH53t0FRXVx511K0rF2c4Mjcmr91ciHSxb2m1Y2xvY/eNAFWa7ZJ8Q7Fx8vyjg0sr3Vq7Ki7VI5wMg/jSafbO2122hGOBkZzV2XUglwsdwu6OI42gdvegDR8LTwxyeYNokzgL13VLf2klzcSSW5UNuztbjFYJEtrN9qgKhCxaNRyK3dG1M3dyFlQOT97acYNAGz4X0GxvLjytXkkM33o9p6GjxV4REM80luGIVchmPGawtb12Wz1iNtPdkli6uec1r2/jg383lXlsv2h8KJA2FLepFAHPakk+m26xyPt8wZKqeM1TsNTu4JFcbCo6DHWvQviPZ+ZYWkUsO29lQM0oHDD2rzsSxJE0MSBJBxnvmgDZstRP8AaUF2IIojGcv8vDH6Vmay0l5dy3ESKg3FmCnoPpTNPdGtZGeZ1lU9en4VFZLHMJw21SQcuzc0ARm4RIC0aL8w6N1z616V8L/hlb+MLC7vrrWbW3aBCyIw++3ZTXlwjVpMPIARwAR1FbOhaneaRFcfYWJErDMeeooAra7ZXOnazPZXUSiW3YhtnII7EVSt3H2olgfKB+4M4q9rt9Lql2Ll1EUwGGIPJ+tQW8v2qNIMBdpySOD+JoAszKksaS7yI4eNpPX2qO2uryJ5Vs0WNZv4epAqKU+XcJCGQRk8vt4JrrJ/CV9Por6nb2csttAMPPGpAX6mgDKsY3lvI2hkWGUEffYbPyqTULFQ7z2as86NmSTPyj/61ZjO0DRgK0syDJdeQRXW+CJvNTUopFWazkgbkD7rY70AaNt4zi1/w+PDXi9EaBFJtrzb80BHQA+lcNbXSCC+hCidRC6K+3GODg1WtLcyvcBz+72kjJ44qnHOYo5lij+VgQTjJAPFAFGiiigDS0CbyL/cX2KVIJ9sivRLDWI9LiMlnveSQYDyH9SK4Dwxapd6g6yKrKkZfBOM4I/xrSeeaeSTjbGo2n/ZFAE+vyQbZJkdZHmOX7gH2ruPgp8K4fiJJqsQvLjT0t7bcsyqHHmscICD/Dw2QMHjrXk09y80bhmxH0HvX1X+ytr/AIV8J/D26uNc8Q6XZahqF2zNDPcqrqiAKoKk5HO4/jQB4Z4v+HHiTwJ4ihtddtVFvv3w3qgvbygc8HHB/wBk4NN0LULLXPFkN1eR+RdbgI3RvkfHQEdq+yPEHxH+GeqaHcW+s6/o95pk37qVGPmK3twDz7ivlnxXongbTPFNhP8AD/xEmo2k9yN1k6SB4Po7ABk4xzyPegCt8Z/PnuoYZpTJM+GO4cAdgK0rPw1F4X+FN54h1OFU1CfEVpgc4Peur8Z2kPijWtEtX06CBpJkh3o3QepqX9rfULOysPDvhLTnRfsw8yVF44xgZ/nQB80KWuZ900hJJyWPNaOq3CzSRQIoghjTGB/EfWqt1AsDKmSrH5uaqySNI+5mOf5UAa1qkVpZ+fcBfNzmMAc59zWaC13cFnzljk7aabh2j8snIq3ayxxpGg5kJyT/APXoAu3EVrIYkf8A1wwrMeB9ags7o6ffOu9jErYZh3FVLr9/PI5JQZ6VLayC4i8mR9rD7rY6+xoA6a0uYLmXEbAB+QGq5HriaFq8RckxtjeqHnFcfpN15GoIJQNmcdOhqzrFjKt88rPuUncrAdaAPRr/AFXTNT3vFNCVOCQBh8elcz8QNJjt0guLdyyy4Kx/3R71zukpLb38cocKwYMc/wAq7zWp7fV5HZYWZ1jAYxfd+poA88aKOGAOW81h1CirELSJZ+aI/kPo2D+NQXlpJDMUj8yVehGOlRzOsFqYPMLNnJH9KAHNumsmOEds5JUYIFVR5rMrAkBeVJ4xViHzhAIItxZ+SMZGKclsXDGOQ5T7ynoKAPTdA+Jd1F4Pj0TUXQ2z53Ky5Dj/ABry25EKXUyJhoix2uOMA1oxWpnADIMKOGJ4H0rOmRuU2lQGxz1NAEhhCy7bUuUx949c/SrEf+mzxxDcwjGDgcVDEsts5RCFU/e3HmrnhsKviC0U7hbyyBHx1x6igCN4ZLWTYY43VnxuA5A96sw30sMEtv5gIHJCjqK9K+LS6N9mtX8J2yBYEEdxJ5gZmPc4ryZxAlukkW5XDcsD19qAOi8SW1vHoOn6haAMJwVkVhzkd65ueW6OmxQecRZ58wRZOAfWuj1mVJdAshDtBTLuKwbnddW1skCucAkrtwFPtQBbs7u2itSjOxQIVby+OoqhoitJFdxo+1mCnG7GQM1FdJGp8tR5ThfnB7ml0SSGK53XGdgIPTPrQBcvbcm1RLfLuTk/7PtW18NfFJ+HvjO016XS49Qkto3WOFpTHhmXbuzg9AT271j3t+11qREShYOydMUzVIDKqlGQt2AOaAPoM/tW6tMdtt4WsQ2cfPdsc/8AjoqHx98e9UvlOhaj4X0G8triBXliut7rkjtzwR2PWvnXSgp1KFJn8oFwN2M45r0T4saFa2VvpOq2Uiz7kVLhkPU9vpQA74TTTL4nkVDJDK6MIvKYjZnsD1x25r3f4VWkVr8UfM1m5JufszC3WeTLZ7kfhmvnn4c66+j+Io7zT9hlP8Mi7sj0rstS+JF3ceNr/VJLKKC7itjFCkQ+4cdaAMD42eIG8X/F/U2WP5Ld/skO05yq8ZNed6gj/wBoS2qRB2U7VCdqntpbldQuL6bMlwxLswPQk8k13Xw78Li6tL3Vp2aSYg+Vg+tAHmTQSxsd6Djsah5LBcH6V3Gt6OlndS28qZlI3GUjp7VyI5uG2E7Uzg0ASpqBV41YbY04G0c1HICuXkTfuOc4zTZArREphmz81W7ufdYwhQkboNrEd6AILC6ESusqB4T6jODRaTSaffxzoRjOfXIqJo5fLSXnFT2kAvV252yDoetAHQ6hoy6kUvLFF2yj7pOMVjS6cbG4AlTcV/u881raNdNZt5c5LBPQ/pUetXdtJdFYZJVXg4BztoA62xvLjVURHk8mKOPCbhuP/wBauO1q0jWfazLDk8PtrVtfEj6aAYpUlBXbtKY/OsNdQ+1NcyX2ZFkb5QnJX6UAUbiZYYvKgVSmcGTP3j6021iWSPbvRQ3LluTTL5UW4BViYz045/KrWh2Ek10kjREwE4JPFAFqzsRMkjxxGWxTgzEcA07ToYzchAWHONo6ml1jVZIZPsWnnyrfo0a9C1ULJ1trwSbyZQeR70AXNYsHim3AgRt92Mnoaqy2qrDCHPzNzgHpVnW7oXHzH5gw4K9VNVl2vYrCihnPXJ5FAEJAuVMcSsAvG0nkmvaj8RP7G8BWfg7Uo5oraeDMs8WO/QE15Jp8QW/tlUKePmLdKdq8k11c7ZXE9unyptblaAHNbyaczNDKJLSQHZKGzkHsaveG9SbTFmiliJS4TapXkAGriQyXfhs6XaWsWAPMRt/zMR1H1rn5vtVtY+XLE0SIcbM/MfrQAIj293OYUJt5VI3ldwH+FQ3VtHa2LvDMGL/KVPBPuK6bwfPayz+VP/qmjwY1+63t7GuZvrbbNeQMxSOEuUR2oAxaKKKAL2ksFnfJZT5ZwQcYORW3PIsOnrLcvukfjavGfeudtCRLwQMjFXZcGRIRubPBzzQBPLte1/dKoz02isocOCCd+epFbBilEaxpIuScbfas2+CiUgcY4OR1oA7TVdGun8DQ3EMISKGTzHyuC2e4rG0MhtX0+WcjYHUuUGT9PrXd+CJ313wtNYSSnyYI23KTy3FeaQyC3vAxDLGk207TzwaAPoHxp4g0eGbQE0O9eK9DhpMpgoB6mvJPif4jbxX49nvZGLRx7YwWPULTPFTSJqNlMwCRsmUYjk/WudDkmWSVQEU5IAzmgC/BZTeI9cVIIwIEABI6BR70ajpYhunVFWNeQoIzn6V6P8GtBl1DT7mWCL73KFhnFZHxM02bSb4rNb7ZYF3NzxzQB5lJEFmClcEdcGkaMbWcfKo6CnhzLK8zMqk5IzzUcLlTjG4N1FAFx/KFhC5+djwRjBqlwFBUcE9fSpriQqAinAPXFSxKktttBAPv1zQBDsZ9roN+OCB1rq9DvQBDDIEKYxh+ce+a5S2lNvORkbc85rQtLgXLSAnbjnPSgDc1u2t4L1oyqO3B3K3B+laemX9lZxTI7SqCuAcYBrhLyVpLgvvbaBxnrSXE+5VZJGyOxoA2J5PtRkmtMxYOAucEisGVWMrKRgrmpoHEzBZWwF6c8k1K9tul826Plw/Xk0AGlpLdM0aS7B1z0xV68u7SC3W0gh/0hOGlz/rPrTYLu3WORbSMqFXqw61jiRlkLnlj60AbWhTbZXF0AR29qg1GZ1ui8ZU5bGCPu1Rh80P8hPH94/yq0wEk7eackLw3qaAEvRuuQu7czgb1Az+RrQ0GUWkzTFfNaDsAeB9azYpZCBuGJCcDNacStFav9lchycsTxigCC0mkbUzNZy+TG77nQnt3yKta7Hb22pRyWkqGBwGb096pK7NIJINqyDksw6+tXBqSXca2xgRiTuV3HT1xQBXleATItsT5bfMQwzn29qv6jZC0022v7UBELYkjL/qKybsIZy6lo5APwNbdtFJc+FrnCkrCQev3c9z7UAc9KJJ5ZZnJIkBIz16VDpr7TJj7xAAGM810GgsG86OZY53aNkROwODzXOaeN0uM4BIyR1FAFy1jVDM90CRnlR1NW7aW3lS5lRDGw4TPSm5WATLJmSIjiQjpUdm4ZW2qfIYY2kYBPrQBmlN0kjKFKryWBr1ea5t7z4NvblH+1bhLvPsfWvMGgeRiFUmOPqo4r0T4f3R1bRriwaNSAphKnpgjg0Acn4bDRajZmJwsMi7ZG6/lUurosOrXkcZLo4+VlPI/Glg0+60V3iv4mjiE20SK2QfyqO6vN89xGQEjPAkHX8aAM/EsGkvJFy+7a747V9Q/s9+F7DXvB+BMJE3bm9Vr5mkXFmEhBeNwdxr0/wDZm8ZyeHvEpsZJWEEp5j7MO/40AU/jjpU1hqWpys7oIZ/IVW4bFeThMWTOYclurk9K+rP2nNDtdWto9S0/L/aEBlwPusOh/KvmTVYJILNInblV6KcjHvQBlQRvgyAhUHU4pJwWXeoAjHSpLHBLBuVwaQ4kjIQk47nigCxbTLIqq65PQk96rIxjumeMD5SSADjFRxghgV+b6UrlFZTGST1agDQ0i4YTyvKjOrDgD1qO98wzicpuzwcDFQtcMoWSAlAp6D1q5dzSXNl5mR83JC8HNAFO5uPOQFlGR8p4o09nFyqhPMzwB6UlusTRYUF7gnODwAK07JGaNpduxV+8y9/agBLyG306dXuv31wRuEan5V9OadBqlzdSxrO6JB2UCrUMNhJbudRiEascqyklquab4Z8+1mvtOuFkt0b5BJw35UAchcspnkIGCSamaPCI0z7QB93PzVLqNusc7MysjA4ZW9aTyfPkijhDvL3OM8UAOkkSEQYBVV+YHruofm5LwMFDjJXOc0l6kcYMIQmdTgkNkCm+WxkjhXyxIBneDnigDb0MqYWYDAGQTjJBrMZkjv5YkbCdSCcljW3dXX2PS4LG2t4wz/M04PzflWFcRvIWQKTMTncvegCwtxPbK/2CUwxr8wyeQe9WWuJLjTzNAxKoAZN4ySe5qnkRhLQKd+MszetTwxTLayw28iOzjLDptoAn8NNGNQjuZcpbCRRJs4Y5NSePbEaZ4n1CB8zNt3rITj5WHGRVC2VopissqrLGN2UPHFWvFV7Lrl0bq5J+0JAAW24DACgDlaKKKALFmivKQxAAGea0o1+aMgfLn71VdG0y+1W4kh0yAzypGZGUEDC5AzyfUitRfD/iALsFg2PTcv8AjQBUlHlzhl3MhPSq9+myUtncB0HYVrQ+E/Eksv7vTZGbrjcv+NWH8G+KyVZ9Jc9uWTn/AMeoAv8Awwu41u7q1aQK844Ge3esXWLYWWv31o7Apv3ITx707+x/EGgXi3cliYZF6ZKkfkDVPU9ZvtQnIuo4TKw28Jg/zoA3PEEglgsluXwQuFFZCgLBI0qDaflwatXOi+Ip7eFZrDKAfISVz/Oo08P+IQPK+wM27sWX/GgD1r9mPxZBoviCS0u/3kUnyhD1HPUV3f7UHh2N4P7X04J5dzFhyvdhXzba6Z4i0S+jvY7RoZUOVJZcZ/OuyvfGvj3xFYx6LLZ206HBRAg3c+5agDzYRbbJsp8465PSobTBYrwCe5rY8WaVrvh+7Wx8QWX2S4ZfMWMlTkHv8pNYkcU4wyr/ACoAkYFY2XoPc8mmW7mN/TPemKJVcgD5umKsw6deykeXAWPbkUAQSDbJlsfNU0bpA6gqGUnk+1aY8Ja9JZvdfYT5CDLOZUGB9M5qhpWlahqpaLT4BMVPI3qv8yKAJpBFIV8tOOgz3pLrS2ihWZmVEY9Ceat6joGvaQI476xMQYfJuZTn8jStpmuywsWs8xoMkkrwPzoApWcAWQSR4fHOT2qebT7i+JmilV3PBTGB+FUWe6EYG1QoPbHNTT3GoBItybFx8uOM0APjtJ4Vczxui42kEYH1zVBYmRxuXIz1xwa6q2bxLe+GmuYrCObSoyQZWA6/ic/pWDa6dqV2QLeAvzwAwH8zQBCFdrtV3HA5HoKWdSt0GDDqCQvP6VoQ6LrUDsRY/Ocjkr/jUY0XWY23/Y2znrlf8aAK6I0s/lRneGOdw6Cte7aGL93C5kCrhmA+6ap2+la1C2Y7Q5JzyV/xqZ9O16Tcxsuo5xtH9aAM7y2jkWNDujY5DE9KkuIw8sYjLMFOAVHWq0s1zbs0csaqw4II5FMtpLkgrAOPQcUAXtReN7mPKnIGCQM1v+H9QS2t9RjuY8rc23lBl6A9uKw4k1aaI+XbqRjBbjP86aljq6rkW/y4xyy/40AV4ne0nRw7xkIQHHGeKrWZ4dd2AcZq5dWuokKs1uoCg45HT86r6bp15qJkWygMxTBbBAx+ZoA1ZZY/sYcMQV+UoBwarrcQq8TTxPt6rtOKlm8Oa6oG+xdVA6Blx/OoJ9N1WUKslqcRjAGRx+tAD4nhW4LSSykSHhSOp9K1/Dk8mkarcQvL5UF0nBVuc9qxBYanhVFr06dP8addjUyUFxAAU6cDj9aAJl1CdNTkhumeSMycJ2z61pagF+1yW0kCgTrnzMdK5u7N1PP5syDeR1HtWrHf6vqFzbwx28ckyDCgLyfrzQBHbKQjLuISM4JB7VCjyWN2t9YsQY3zuQ4xWhPo/iCW4aZtOCnuqlQv5ZqFNG12LJ+w5U9QSuP50Aek2fxGfxFog0u5Z1u1GEz/ABVSvfCLTeHpbh1K3DZxjvXn+nWuraXerfQWa74Wz8+CoP0zXe6t4s8d32gfaZ9Jso9OjHMsUWPz+f8ApQB5rJFPprHzE+ZsrgjioBHIkgYqQG74rZOt6jdwLGbOzcbshtnOfzpt/wD2rPEI5bKGNSOPLAGf1oAxUYwS5PT+dEu4N5gXapORVuK3vLTJa1Rt3HzgH+tXdG0jV/EeoW+m6Tp6XF0T8kSlVz9SxAoAg0XTri83ywxM8a/ePYVXVGt5m+bKoTgV2GrN4q8OXDaZf6VaWk8X3o12Ej8VYiuevodX1FTI9kgBPJjAH9aAM2FTcXgYlUBOSVHAq3qsv2ZI4oMqG+YsOM0lnY6olx9mhtC8rDOw4P8AWk1DTtUMoF1bFWUYxkcD86AKD3MjqA7k4OQe9bugX80VrODIwiT5sk4waw5rSeEZkiKirVnp2o3mnz3Nrbs9rCf3rqRgfXmgCO6vpbm4Z3JKk/dq1pU80Rlt4tu5+T2x+NU4dOvJVDxwMwPQ5FXjoer7wwsiDjsR/jQBTiOy9kMpB25ztPWrWmsLvUoyyooQ9c44pZNF1ZsFrLp7r/jTP7B1Yci0YZ9GX/GgC5OIX8Q4Z3MSEb8t29jWrHDp97qQismZc/dTdndWDFpeqWUiXDWQO08byCP51TuLi5e8a5KrHLn+AbQv0oA6W5Gl2F40c0LPMh53sev9agW8s7++ZLxTC8pCqV4CjtWX9n1PVvLZYfNK8AggE/malGgazvJ+xkt6l1/xoAl1QOmsxRtFt8vCgx8gj1NbetwyXNpPcspaKCAoJYxwxxWCdI13If7O42d96/41eS81600e+tzaQi0njIlZgCVGOSOeDQByVFFFAHofwRg+0+KL6POP9Ac/+RI6938JfDi78TaRe6ufEGn6Va2tzLCVm09pdqx4y7P56D36DFeK/s9RNL4x1BUGT/Zzn/yLFX0TDoeqeIPgJ4z0nRFJ1Ke9nEaA4MmHRmQZ7soK/jQBX0D4dpq9xPFoXxE8NajNbgealrp/nNHzj5gt0SOh61TtbZ7V9S0+/lguLqyvJLbzYYTErhcYbaWbHX1Neu+BtUsNQTToYPD+qWN3Z2CwtLe6a9uLdRtHkLJIo35Iz8m5flySOM+R3jFPGXic9v7Ul/ktAHC+PdNHlySEnGPyrxBIUl8RwIDkNJzX0D8R50h0G4dsbmHFeC+GUF14qt9w+6S1AHqEylpo0UnCr61p6GI3uC8wJCjislgZb1ivTNdBpGyON0ZBz3oA5nxQ4SMljld7cfXpT/hyNPi8S6TLrUksVszhC6npnpS+K1TzY4lH3uTRZahZab5cd9arNjGG7oaAKf7Tls9v8SIwkpmtGt0MEhOdy15vY2r3ZKRZMgbIUV7N4+v/AA74nt9NuLiUbrRQG/wrKsNQ0OKCS4s7VQV+UEjFAHDWOhi8um+Rk8tec9zV+2s/sdnJLIxG04ArWGpRPczvEoXPpXN6tqD3FuYl4+bntQBPcXLsvlliUZeADxWVoCeZemJcqevHtUM8jR3ES7snaOlbei2f2e7M0akvgkZFAFnWNWmvtonAIgG0A1n2stxPcvHO7CBhgrnioVs559QlRQwYkk+lJKJYZ2VgQRxwKAJW0nTbckXVyyKeRzU1wNKZYkk+1zRp3XC8ViahI7yp5ynacY4rUhgea0byR7bmoA9Pg1jTZPAe+wt9tnEPKMeOje9eZ6Upj+1AgqxOVPpzxW34HvlgtNS0K+UCO5+eNj0DVELaRmkR1UOowCPagC/Y3Ej2ivMdz56itZApjKgdV/WsnRoW8tkYg4ORmtS2V8SFiAV6CgCAx7sPzx2pSN0q7Ccd6kuMypuiPK9QKW2VSQXBzQB5x46tfI1feowsi5/GsK2cxy8E8jHFejfEfTxLp0M8Kf6vlq83t13SfrQB0+lXOF8sk4P608s8krKxIA5HNUNOjcMwfHPSteNDlGkUn3oAz51lktmBBwFbn8DWx8JYhJcakSOFWP8Am1SCAvbzEKNmxj+hq98DIhLPrIYcBIv5tQB6/wCHvh++t+Cf+Ek1PxbpOh6c888Tfa7ElYhHcPCu6UzqMkqOw5bFWdF+CNp4gjlm0P4h6JqcUZ2yNZ2AmVSexK3JxV7WtMvtW/ZO1Gx0iyub67kvrjy4LaJpZHxqrk4VQScAE/QV1vhyxvNZ+M1p4j0zTNQ0/SLTRvsV7cXlpJaNeTEgqojkCuwUfxEY4wD0oA8EXw4YNS1C0d0keyvLm0aWNCiv5Uzx7tpJxnbnGT161zXi7TPKt2Ma5YA5r1S7QLqniBh959Z1H/0smrjvFsDxW5ZfnDjHSgDxG7JDgZNdR8PMvq/muNwjXPNYOtYE4GAGyc11Hw3j2x3k5PAGAaAOvinaUtuXG4+tXJbc/ZYyB39aztrFVG4jJrauI2W3t2R8qFyaAOKgbN1fWsi5D/drs5NQSD4UalYsoLgcHPSuY0+NX1ueQEHgmr2s3lvb+C7+JpA08rYC0Aea6E+4eUUyTkg1rPbyS25cHayHoaz9KguEWAxLh85rYcO7hd5HIyKAKd2kwjSOQZ3Dj3p2ivcWt4JbaYwXC9GBwRV28K+apHOwYqquFfzGGM96AIL0TSXctxPcPPO7cszZzV2CS4Ww2H5cnI9adb25mnRsfITnp1qa+Urc7R07CgDUsNZjt5YQsIM5TbvrA1CWfzp2mbJduDUsh8tgwBDiq8sqzJhjhie9AEWpiI6RHxukPWoPDuqTWdjd6erYjufvc1ofZWW0YnDN2FZFpZk6jsuDtVuhFAGha77S1lQ8IpyOa6m0kW506CWNsnGDzWRdWJ+zyKMnavpVjw+rHTSqNgK3IoA0Wt2kjbAJIptsGClWHHSrMTusbYOBVVmdX77SaAJZbZZoGjxzjNeb6h/o88i7e5Fel2yO7YLgZ71xfi+xNtfO5UFHHBoAy7G6ntCCjEA8gZrp/wC1tqRyMTnvXI2TBwBITkHitRo92cNx2FAG7Jq6SchgF9M1UvbnzdOuVU4BjY4/A1iqCpXPPOa1tSjRtOlaP5T5bE4+hoA42iiigD2f9lMbviNert3btMkGP+2sVfTwsPFHhcXa6NqmjC0u7p7oRXWlSyuhfGRvW4UEcf3RXzB+ypKYPiPeSKMldNk/9GxV9jXd4lzZRmUfP70AcnNr/jiJNzap4bzjp/Y0/wD8l1x0FnchdSvdTmgmurq5a5keGExJubHCqWY447k12l8HQOOMNnFedeMdbGmW+yVwqjnb3NAHnXxm1GOO1WDdj2Brzz4dQLNqN3dMD8q4U+lP8ba0NUnlm3bgDjbmt/4YWIGhyykDLnOaAOhs4VwZGypzxWuu02uc4Oe1VSu4BOFArQtAkltIduETnNAHN3SmbU0BG5VH5VieIXSOC4TaS8gIDY6Vq3Eji5eWM4BPH0qK/hM+pWoQCTuynvQBzGg6V9u0S5gXPnrICG7Yq/c6VJa21pFLlYB98r1Jr0e8g0zS/D00iiOKdhnA9a8wivLljM0khdG+6PSgCHUltdPWMiXHmDvWc95p0MYVlUyeo5zVi/iguDGLhckVGsNiibViG4nqVzQBQF9Zpco6oS3Y9a2ptelSIJZ2bAH/AJaAcmmIIAAVRQy+iip0BMe/eAvSgCj/AGvdRHKWr+aRzkdadbahcEk3NmST0ary4EZKfMfcVIJCrK3ljZ3460AZl3NcXEkebXAXpwK1Le4VrCWCWAxuBlcDGaa0zMhOAnPFM3yswGQTigCHzBcaeHC7JYmHzeorpLy1MtvZ3MRJV0AY+prDTTtQmEscceFILEnpW1oE0/8Awi7xTKQySYBP1oAl0eMGZ88HbwK0DA0USuMks2CPSs2zZk1a2STCiRsZ+tdLqVu9ldSQKQzEAqfrQBQtoEid1IJLVZghVUbK/NUtsqhV84jzKdO370rkfMOKAIL2wS7sZYXAKuteGX9nJZ3dwqnHlMR+Ga+irSBra2DSAMHPXrivG/ifYNZeIZJAm2KXnjpQBm6Y6TW5kd8MhwRXSxN5tvGAgIx1rg9OfbK3uOldRody4jA3ZwehPSgDWjV44LhWPBjYY/A1d+ApxLrpxn93D/Nqq3qlrSWRjtGxv5U74GXKw6jqUbf8tViXH4tQB7r4X8VeKfDekDTNJudENkk880YudPleQebM8pBZZ1BwXI6DgVtwfEHxzLIF+0+GwD3GlTn/ANuax4rUNwPrWnDbeVaA8BxQBzh02SKO4lvZ4p7q4up7qVoozGm+WV5CFUsxABcgZJ6Vy/jezMelF0PODjNd1qJATLdBya8w+JviCMQLbow9ABQB4nq4K3rhzlu5/Gu18Gp9n0JWJ5kfNcRe/v71ufmdq9LsbMWmn2kBH8IOKANTbvK59OlW5pCLVlB6LVNCftIJ4VanupCsMhAySKAMy2iWGJ5VHznvXMXf7y9ZJiShPGeldnav5unyEj7ua56/siUWcj5mOBQBSs4pDI7AbRH0q1Np02I5lx83JGahu5Z7YeWjAlh1qBReTLt+0EDtQBKlpI87GQhV9SaS5t1MQRpkQA9zTE0yZwRNd4z703+xVcEPcE/jQBq2ctjbWitNcAlemO9VjqenTXCSM2GHtVUaNEMZckCp49HswcsueKAC5vLCa5JJPPHFRXiacYh5bMH9qtxWdinPl5PvUhW2P3IBketAFFZLfySgZix4quhhkJXOWHStYxws64hAY1W8qGJmkC80AaVlve3UOvUYzjtRolqIrm5iH3cEinabdBoFbqM4xUhdYtTXb8u7jFAD2wU29KURl4wMZAqaV9oIYc5ogQ7t+c8ZoAT7P5eyQEn2qv4k04Xuks+PnQbq0A+7g/hzU+3zIWXPzEYPvQB4tcIYZQ6grzxVuG/kYqHGAKu63bmK7ni42xkkVkSSHKv60AbaRrOFcHBzyK1dVt/K02RiD/qWH/jprJ0z95LEc8V0OrAyaRcAMMLC/wD6CaAPOaKKKAPYf2XVZvH+obev9mSH/wAixV9WC7QsI2BOB1r5W/ZZ58f6kB1OlSf+jYa+ndPEs0xjKj5ecmgDH17W1tNPuZXyCmcV80/EHxcdSeVwcEcKM16H+0B4gbT1e1t5FVn4ZQa+bp5nmbMjE0AKm6ecBiTubmvcfC8SWOh20ajG4eleR+G7UT3O7GSDwK9qtoHe0t8L91cYoAlEZeQ89TWhclYNKlii4JGTSWNsRIz9fY1R1CRkeRmzgjpQBhTMBas+3POM1W0mYI0t7c5EScA+9LdSGNBEQCG5HNRWiPLpssQXKiXJFADtbnutRt43srWWaIHLsASBXJXF2/nGO1GGHDLjvXpMnxBbSbH/AIR3R9Ojad4/nkI56V5T9ku2vHuHmRWcknb2oAsOZmcGcYx7VMtzBCp3sufdeasQ/wCigIsgcuMkv2p6pFv811EuOuBQBAb22Ee5uM9DsPNV11C2wVLY59DWsbxUtX8+FCAPkBpiXNiLZJjCCxPICUAUEvkQjYkrr6qvWrUzXKKDLblI35Us39Kv3M3nwKsVuvlY3ZUYIqN7+RgizKHSIYFAGKbhySjKpAPUZqCXUGjkCrGyoT96r7XcbTFjGAD2FNuRHJGWx07GgDZN7fppayQOMONoHc10PgNX1+NNIaP98so3Mo65rkbeVk0xXC42Dit34a+KofCum3d06h765kIT1XnrQBo+KbE6fr1zbqfkt22g+9adtdGdIppPmYAZJ71lanJNqCTzynMs2ZSc+vNXPDqvfaW2wgGP5aALF6qyuZYmAGORUKEyxYGcrU4t2hI3fdqzBaEzthT5VADILq4jg8tmLDORWF8UdO/tHwtFdxrmeE/N9K6mSCGFhIx9ttQ3RF3ptzbPgRsDQB84oxRww61sadKQRtP3yKr6/YnT9VmgzlQ2VPtVjRo/METZxtPH50AdmYWks2ViSBG38qzvhAxGvuAM52/1rpLeNV0uZsfM0bD9DXO/BogeJsHgED+tAH0tanY67l4x1qee4Ty2kDcLUU+6OLjB45qJAHtnYqNg6n3oA5rxvrMVhYMd2HkHFfPXinU2urwbmJPPWus+K2sSSaoturZVD0zmvNLp/NuWJ+lAFrTYTdaxBGnJLjP4V6y2ySeOMnlABivOfAcAk8QIzgFYwTXoEWTeMyj+LNAFlI/35D5+Xmnysjyeik45p+Cm9yBkjrVaQhSuTkZoAjmkEf7mIcuewrL1pmEyxKw+Rc49KvpIp1OIgZQHIBrEuJY31m+muBwoOB60AU5Jo8gvktTjdwlduCD9KymM91JlF2AHANalnYHy/MnYMAKAJYp4d2JMgetSLd2eOJCMU3yYMZbBqzFa6eZQvlg5Xk0AVzeWoyfNJHpTU1K2T5juP4VYW209w5Efyp1qwIdOW0JSAEMOD6UAUF1PK/LAdpPDYpqX0juyFSp9cVprPGbKO3Ma7Q33gO1VpRbea23gUAUJ9SlhbBXI9cU2C4aTLOpYEcirdzCjR5QA45qsZmS0YpGMDqaAN7w7Zpc7Yocl85PtUmsQ+XeB8cxMFOKt/D+/s7HTbu9vmXzZPkj+tLqA863kbGSfm/CgCxEkUxidvuuBmo7iIxXTIuSnbFQ2Lu9irrj5OKkfe0qY/iPNAFeQN527GRU63Ch13Lgd6e8RZiDjAqAwlQ28g+ntQBy3xDstjw3EQ+SQc1xLRkJznAPFeo+JLRr7R2X7xjHFeZbmBKk9DQBpaJuWZAc8DmulvUDaPePn/li/H/ATXPaMrG6Un7p4rptQi26ZehD8gt3OP+AmgDzaiiigD179mKVIfH960hwp02QZ/wC2sVfRmueILfRrOScyKpIOPevlP4NaiNM8R305IGbF1/8AIkf+FbHjHxdNq139ldykSn160Act8SNcm1rxJcSzMSobIGa5MDNei+E/Dvh7xBrF5ZeJdam0We5iUadeOgNt52eVmJ5UEYAPA65PGDjeI/BGs+EvEbaR4itGt5iCYnHzRzr/AH426Mv6juAcigDY+GFjHNcNvUmQc9OlevafabV3NwBwAa5LwBpP9maW92Rhn4GRXaqRJBEmcOeaAIkzHcOu0jNc7rmURy7cHgYNdddyCG3kkkAyBgE+tcTqhO5A5DA/Nn1NAHPai+6T5TwtdLpOnta6W01ziOS6I8pG4/GuZhjD3ryzLiCNsn39qh8S6pe6h4v0CPzsRGRNsY4A5FAFfxDpV1pXiya4MmG8vII9xXLzzxO+VY+aScj3rrPiVqE0PizULdwG2kbeegIrmfDVtDda0JLgfImdx7D3oAqyTHy+SxY8fSuw0e2it/DZnuByeua5i0ha51N4bePzCzkjHOBmtTVJJ/LayEnyAcgUASXiW80UTwyZBbBBqrrNuLK5jt4JNyyBWAHqab4dtnlaWDy2dl+YCukv9Lt9J1DSNYvlZ43IBQ9ARQBLpTG1t7hJIx9zHzDpWLFBL5ZExAQnrXZbLLWU1dpp0tcJujXOCRXmF1dMYRtdmiRjgg0AO1FWt7whuVI+WrCSmRQioXlYcAc0+WWC68kOpbjrT/DepDTPELStEsoUHapFAA1wYEWCTl24KelJr1qwtRLbIfKjxuPpmqjzy3WtXFxIFRnckL6V032OfU/AF6LZ/wDSY5R5i/3h6UAaeiXX2mwtzK3ITaT6itDwvOlnqU0GcI4IHoTXGeFXk+wRwy/KVyDmtczeTdDaRlSOaAPQwEZGVhzjIqvazzo4jYbcnABotX89IblDlGHPNKJQ0xc8sp4oAuT2zeUWIJJ5xWNdjy4WdCcdCK6OGWRkQgA57VFJpLap5sMICOq7sCgDxb4iWJCx3Sx4U87gK57w9L+9aMjPpXpfjmDZpwt5wBCFIP1rzvwfsGohH253d6APRIWLaW24bcRMMH/dNcj8J3EevMx7bf6122p+WbJxHgERtx+FeceAZ/s+r7846f1oA+oNOuVnt23t0461m+K9fj0nRpgGAbaeK4qz8TC3Eu58YHHNef8AjfxHLqMhUPhT2zQByWs6lJf6lLcOxO5jjNUZVKSkNxzmmEYJqXDTSogOWOFFAHe+CLJYImus7i/Ars44f3hABz1rmtKt306ytYXzkAE101pKxYsOQRQA2diVAXoKzrtwsgAPPf2rVfazYUAADkVz95IfPdQhJbgEUALZRSXWpRiBS23rjtR4m0iVdMnuY1y4b5jUz6iNC0iVIVU3ko5b0rEtNdvn8OXUdwQyM3U0AVmZJbWJJP3bAduKiSVhA0asdgGTk9aoySG5SJFGG6VcdPs5VJsBiOaAH2kbTv8A7Iq1EHZX2nBTr9Krea6ECAAAdqZZ+Ys5Vs/PxgUAWUcxxu0fO7g1Z06Z2DI4yh7YrNkhMbGN2K7TyK0NHi+3anHa28gXIyWNADn3IxVVyM8VT1AyQyRnbw3Oak1QtDdzwecCYmwSO9SNJFcW0SyPlsUAIkqmMFsjI4HrSO2LFkfgN2p2nTR2uuRCePfCvOMdarX8v2zWrmRR5aHOxOwoAreInFpZ2Hksdm7JHvXc2Fwt3axt0DJgjHtXN3+k/wBpeDDLDhp7eTketL4UuXkskt3JEqDHNAHQ6SfLeaA9ByK0kTfayOchlPFc95rRX6EMOeDW68jhmDHKFaAI4ps9QfeieDA5B+boapwOyyZzkE4wK1jcE4hKZAHU0AUYG+UwsODxXlfiSwex1GcDhWbIr17yd86BeBmuP+IFus8cjOArx/dIHWgDn/D8oBjJ5B4NdLfj/iX347G1lI/74Ncf4fIZcMeK2J7yQQXSk5T7PKv5oaAOIooooAu6ZfSWEkskX3nj2fqD/SoZJ3lnMrnLZzUI5zijFAG1faiJtNWJhlu1el/Djx0p8PW/h3x7ZnXPChcLB1+1aew4DwP1wP7uenTup8bGWIUcnoBXo3hLSnnvtPtFQuAQzCgD6D8Q+FIrHRbK60mb7fobgbLuMdB2Eg7H36fTpXNSoIbpdn8IAFbPhfX7/QdZmittrWzDbNbScxyjGOR2Pv8Az6Vsa34ftPEmnzXvgri4i5udMZsSRe8fqvt+XpQB534guJJGWMcr1OKyrqzc3Eb3JKW8a5Nb9vaNalpbwl3Q4KHqCOxrnPEs015O0yE+TgLtFAHN3d0095KEG2FMlRWr4b8Oxatew6tqEgitLVSxbvxyMUzSdOa/eaOCPMzDArrJ9JuNO0OOwvF8lHIzz1oA8b8b30N/4hv7oMwVnCgnuAKz9BkZtRjgsA8ksvy7QOtdPqPhVtW8cLpVhlonRWZl/hNfSfw0+C2m+GpIbya3864AB3PzzQB5r4T8Bx+GdAutS1RSL6dMordh6CvGLq5ddUuHYnDOQOa+o/2gNU/szSpQwVXC7UA/SvlG7ikEX2hmJLHp9aAOn8Ca4dD1e5muYhPG8RVQfWtDxrrs2p6dZxvEgwd4A7VzGmqJYuBgheTTUMjSgklxGcAH0oAs3zRHTU1P7Vi5Q7GhB5IrFOoCcz+UgRX5K9s+tXNRiCSMVXKSHPToaq2mnm4ujEoIY57dKALugoJJhFM21OCG9K7C98LpGsNzGd24YLLWNoukyrZTKEw685Peum065uLawhSb54e6nkrQBzfiTwtPa2xvLGXzFxkqeorV+EU011FqGnyxu7zkEEjofWpNRvJpGb7LG7Rntirvw+1QaJ4hWW7gCxT4V1xyPegCzq/ha8tS72ttJKu48xrmue8poy4mRlkBwQwwRX0bHpV1dGOfw/IJ8tvMeRyK4fxH4M1HXNRvria3WxePLNkYHA6UAct4WmElu8BbkcrWncW8kJ80DIrm9FnSw1GON2GVJQ16NcJG1tvBDKwoAyNOkkuZUhD4c9K6/R0i02Z5r6T5lQjjvXHW5TT9RSRuTnitnVtSjktXc4+YYoA86+KMEl5aTyQE7SzMBXjdlK8F3G6Ehgwr2nWpvNsZEY7iTx9K8VugYr2XHVXOPzoA7GLWJGMkcowDG2PyrnfDfF6DnGCP60r3HmoGzg7Dn34qPQ/9c3rlcfrQBta5qfkXJjB4xXN3FwZpC5654rQ1iB3uXwMkc5rONrIE3MMA0AQEkkmtXwvAtxrltG4/izWbECWwK7H4b2Pm6lJcyJkIvBoA9DurJHszJj5xgCqkCtCFQk561rOSFyxHl1n3MbNIhX7p6GgBGLsJQgy5GKpXxj0+yjLkPdMenpWqxMatHFzMR96uevbaV7tBMSTnrQBjX6z3bLEMmWY4HtWr4t02z0Hw/b2ImD3sg3uoPSruk2MkmqxzKpKxkGsPx3FJ/bUty2WAXAzQBy9q5BRwQChrZvpBcyQSt1wAaxdGs3uCxPA3Zrp/s2LTCrjb60AZT5juQc8da0bGcRatZ3DqHiRhuB71V8p5SxGAFpNNfzZWQjGKANnxLqEF3rUslvbBInAHFc7FBNI00ltL5fkjPBwT7Vo3it5wRTzUU8HlgugbBHzUAZkEwuQdxPmfxE96vWMYklVGPA5qtbwK0hC/L9K3dLsvKSYkZOMg0AUGV47kyE9+KguJWYPI3D+tdG1kJ7JJG7GsbUbcBCACN3YUAavw/NzPJPagF4ZetaGo6K9hcmVF2gHsKp/DnW4tK1cW9ymI5Pl3ehr1LWNNSa3LwssifexmgDyq5Q7A/Oc1vafJ51uvXIGKdrFgpiDR4Qg9Kr2DrHJGMjI4NAE7W4hcHsTkVdizK3yDBAwakucFAMZB6H0qtBL5EnyNk9MUAXcqJVUDLDvXCfEKOUP5g5Xoa7WK4VreRukmeK5vxeRJYOeCdvJoA8vtZpICdo+WtGG7822nDcN5Tjr/ALJrL80qGjI4qWM/LIR93Y38qAKNFFFAF/Rrf7TdFO4XP6ih7ZjdzR8Db2q/4PjEl/cjutuSPruWnXsJe5QIfmZvmNAGfazxw3cJdA2zrXqvwrvTcahd3hQL5SfLXlN9H5d5Ljtx9a9I8BN5GltIo27xg+9AHoF1ft5fnA4lc8mtDw9rF1ptwZ7VmilAysqnlT/ntXMI7T+X5g+Qenetbyyx2o+1DggY60AdrJqOmeOpPsl/JBo/itvliucYtr89lcfwv+vpnpXmXiewvdD1h9M1OB7W6QZMbdCP7ynoyn1FXpLN5JSeCO4I611/hbUovFstt4T8Zxpd2uGa01OSdY7ixYDgK7ffB4AHJ9dw6AHM+GbaSytjKyGLzTkPjtU2vXEms39vo9izXF2+AS3OBXpPxE0S30a8sLaxX/QHUvGAd33QARn8j+NeffCOUy+ONZv2jDtH8kQx6d6AOn8GeEbXwb4iiluUEspAaRj616vP4otmjmlmmSGBRlcmvKdb1C6klnuJGzJk5/2a8c8ZeI73UrhrCC4YIODg4zQAvxg8Uv4p8ROtoxks4HIBJ4Y1w32CcsiuhKvyPQVaEN7a5WSJduPl71FNeag+I4sKo6HFADmtpbd2jhCjHXNbWn6OJbATI8asT82TXLvZajJIZGl+Y9Tmp10jUSoLXRCHspNAHUW+j2sjbbi5iZhyAppbuzsIrgeRcRpIBgnNc5Y6Dcrc7/tTrxyRVqTw80f72edyGP40AazarZWEJElwpY8ZBzmtrRNRsmT94u+BhySK4/8AsW1WVGcO468mvQfCumWF5BIrSKibcbT2oAWznthI22HFrIdqPisnxVotxpmo2zTHdvw6HHavevh74I0e/wBIWO9ZZIo33gL1rY+K3hKxurbT7i0t1DRfJwONvagD5zh8S6to2tW1zpt9JAuOVU5AI9vSvcvhrcSfEfRNYfULnbex/uiI+Mkjg14L4ytI9O1+VVYNG5Az6H0r1b9l+6Fv4n1i1YkfaLdCo91J/oaAPH9b02fSdbubS5UrNBIUIPU+9dh4XvvPhjtpJMgL37VS+Il9/aXxA1mW5Xyg100a/wCyBwK5yze507UDub5c9R0IoA7fVU8p9xIOOlc9LdF90crnax/Krk9w84TfkhhwayLqGZJHRl+XsaAK2to9uqyo2+I9a8u14AanKwXG75sV6des7WwjHz4PSvO/EilrtnI2sOooAyFychewJrV8N25nuHA6grj9azrUZ80d9hP6VqeFnEd07E4wV/rQB0E1jjzmxlgO4rGkgZrRm756Yrsb0RNbeapA3dfeufWINPOVOUVTxmgDBs4lkkIC/pXpPhO1NlpgJXmRua4nSkxdR4HO6vSYcJbpEvGRQA+V/MfYpOBVy9IRYk24ZR3qk5FsikD5yc0lxI9w5aQ9BQAl3MsMbN/ERwajsVE7RtIc85OaglhklQBh8uan0mAyXjxKccdaAOhE1nYWsk7EKMcVwPie5jvtPlZMbmPFaHjON4Bbx790ZOCAaw7pDFOsRXMRGQaAIvDarHB5ZXDdmq3drlWRWycdBUcki25UDp6CqTXUyvmBMk9+tAEhilUqB361LFbeUxeIAMRVFotQkcsXxu5605dPvZAxM+D25oA3dLtPtHmNKyrIvSnx2sUkb+bNGp6Y9awodFvGBY3ZU+m6njQWMoaS6IB/2qANg2llFEQZ4wwPWmC9sUtmVpuc4zVI6HAJBmdmx79alGlWYTDKTk880Aa1tqFg8Kx+eAAM5Pel+0WtxtRVVl6BvSsJ9It5HIRyqgetXtI0ZoBlZdwzkCgBZ9Njtb9UbHzYKmrz6ve2EpCzM0eMYPaut1PwXqc1vY3ogYxsASR2Fcd4ksvs17IA42kYIJ6UAb1pLHqWnZY87c5Fc5cHyrtTzgNjNdF8OLZLjS7sE5dc4Fc5qCObu5ibgqxoA6m3ZZ4kC4wv61TnQLIxXO41l6TPIFRd/HStplZyUIGccGgCnCAzFZGIJ6cVi+Jd8FtMhG4MOOK15I5Afn4I7jisnxFIwiUlcgjGaAPLnP7xt3XJzUsIwrndkFD/ACpLoqZm28jJ/GhkHl7kJGeooAr0UUUAdJ4DI/tp1PRoWH6ip7yOKDUJ2ZgCrfKKwtIu2srsyocHaRmkvbtryRpH+9n8xQAqym51IM+DubGK9n8N6VFPpMcSHy327hXi+kR+ZqEIJwAwJr2bw7cyQ+SHOEAwD60AWora4t45BKOAcCtvTzvhjDryB1rYt9I/tKyUhSo6k1BLZtbS+TAD8nG40AUZ1Hks6kLj8M1Z0KKK1sbjULjaXH3M+tLrAt4LRYy2Zj98DtUentFrV1aaVYc7CGY9iRQBainubhbq7lYs/lEKD6+wrs/h34Vg0GyS7+9JMNzse5NU7XQpYNQ+ySAAucBfeug8ZX95p3hmH7HAF2IQxH0oA80+I+vW1hHcwWTBp5Gw2D0ryppbWCQTXMRWTqWNRarcSTXk9xPOTIz7tnvWBq+uzXcixShVVewHNAGhe6k9xIxD7Y/4RVaKUFdu7LE8GscXQdwmMjPWtG3xwFyz+goAvBnyCHqT7S5HltMMHoMVGkbdWfHt3qN4pGmB680AWFkcDaZT6+lacU6zWu1nO5emeaoLYTyzKAjbWH3gM4rd0ttMTFlcRlXB+83c0AZYsdSlieVVPlAdazoXuLQv5U7DPXBr0ny1tLCdEkXZInBPQVx954dSNI5be5Ls2SR1BoA3/BnxG1bwwU8k/aYz1QnmvW7P41fbPDrHULdYOCMt3r5lSW6tNVwMOqdOOAfeugigGq6DI0zlJI5MhexFAFPx1rTaxfvLZgmNXLbvXNev/s5OyeI5dSkyY47X5jivDLRnNwsCr8jNtYn1r6L8J2cXhL4f3aBgmo3kW5d3UDHAoA8x8aXX9o+IdTu0QFJbhyuPrWDZPIZDFISV/wBodKlkM0UrJKWzknJq4hDiPy1GTwaANzQ3hlU20zASjmIk8N7UmqF7eb9+hAboMdazUs5obnbOSndDV/VtSR7BUuv9aOAR/OgDA1VJIZUEZwHOa4DxYrLqTj+EAZxXpTRNe2zSowkKD7vevPNaaNxc7vvEcA9aAMXTdvnsHAOUbH5VLpMmwS4+8cY/WqUTbWJ9iP0qSzl8qQHsSAaAOkXUS0kcBPCjmh7pY4p2ifLHIFc5JMy3LOrEU+OXahGSdxoA6vweoluhvGTnPSvQZ4A+DEcOO1ef+Gc2pjlXl27GvQLJi0icDJ5NADnt2NxEG5A68VBcKyTsiKcZrU2MrO+0krUc0ZlVZAMZPNAGPqbNFGiE4z6Vc0RCtvJMQS33QaraoqLcRox3V1Wg2SvpbqyjcOaAOX1+BZTAjg5PIqo9t+8VZwBgd67q+0pLuyjMaj7SvQYry/Vbi4m1ia2LHfF/doAhuvJ+1PvXgE4FQBgVyCAPaqt3LJGdxBZs+lVHlujjIxntQBqeaA3ykkVZR1ZflP4Vn26SMqbkOTxVoQMCVagCckAglqXKZ5fIqtPbybQxOM9KtRaZJOg8kgueoJoADOhjGw+2abh5GChiFxzTprR7N1icAjjJrS02xtiskk8mEK8ZNAGMwiRiBLzV62vGhVPKbcR2q9LpVhLbq8L5bPXNc/LbtBqY8t+B2oA9d0r4mumgrbXmFES7Rkda8p8S6qb/AFF3hXCMSc1fgghu9JuTIP3qnIxWHGhvLu2s0HzO4UY60Aem/CKDytE1G9mXKKDg9q5HUpvNvbicfxuRxXqF5bQ6B4SOjIwguZYsnPBJIryU2t1ZrKlypA5Kt2NADLWcQSENnFdPY3kbRgtjOK420Z7iUgYPtWpaMYJBFLxnpQBtPMjZQ/MSDXPasWd9j/cHGKutMI5CT90Gma1bibSHktjubGeOtAHmF/A1vcOh6Ekiog5Awem0j9Kv3Ra6iYgZeLkmsugBKKKKAFoBxRX0l8Ev2fLXxX4Kn1vxPcTQHUYsaYtu4JhGf9c/Yk4wF9M55I2gHiHg7TjfXjc8LgmvZPDuiSX7rHEvyR9Tj9Ky4/AGq/DzWrvT9bhGWyba7TmK5T1U9iO6nkfTBrtvC+vWOk6X5YXzL4uTgCgD0Tw1posdGuZdUZY4YxwD3rz7X9egvdQH2JfLhUHLDvWdruv6tqksiXEzRwHgRr0xWXAFjwJRkngfSgCtr87IhdSWDdea6v8AZz0e41DU7vUH/wBVGeG7ZNctDYvqF5c7P+PeEMWzXu/wXs49J+Hd5c7Aiu7YP04/rQBsayILDVorqYbiDlTXlP7Q3ii607QVtLKXbNcKX2j+EV2/iXWxiziuMCKWXYX9FzXjPx5uUuvF9gLDbLAYCoHpigDzXS9U0+20m2ivo2ku8+YWPNZt5PbXcxuYkVHfr7Uy6jWSeUyw7JFGAMVn/YGbT57wzKioeEPUmgCezijjuWd5Q4PY1vWckSRyOVGa5S1hfYHfJjJ4q7cXRTMcXyrtxzQBqPcIY1lQHIPPtU9xNC1qLgOTKflKZxisvT5NltI9wwI/hX1qeO0nvdNmuIYWMMZ+Zh/DQBuadqhhtBsDZbk81St71r26YqFG48Z61Z0nSftGhy3KNlQCCR2rm45Xt7pUhPzIT0oA6zWJ7+1t0hnUhWwQG7imWLXc8RiiG1lBLY6CnW+pjVLVl1LB2r8rVoaDare6RdmC4VZSNvuKAOMju2d7hDy7d66zSmsbXwpLJNKXviR+7B6CsO90+TS4TOpVwTtLY6VQ02/W3EkzYlZhtCHsaAOr+F2lHxB4j2FD9jifznYjpjnFdL8cfHFvrHj9NO0dvLs7KARbkONzgc1oeDdYs/Dvwc1bUIVjGqXLmNcdRnivB76d4dX+1Fi7sdzZ7+tAHomma5bX9o1rfKPMUELJ3ohR4UXBJBOQa5aOSFgrRdSMjFdNomqKi7L0ZXoDjpQBoardzXMEe88xjqOuKpysZbdDIcg8VY1KSKFflcMrjINV7bNxCUIzjkYoAzPtctlOz27suwjIJ61S8Y2ltexLqenkoxXdLF798VpX1szbmcdeOlcrq0V0k/lQswj64FAHP8kk9zzSL0/GtfSdNebVxAyFlCsxH/ATWQv3T9aAA81PABtDE87ulMSPcBjg1b0yJTdqG5BPQ0Adxo1ufsEchQ4GMGuhinaNkaM/NirNokMWmwRsBjAPSpBbLdN5i/IR0HrQBbivXSE7sFnFOWVTCqvwTUHk4yx/hHpUF7KDGDjGOOlAGFqErS67Dbg9GGK9e0KyUaeWOQdteS+F7R77xFI7/MI+c+les3V5s0Yop2Mq9aAK2lXDJZ6td3AJW2Q7OO9eGeHdRkj1PUdVuE3+Y5ABr2CbXreLwDfQAA3UxK59RXjN5EYLdFRsBjlgPWgC1dav5tw+6EKH5FZ6StcTB5G+7TJ97kFicD0qBAZJPkOOnFAHT2dwmQwI2r71F5zTTttIK1kOGiTDE80tq4EhCu2aANMXLOhSU/cPFSWd00EEkiyHceKzyHug6ofnHPXrUsUqqPJwCwHzUATxXxu7oJKxx71Ya3nMUzNkxYOMVivIqNuBA54xW/o2obUzKQ0ZH3T1oArWsrJZlEbDA5qqryTyssXJ9aluWQCRoyRvP3fSqsrS2ygwggMOTQB0tvfWdp4buYEXfekfM1Ufh7EreLNPu7ofuYH3sT04rDtJ/It5kYnfIe/pVo3ktvbxRW5C56kdaANb4p+NJfEfji8lt3KQQDZHjjpS6X4ljvNMNpqYG4DAbvXEaxA1vei5RDtf71T2p82foQrDigDorKze21hXtW8y2YZJz0rQuXjluXI5APFZGg6lJp8r27rujfjJ/houJDDfNGjfI3INAGvaEyJIGUHHrVI6q2k3KyzIXt24dD6Vo2SNNbkA/vB1rG1hCVYScgcEUAZ3iAWYga+0Vh5Ux+ZO6muScEHnrVm5Els7R/MqNzjtSqGCOdu4bSCfTigClRRRQBb06SKK4LTruTb0/EV7B8F/ixeeCNTlhtUlutBc77iwLY2nu8WeFb26N3wea8Vrc8PbmguIYYyZpcLvx90UAfoVbz+Gfij4MWSF49Q0m6HUfLJC4/VHU/5xXiPiX4VXPg3TNS1S51Nbq1iuIo7QhcO6O2CZOwIyBx168dK5D4OeJU8F65FdX11fW1j5RE9taw+b9rOMKrAnC467uvGOhr0T4k/FzSPE3he60jT9N1JJpmjZZZ1RUUq6tzhie3pQB50k7S3wiPEWOtatrapPqFqjHKk7ay9Ol+0hI1QGU8cCvRNM0mG3itp5I8+UMk46mgCprvhpNP0J4dMc/abhxvPoK6Vtaj0/wlp+g2mDtAMzeveuf8TeJ4bG0lWVR50nyxDvV7wlodzq0XneS/3NxdhgUAeReP8AxjcXOu2+mwuRDbP87A8VxmvatcXdxFLHKMQNtV89Qa9a8XeDdObwvquoMpW8hVsnHevnCCWVFMeD8x+U0AdPqNyI7pLh1Dll4A6E1Dp2gNqjSM0jrFjcc8DPtW14P0A3cMd1qT7IYzkBu9b+r6hp8ayLAyqiDjHegDk9Vjh0vTVt4yrSD3rk7zzJWyeCBV7V777VKzxqWCnA+lQRL9ojLSfKcdMUAUreWQv5bZOeBXoHgPVZLO21HRiqOt8hAZjjacVz2gWamRpZY9wXuRVq1jdb2aS1Yxzg5jIHSgDo/B+qLpfgTxHpt3CGkD4jc9c+1edSRXELxzhiDk5PpW95t35csTNI+9tzg/xHPepUgkkh+eI/QigDEgu2jGWJaIZyK1fCer/Z9SUy5MUrbevQVQmtZEm2hMKR0xT9Psfnkdz5ewZFAHttpY6deWzxtEstu4yRXA+O/Bv9k3cd9Yo32Jx90D7pqDwV4ol02V4brLwk8Z7V6JqGqG70GUTRK8bDMeaAPHYddittLvtMu0l8uX5oiD0as+6tmurUGNQzhQw5qbxDA8M/mz24eI8ZHG2pfDMcd9cLGsuwqRhT1xQBWsZFSKHH31HI9K3pZ08lC56jisq/shY6m7bG8mTo2OM+lQyzxuVDkiMenagDbhuGnhMbtnH3fcV0ujTxR2KNIQsoO3BPWuDa4SNVZSRg8etdFd3imO0khYB2XlB3NAHRX1nK0hccgjIAqto3h2bVbn95GyRjAZsVo6bq6yxRsy4kUhWBGa6ew1IWxKqgVDyaAOR/sX+x/Esqwqrp5D/h8prxVRkH6ivddXuwuuTzoxIaF/8A0E14UnQ/WgB24qCBj61o6FC1zfwpk/e4rNRd7qg7nFdP4ZsHXWIQuRtOelAHpkUEJiVGY7o1GR61fhCNbjywN2OK52S+LXLhR90YNXrGeVtpjzwegoA1RHttpPPHzCqGpiGPQvPA+Yv8vvWqwaRNj/ecVz/iaXyo7exAykR3MfegC94IthBY3V02PPl4X2qfxzeSWnhgrlhNIcKRTPBbyXCyzqmY87QtdXdaBPrtxBtgEkVr+8kT2oA8f/tJbfSktJH/ANI27ipPNY9zNEbZWVssTR8Uri1m8YXLWC+UigIVHGCOtZWnq0NuDdD92xypNAGko+RGYDBPerVitpC7tMpJIytUzOrFUXBOalv96SJhcAjrQA2fEjE9s8AdhVIqY5soeO1WhBNGPnBKtU0du6KGCE+9AElgq+bCzEqxI3fStNTpNr4iudzFoGiIT2bFVbcbJkZ1OOhFQ6npLwagrAFlkO4UAYe12Muc4VyR9Kt2k5Kq0Z5XtnrW6+myG3lQRjeV44rnLG0uI5SjKQwODQBYE7tIz9ST0xWgZ1eHZtz0OaW1iggdjOM5GT7UWJKXWNu6I9zQBVuId0yuq5VRk1k3NzJNfwyLlYlbge1bUxNvHdNvODkAe1Y7y+dEzxKCU5xQBv3MMV9bvEsnzlcgVgxh7c88FDit/wAJahY3c7RXKeXc7cKT3rO1cp5lzExG5GJBHegClPcS+cuHHzda0NPaO9tJoHbFzEcxt6is2yZHT58mr8No0MqzQnnPSgDa0m/eHCyHMgGGpNUlEkgKjcGPOKqTt5M+5VOXHpVizcyMisvzUAZeraUSokbaQQcD0rK061k+zXhIyixOefZTXZ3VvvxGQS3vVCe2EWn3xGVPkSZHr8poA4GiiigByjJ64rrPBMbyu5iIGw85rku9dn4ViNpYCbJ3THI+lAHX6iocowkCsBzTrfa+xYyWPT61jzXG6cR5y9dZ4P0t7phIwIVWzigDrfB2lNxKBhg3UnvXV+I9aFvYx2kWNifM7evtWZY2xtS8rbyOiqOmar67pht/KmvWKwON7Ank+1AGJY2h1jxENS1Z/L06MjYpPLY7Cu6m8cXdvpt39jHlqgwkaj+H0riNJuVvvEoQgeVGh8tB0QY61m+KtdTR9JvZIgGdSdhPc0AeyanrulT/AAkm8Q6xbRwpLCYhGOrHp+dfEgb7TrEssSFU8wlE9ATwK1tZ8ca7rejxaRcXJ+xLIXES92JzVhbJ4oYZSihzjc2MBaANS7vbpNOht3JVW5bFc9PexrehT80YHNWfFWqqixWtm6ycZZ+v4VhJbzSzgoCSwzzQBt2UOHJUAROe/pV829hDJ5Y+eUjJx0FZ1vbXBjETnlRVyOzi8tc7jIP4lPWgDd0++06LT3tzE28HJNVDPp32pZ7PezIMso7VQ+x2iI+7zC54zk8VLZ2cMYOx2Qtx9aALP9s25L3cUJKp97I5qRfFka/vfsiFTwATg1SeFCmzAMfcdKfFZW0UeQiknnntQBT1DW5L24EkduEHYAVUvDuiVpcqXbkgYFbuIAvyxBZB3FOUpMipIismehHQ0AUbOyilwI2+XHHPetnRtaZEXSNUYomcRyZ6fWsi6jhSRVjcwMDwwqtOshvPncTYXvQB1mpaQrQy2sjB0kHDdq831KyutA1MYyMcq3qPSuw8L6xHNFPp9/NsmGTC5/lmp9V0v+1dPlVpAzpyvvQBx41GbUJollmby85KZ4zVa8tpIbn5Hyuc1n7XtrkqwKyI2CDU91cO2Dkgt79KALEk0nV14q/EjSxQSRqxOcgg8isaW7Z4FjYfMO9dp4GsLnVPPWBQotrcyPmgDp/Di2bBRfFhKMEe9X5rvN25U4izgVzmhXsEtwr3Z2lTgY71vXaQCXc77Y26CgCoZozJdC4P3o22HPsa8bHQ/Wvc4NK8+3mdIXk2oxBUZ7V4zplqLoS/Ngrgj9aAG20W1llzkjkCu/0e6tktFfC/aivSuMSIRyBSMqOhq9ZN5TM7nkZCigDqdMb7RK43YJbmuv0y0WJGdTuI5rj/AAihvZ3jUfMDkk16xaWUcdrEoQb3IHSgDIWGWW1NwRscHC1yXiPzU8zahkH8b+letLpojLG5IFui5NeS+JdQa1v7iGDDwzthQaAOn8KxfZ9Htmh43fNn1q5qev6hoj3d/Z3QjAiIaMn73FWreIW3huxghXEmzex9K8Y+I99Pcag4MpCL8pUHigDmL+5bVb25u5gFlkfcce9WgHfS/LbhU5BNN0gKtlK7oCM5pl/cPLZ7l+VCcYFAFO1uXhlVic4rqYbhL23V5WVQnrXO2WnyvsldD5ZP51qQ6VI84ZmxEfSgDUvdQjiYIq7hjiootXlHyLBu/Cp0tII5FLfMR2q+uyPDhVGelAGXJq0sjBfswU/SrialdPHuaDcV6EirLYYEsBx0460nBjzuGCOlAFFtQ1OQEKmHPfFUza6sv7woSTyTWynEQIPANTi4ZCFDZBHIoA55ZJ4nKyxljnnIrV0m/spWOB5Z6YarWECu5AOOKzprSJjuRQhY8gUAS3drGZ2WNllQ81iyWcf2hzC3lgdVNaZtpLVGeFvnPSsq7U200byn75yaAKOsWrWskc0bbNw+8OMVnxs/m5ZywJ5J5zXUBI9Rje3IP3cqTXLSo9vK8R6qxFAF+DDSPETsGMj3q/DcyW0aFzuIrHdzsSXHUdKso7zxAr2HIoA24Lz7Vdwr2IrRs5XF242D5e+KI9EjtfD0GpTuEkc/KO9S2qSnDqvy9TjvQBqO7yw7wACOM4qhqkTHSrxwOfs8m7/vk1r6e+5R5qkRnjmpNatohoepPGcKLWXH/fBoA8XooooAUV6HpYb+x7YKBhF44rzwV12j3Vxc2MVvETvQc0AaMCO14HGd2a9s8I2ssenrNKnlKRgA8V514V0wxqJbxAXBBGa9SsI7vVVUj5LWMdTwAKAOu0lrYWWHUPs+ZmPSvK/iDrkupakuyX9yuSEB7DpXU+PNdgtfDqaforAuP+Phx1IHavB7jUJbi5Mwk+b7uB2HpQB6F4WLGSSZT87Arn61zfxmuDaWVtaqgBkOSa6LwIrNbTvJ0jXJPvXmXxQ1uXVNZ8luVi4FAGR4Pslur93dcrGuQfetPV7h47KaBn5dtoq34ViNlp0n7vMjjcTWRrD+cyMExh8kUAZtjbbJwJFJ56mt+xA3BsY54qla4kfdKCE9RWzpUcIZ5H+ZOi0AMb5WkbfyRSWxKKSpyetWr7Twp85eFfnFU7crG3z52kc0AIPNZzIT1PQCpDKdqj060j/I4aP5gRTUABYSHg0APdiRkP2waaZf3eFbLDrU6qIoRlQSR1NQRxuWJjA69KAEguyd2QdxHcUiXMgGMYIOelWVgRZMkZ9h2NT28CxRzO+C3UUAUZ3knKeYnIPUDqKgvpI/MMagjj1rRcPcW6ugAZeKxL+KYCRsDevOPWgDK1Ak3UAiyShzx25rs9CvPOfCMQFA3e9cxZQsWd5l2bhgZq/oNwbS8eCQZD96AE8c2P8ApKXMCDaw+bbXKiQ/x/MPevSL6a3uLV0hTzHAwQa4O80m7t7b7U8DC2LEB+w+tAFdts3lgD587SPUV6L8NtZS1stat5SEnktXwTwTgYArzSN2jkVlOGU5Fb1ijahc2xgxHcynZx0Y5xQBqeGZBcsEnYCQtkCvYPDml6XbT2L+KJgiN8whJ5x7iuGsNAtfAt5Jc6/OpvGj3WyEdCe9X7XVdNvnaeSctcrzvc5JoA9R8Q+OtNsorq08OaaiwiJl3suAflNfKelSCNnJOOn9a9O1XX1dpRbqNvlsCfwNeSL90/UUAXprwyTEEhUHQ06a92qqD5ipzms7rVvTrUTTKZOIw3PvQB6n8L9MlvGa5dzHH1J9q9WtmVruKC1Bdl4Fcf4FtXuLYrbrshVRk10Op+ILLw7En2ICa7J2sR2oAg+JfiFNKsXsUfddsMsAeleLNqgutZsiwJ+YcfjXS/ELUE89r2U75516dcVxPhiF9R1+0QjADgnigD3ueVI9OZ2cJ+64/KvnjXJHm1ecM+9Sxr174gX3k6d5URwVXBxXiMkha9LHnLYoAs7vLR0VsAr0rT0+1WbS42bklumaoQ24l1NYW+6wzxW3ptqAxjE2Ah+7QBYVXRNoxsAxinRxSKn3855AqWa3dGLA5B9KW6V1gjlTqBzigBEyfvrz6mniMMMuflHTmolug7AOMZ45q0hTythIx1zQA5lAfYDnjtToo3clVUYFNXqCo57GpYpE8sgNhqAI2DBijDAqFYpY7j5QW3VN5ke/EgJpst1GrfJ8uOOaAIyrFtoJyOTzTJsAq6k5B5pm7czsp5x1qbZuhVRg560AQXV4GfJI2gYrF1VluriJd21c9a0bhooY5klXk9D71lAQyYV22sDwc0APsrj7NevGfvBeDVTU4RLG84HJb86rXwkWfKE8jqO9XkBk02EOwGGOaAMuFDNEV3cpyBVuzm8uHOMuTjFQXKi1uS0bdew9KWIFjvToWoA3rm9kuBFbXLkRxDIWur0Odp7UxLHyRhT61xep2jvqMGM7GQFiK0rTxIbe5S2tyqKnG6gDuLSylMflzfLjkVBrKqmg6mu4H/RZeM/7BrPTxHNdxCJSpdRy47VQ1KeQabehiW3wSZP/AAE0Aeb0UUUAa3hvTW1O/aFRuKRmTH0IH9a9F0rQmtpllhTD7eVrA+DlqbvxRcIoyVtGbH/A0/xr3mz0CF2aWT5JMcCgDn9K0828UdxqreXD1CdzXU2Wp/avMZE8myVcInr7mrWs6ILrw6hYq0sbhiT6DtXNXouJIGiso23YwABwKAOE8Sa1JFLfCBcmRiAT2FcRZKyybXJBJzW74ojuLVvs8q5ldsED1qppUNhbaslprhljEwEasvVGNAHoOm79P8HG5zt88lgfUYrx1kXUPFDu5/dhtzE17b8R7JrOw0vSbDJbyQo+p7mvNYfD8Om6u8LyF2KgsSe9AGhJILDS3eJQyscDNctrskgtkZkCq3PFdJrimMCOBWeJBkgDOK5PUTcahtKH5E4C+lAFzTrktZozAMO9WVmVMGPKx5yRWTYZTEIO0e9a9nIkW+OVdyN3oAmubiaZUMMmVxjB7VSup8orH5ZV4KkdauTW0CNGbSYEuR8vXFPvLCSR0jVQSepxQA3R7SS8TdvUJ6VOYkWY22wHLfeqK6tX0+Py4X+fGcCq8U5QK0rZY/NnvQB0EWnAXKbn/dAVSgsgNQlEpIRuAQaw7vVZp5lgidk9Md6umSdxDG0gyR19KANCaCHTxIHkDHtzWLLcSmBnViMH86tarp8gRZGctwKlhtY2sEOACo5B7mgCGLUN9nFAqjeT89VdQlEEqKWyR3PeqlxKILtAgxtzkjuap3Qkv5VhRWMjOFVvXNAFm4+16jewQW6MxkIVVUZzXrGgfCPUbu3E6rKJVUHLDgV6L8D/AIPrbWNrqt/tec85cZx7V9F2trFbQiKJFC45wOtAHxBrXhrU/Csck13prlCcNOg3IPr6Vy3iGW5uPD8kVsw8sneyYz+VfoLcafZ3Ns9vcW0UsDjDI6ggivCfid8CRPHPfeCGSGZgS1jKfkP+4e30oA+Le9dL4aYLLps7cLb3IJP41U1bRp9E8RCw1qCS2kSQCaNxgrzz+Fdl4v0Oz8O24eGQfY7wK0Zj5Ge9AGr+0nbXJ8Q6VfOpNrPaKI2HTIHNebWplE8Ma7trYJOele9ePrZtY8LeAFTZLG7iB3foAVNeT+NtHHhXxObSymW6hcZG052+1AC4Zo512lV8piDj2NcRDGHRyWxtx+Nd1bO1zZTNwuxGVh+FcdpVr9pZ+u1SM/rQBVRWdsRgnFbGmwbZovPYKmckVejsggKwx4Pc0HTpyN4G4A88UAeneEtQ1LxFq2neFvDLQwXF5uQSy5CqFRnJbAJxhf1FVdZ0XVfDeoTWXia1ktL1QXAc5WVf78bdHX3HToQDxXoH7Jvhl28Varrlwn7uzs1tosj/AJaStliPcLGP++6+jPFvhjR/FujyaZr9lHd2j8gNw0bdmRhyrD1FAH5zeJLx769OH3KDxk10fwks/tPiKSQ8rCma7D4xfArWPA/n6tpLyat4djBZpsDz7YZ/5aqPvDn76jsSQvfn/hLtsNM1W7k4ZhtFAEfjy+Ms0gToSRXm+AcE9c16W2lza8ly9suXjUkCuFn0u9iz9oheNVbBJFAC6NIP7ULMMqq/lWnYOReSMAdh6n0rN0orBdMHA2sMZNai7UJ/hUGgDUSUKDz8vvTop2cMMAoRzVaF1mVVA9s1cbME/wBnjUNkc0AQXFuksYcHbjqagWGTIC/cHfNbTwxC2VZOD3AFQXNxCLTyoE+bpQBXtZC6YP8ADwPenyTJFA8nG4dOarR5EJG3kGqOo73eNFJCHrQBcNyxRHVRz3NRTyeduUjDYqZCptVjUfdxg09YvOIY8cY5oAZBbmKwLtk571BbuPtKBWOByRmtSEK8EkQbgDOKwbmQQsdi4PI3UATeIZPOh3JjGeorGis5HWNz3PWjz327SxIY112haXFPGjNJ/wABoApQ6CbiIiJiZAOBVmTwxK2hO+xhMjZxXs/hPwdBdWIltgPOx0IrqtL8JsxlhkhDMByMdaAPkS+0p4lZ5AxYjgVRsi4DbBk5719U+JPh3HeZkt7cKwB3DFfP2t+Gb7QdZuzJExhTJyBxQAt1LHFp8Ekh5IwfbisM6M0sRksy0pHJUDkCl1C6W5jVV4Uc4rpPBmvQ+Gre5uLiJZXmjKIjDNAFXwwkQt2XeRISQ2T0rR1EBNJvFjOcRSZz/umuftJxIZLlRtd3LFR0FdHqMyTaLclMYNu//oJoA82ooooA9W/ZxjaXxvfKgBb+znxn/rrFX0ZcaaxkeZnCqgy1fOX7OIc+Nr/YSCNOc8f9dYq+mngE+lXLeYTx82KAOdtNQi1N3tVY7QcVq63ZyafoBexhDSYwCe5NYy28enbZIIck9T3qe81a+utT0pChjsUYM6nq/wBaAOATRrDTtPvfEfiO4BWylISA/feQ+o/GvKLLfr3j2C8UfuGmE230wen8q9M+PniXR7mfVLe2QsWdIxGpwNwHWuf+ENnYamsUsCmO4gJjlT1B5zQBpav4kim8cT2945B8tViHbPpXYaP8P4PFmqWTWDzQuy5uFdcY/wBoH0rk4PDS6j43ti6Zjmvcg45KrX1x4Y0C30p3miXDOioBjoKAOET4LaZFpUkCz75mGdxXgmvkLxzp7eGPF+r6QwKzRy4CnpyK/Rivhz9qe1EPxpuliXD3FrC+48YyCD/KgDzI21zIQI8Ejk4NbOmLtE25ckIcU1dOlsdCFzM58stgbRnJqzLdW0Njbrp0gmdxl2YcZ9KAF0S3ikWS4BO5SCAfU1fvAQjTGTCjoBxmpvDN3bpa3QkjXcxySO1Pma1a1dNjMw+Y8dBQBl6dBJfytIWVSgPXvUVxppjUyysNo6AdzWhp6pdyhLVGIJwSBSXUSwSyQztyei5zigDmoFjWdd4y7nt2rTa28hQP4i3XvQ0bcLHGu8HOa63SrTT9X04FplW7hHK+tAGFdExGLDbkZRkE1SErKtwVA29MHtWtfIckLayOwHGwZwPeqi2StaEySlAxyFoA5HUofs5Rg+55OcelPtJGhntp4sboHEmD/F7Velt4rx9kZLSoeFUZJxWJqF4nmeUqkbeD2OaAPvX4JeNdP8U+G4oLZlW5t1AePoR+FekV+dHgXxlq3g3U/wC2NKuNsyKCY5BhJ17qfevu3wD4zs/Gfg2y17TVLmZAJIFILRydGU/Q0AdVRSA5AJBGe1LQB538XPhdpPxB0s+dFHBq0XzQXQXnI/hb1Br4d+JFjqmheJLnRdUjkga1OBExyp/2l9jX6TV5B+0N8K4PHvh1r3T40TxBZIWgfGPNUcmM/wBKAPB01hr39n7zwpE1nIFR16oQcZFeM6a8t3fLPLcEypyd5yWFesfC+MXPw18WaNegrLAWJhbqDjkY+teJo5jcMpwRQB3k0/mws0YC5jZWx9DVT4cWYu5L/cMhBGf/AEKrPh22iuniLMdqxs7emNpqz8H1y+rnGQEjz+bUAdL/AGMkZ3EAk9qvWul+W6qseVPXit5PIMSYjyR1zVtZUjiL7OgyAOpoAw4NV1XRhLBpuoahZQyMGZLW4eIMcYydpHOBW9Z3l3run3KXWsaruijJO+/mP/s1b/iDwbqOhSrJq9uv2dgNs8R3R5P8JPY9uevbNed6zqcNla6ikDhXYEAKcZoA8X165lk1WdJJpZgjlQ0krOcZ9Sa9BsoTa+DJZYeDIM8V5bIzS3DMx+Zm5/OvZtRs5LfwRaJD83mICT6UAYPgy/vraN5rZ/mX7y+or3XQPDNl418Gi4ktc3ecEIOc14V4atZhHK8SMSow2O9fZfwX0hNL8CWEmP310vmufTngUAfHnxK8Aah4cufMFq8VuT94jGK49bhIYxFjzGPVq+7Pjvocev8Aw01iHcqTQx+Yjkcgjt+VfBt6osLCEwkM+7DE0Abuig3AYBNiIclqvb40vFuBIDjjGa46HXLiEeXGR5R+9VuHUreV40y455oA6KS7drhhjINKtmxYSjgk55pltLYSTLGsn7zHBNDSXEN2vmMWhB4ANAFm6Ro4gqAEt96qTWqygOzYx2q7qeoxG8SJE25XnNZyXYVJZHQ+Wp60APtkVpdqHAHODVyVVjgZzn04rHTUrYXqtkqnWtj7bDfaZPJEoVIecnvQAyERxxO47jpmsW8Xz0dcYFVRrfnEqAqr7CtTw1Ztr7zQW+TKoyBQBgWwVHwwJKnv3rorPUxAvnRZCoea53VxLYajJbTL+8U4NVY7yREmg4KyfpQB9U/CrWxPp0MqyAMxA616xZz51GPYRlj1z1rwv9l/TotQ0O7mv2PlwthTmvWfiFp8ui6LH4h0a4LxwYLpntQB6SmmwSo7Y+ZhzXC+MvBVjfWF0jwJl0Iziuu8Ha3HrHhCz1QlVEkeW579KsTXEdzbtHMuVYZBoA/Onxl4dufDGuTW1yp8veShHQjNUNbUlbZ/4SmBX1P8ZvA8er6JdTxxj7TEcqcc187+LdIaz8O6dI6lZEJVwaAOf0+5C27JgZHf1rrdOjM/hrUpSPlW3k/A7DXC2WTcIgGdxxXZahqcdjokunW+NzxMH/EUAcLRRRQB65+zMXXx1qHlpvJ0yQEe3mxV9laF4YjTR51lOJLlcjP8FfF37ON49j45vJYzg/2e6n6ebFX2Lpfji2htY4rtJHlAwCo60AcpqmlyaTdJZ3qCRj8yuBxj1rgvF2uWVrdK9zerBZwvggfef1Fez+J9RtNf8OXc+mFf7Qt0O2OThvpXxV8WXYT2qM7EnJYE9+9AFL4p6jZ6pr8l1pIAs2wOB1bFd/8AszW4X+3bmePEIhwJD0Bx2rxvySNHLk8B8jmvo34G6MZvhxIuSgkkHmY6kFqAPQ/g5oiX+preXcH/AB7AtFuGcgnrXuVUNG020060iS0hWMbACQOTxUPiLWrbQ7WG4u3VY3lWMknoCeT+FAGrXz1+1b4Z+3v4b1WC2iDCdrW4uSOUQjcM+3Br6EV1dA6MGQjIYHIIrw39r7Whp/wyjskz519dIFIOCoXkmgD5MufEQtLS/wBHQG5tRIfImzhlPrXNJdTpGipIyqhyMdq9C8BfBzxT4zt1uNPt0htv+espwDX0b8OP2e9J0VEk1+GO6uRyTu3AmgD5e8IXGq+XIiabdXCud3mJHk1txyXvmTQ39neQW0g2tK8RX86+5dP8KaNYLttrGFFxjAWman4X0m6jbzbSLy9p3cUAfHl5oY03Sre60O4SaLId5Ac9q4yeOWISalc3COXfleuK6/4y6no+lahf6d4YM0SbiJAp+QN34rxkzyGJkaRyrHOCeKAO/uUNppUGoRCRlnBDbl4B7YrO0b7RaTtcSBk3cjtmorzxi8vg+z0RIlzCcmQ1g3Gs3s8KxSTnYowAooA9N1ma+svC6apcExrOwQNGR93vn3rltV1uFYkiBzEyZR15rlJL+7mtVtpbqZ7dTuEbOSoP0psFrPOI/LVirPsB7ZNAHuv7JVnHqXjzUWmtI7yKK1JAkI+Uk9efXpXnHxDtP7I+JWqfbrSNIvtjkwr0UZ6V6p+x40Om/ErVrG7lCXclmViXP38MCR+Vcr+1Lok2j/Fi+J3G2v1W6iJ6Zb7w/AigDmPHnibStX060stIslgWHl3xjNe+/sR5bSfEhMshCTRgR87VyM5HucV8lMCpIPXpX1J+xV4ks7d9c8PTuEvLh1uoc/xgDawHuODQB9VXHmeRJ5BAl2nZu6ZxxmuO+HHjCTxDY3UWsLBa6ta3DQSQBsE46EA812tfIf7RPi+10741aYdCdlu7CNBfGI4DyZyoPqQv86APryisLwX4ktPFGhW+oWbgllHmJnlW7it2gD59+LvgiPw5P4k8S6VEI7W/tvMnVRwso6/99A5/Cvju+0+a0jt5Xw0VxH5iOO/qPqK/TXxDpFrr2iXul6hH5lrdRGJx7HvXwX4t8GT+GdT1HR9cZks7CYvDKf4lPTH1GKAORhuJNO04QEkNPEXJ/wBnB4rrPgpgzawD0KRZ/Nq4e+1MXEkgCfutuxM9QO1d18EYjJJrWDjEcX82oA9SjTaG2AYNbHgjSZNX8Y6RayL+7E4mk442R/OQfqQB+NZ1rbYAZm+X2qeK+u9LnaaxuJrecqUEkTbW2nqM/gKAPqGeGK4gkhuI0lhkUq6OoZWB6gg9RXzH8ZvgDqCvPrHgCR7iL70mkSv8y+phcnkf7DehwTwtcV8S/F3iCKyhRfEGsqzddl/Kg/HDCvHNQ17Wr6YrcavqM+Dx5t1I/wDM0ARafZSP4iS0u4ZIplmKSxOpVkYHBBB5BB7V7P4qhkj0yzsofkQqMV5j4AtDPrnmS5Mmc5JySc8mvX/GrJ5mnIPvIvPNAGLpUz6Zp72sUatPjcxxXv3wl+JumXWgxafqD+TcWo2exFfPms+ZYyx3AX5pRtGK3dF8GagsaXaKQJPmNAHqnxe8YQX0J0y1n2RXC4cg9q+QfE0Ctq72dmGaOM445ya7Dxu99F4hMMs7Lt4AJq98I9PtL7xLI2oIJGXkZHWgDidM8JapqciraWMpUcZKmu10X4Q6xcMPMt2RTySRjFfTuk28CxJ5NvFCoOOBXU2aQn0KnrigD5aHwdvoWSVxtC9wa4nXtNuNC1RvOlDheimvuLV4bRdHupiwCxRk8nvXwX8SLy4uPEF3OS3lFyFPbrQBh6vqMs920zfKw4GKlsNblh0ya2liEivyDismORZFKyde1QtIcjacKKAJJrgycAbcdPalS7uBbPAshETcsPWonG6QgAZphUjqKAHxI5wUBxmvZ/2WWt4fiOLXU4g0dxEVUN/ewa878Naak8BluBhF+bNS6N4pfRPGNrq1h8otn496ALnxmsXsviZrdv5ZTExKLjt2riWBB+bIb0NdZ8QvEzeKPGcurSgBpNucfSudu9rz5YdenvQB69+z14vTSJ59MunxBMcj2NfQGveILCHwfqVs8wkt5lPGelfE+nXJ0+7SWA/OK6OfxVeX2nS2rztuY4AzQB6F4e+K97pVsNGilb+z/MOBn3r6D8H+KI9V0yORpRu2jAzXxjoPh3VLpzIlvJIq85ANeg/DzxBPpeovb35eMKcbWyMUAfUniOyW50FpnI+YgcV4n+0V4Q+xeDdL1CxQYyDJgV7T4CuYdbi8qVhLAq7gM9a0fidaadP4W+yX8SmB2CKvpxQB8AWumyWkyX020W/UY9arzkSfaZAd2VYj2GK3/imBZa82m2uUs4xlV9a5IMURwOm0j9KAKdFFFAHrH7NtsLnxtqKsMhNMkc/hLFX0Nq0EkVkl6qBUXivB/wBlYoPH+qeYMqdJlH/kaGvevFF19qtks1OyFG3NigDk9Tv5rS2Dxyuskpydp7Vxljb+HvF011Z6yixagSUhm6ZNbWtXKuHMbfJGGUZPTFeQ+FtetbPxJIL5WkEk+UbP3DnigDY8dfDDVfCWmxi4R5LaWTcsoXgjPFfQPwct1tvD9rbNHtQgTOPXHSup8B+INN8eaPdeG9at0eWGIYDfxJ0DD0Ip0nhu+8MwrHZQy3sezYrxJk4z3A9qAPTLGUz2scjLt3DOPSuT8U6S+v62tnKN1vHFuwenPrXV2RKafAZV8srGu4H+HjmqHhnVI9a0n+0LfaVlkcKR0IDED9BQBxniTRT4c8C6gk+qS/Z1jcrGGKhOOAtfNOveI08fJ4R0Np3uRFMqSMxyeTivff2ovEtjo3w3u7Odla+u8JCgPI/2q+Ovhvqv9l+LtHmcDy47lXYmgD9HdKsLfS9Pgs7OJIoYkCKqjHQVbrnbfxnoctgl2b6JEKgkE8iuL8R/Gzw/pOtWenRN5zTuFMmeACcUAerVQ169i07R7u6mOEjjY/XjpV2KRJYkkjYMjAEEdxXlPxw8caNoumTaZe3SrcFA7IDzg9KAPifx608niW8uJV2LcuZEAPUZrnevtXSeItZtb3UpZ4ohImR5ef4azZ4oL7Y1ijLOfvxk9T6igDMOaSnujI5V1KsOCCMEU0igAFe0/D210f8A4Vzqc+sQ7Ht42kjcDkt7V4xHt3rvzszzj0r3G3vDJ8JdUk0ywb7P5PltKwwqDnv3NAHmHgfxPN4b8c6V4hO6R7W5WaQA8umcMPxUmvV/2qPHWh+M7rw3JoLmUwQu7yFcEBtpC/pXgnenyuZGyx5xigBrHccnqeTWn4Y1y88Oa5aappspiubdwysO47iu38TfDqTw78MbDXr6aP7VeSBkjVskKa80PBoA+v8Awv8AtJw38JtNQtUjuymEnzhS2O4rgfAnwzv/ABl4q1LXNRk83z7hyv8AtknrXz+GPABI+lfYv7JGu2U/hx7O5nX7YjnaXbk89KAIdNg8UfCLWJ725025ufDv/LZ4BvVV9TjpivoDw3rlh4j0a21TSZ1ntLhdysp/Q+9aMsaSxtHIqujAhlYZBB7GvH7bRL34VeI7y/0xHuPBV4/mT2yctYserAf3M/lQB7FXz9+114bF34QTWYEJltz5cu0dV7H8K96sbuC+tIrm0kWWCVQyOpyCDWf4u0uDWfDeoWF0oaOaFl59ccUAfmKFJUsBwK9Y+AK7pdeGP+WcP82rzrxJpkui67f6bP8AK1vKy49R2/TFekfs9ui3GvByADFF1+rUAewpDH9nUMQADn61jeIL9VvrdFACYxVy4vFFsznop/Or7fDLVPFvgK08QaFdqmrO0kkdpOcRTRBiFAbGVYhcgnIOQOOtAHifxJkL3DZzjHAzxXn+nRCe7OGCnHQ11vj+XUIHns9Vs5bLUbZtk1vMu1198dweoYZB7E1xlhEpJlmcqo6Y70AeofDHTA2pHjfITxgV3FjpU3in4h2+m2ynbGQHJ6ADrWF8L7u307T3v5UO9VIGe9dL8JvFkGl+J9R1aUAh2NAHd/EzwdpmhQ6Y0km8FsfN6ir2m6mktwkMahbSNMFu3SvJ/i344v8AxRr1udvk2MJwg/rWBrHj+SxtBYWUgaQrhiPpQBz/AMV72CbxzO0bgoh6iqvg3xFHp2oSzgFSBmuS1Cd5bqWWU7pHOTTLWNhG00uFT3oA+hPDPxVtZZUW+l2oDjGa9f8ADfiyxurCaa1cOhHevhxZI4wXIOO2K7DwZ44n0uJ7U5MTmgD6m+IPjWytPBNzao4N3OpA5r5G1u9+2abNbOFMwbdu79as+NvFc2pXyCFz5ajB5rmlJly6MS560AVblIRbxmIkSLw4qvt8wZUYYfrV42E8rHyozgdcCq5iktnbehC9MkUAQFHwDtPtTwHJIf8AWrFtOgYb8bDxVtNPhlyTNwTxg0AegeGRbWvgi8nuSpZkIWvKAcknHU11ms3EcOmR2VvIfKC5b61y1vGZXwDjHNAEigYy/U8Cpry2mihWVlYIe9NsxHLqVpFKwEfmKrN9TXf/ABb0+LSGsUsXWS0liByOmaAPNV4wUPPcU+OQrOjquCDmlgj3Nkg4qW5ADBiMe9AH178IVtpdCsp4UjdyB5ikVz37RPhywju4L/SFW3mkXLheMmvEvCHj/UvDyRrDIxRTmt3xZ8Qp/EixNcDGzqKAOy+FHjXU9DBVZNzLwQ3evQ/E3jtvEOmhriRYjFyEHc1852ss0jiS0ZgRycV2Ph7WLM3kVvqqlUkAUv2BoA5j4k2TXrjUFOX78V55DmTzFPUIT+Qr2Tx7p32W1mCr5kDAmN154ry/T1hSG+d0+byXUfXaaAMKiiigD1X9nO7Fl4z1KQ99MkUfXzYq+hUiR9MmmuG+ZgSTXzV8DWK+Kr0gE/6C/wD6Mjr3x57n7HICCUKHC4oA8u8QavBDDforgN8yqe9eNzWlzBtnmjdVY5Diuo8UWup3d5eSRW0hijc5I/h+ta2i6TBpmltf+I72N4wu6K3ByT+FAHofwM1uW1svtzMw1QvsiLc/J71758OfiFc+JfEl3pFzDGfJhMwljGCMMBgj3r5m+FWoXXiPVb77FbCJLeElFQZIGK774FeK9P0LxHr9zq8wTdGsS+vB/wAaAPf/ABvFPqdhJpVpO0O+MyXDqcFYsHjPuf5Gm/DiO0svBemwW0iCKOM9/c14l8Rfi0bHw/rDacx+26pKIYmPVExtGPwz+deY23jrWtJ02SNJ3e2hi2sd3TigC5+01q9v4j8eNFa3KyQ2q7CAeMivDbcSi7BgUsytx7Vu6jPBrHmTQtIt7KdxB/iqnBp91GDHHlWY4+tAGxJr2qnRmg+0NhXAyDWRNHeNq0RvJGLKQwcnsOeKd5VxFi1uPkGc0+31OSS7kgaNZQcqmeDQB6N4b+NGs6Ct3C9zO7Iu2D5+Bx6V5jrGvXmu67LqmtStdzytufec/hVW92Sp5oDLKG2urdRV3wtpa6rfrDglgQSvqKANa/8AC0t7pUepaXA7IwyyKuePWpPDPgPXNSVrm2R4Xj+ZCVPzV9nfDXwppB8GWTwWymVUwwI6kV2lr4c0wWkaCySLqcKMEUAfnj4ia9tb5Ytf0tUlX5S4GN3uDWbcPpGQ1uk65GCp5xX278UPhPo2u6bKZjtbBKN3Bx618OeINPXS9avLFXLrBIUDHvQBoaXa6bPEXkPyowZl/ixXS+PPH51PQrbw9oqC00mJQZEQY3t71xGmqFlVskhuDVOUYkcHsTQA0YzVzR1VtXsleEzoZ03RLyXG4ZH41UIwOnNaXhl5YdctJ4eGhcSZPOAKAPon9ofwLeal4ZsvEXhu1lg0S0tw01ozfdPdgueMV8xHrX0H4Y+ImpQeGvFVlrly02nXlqwiV+QMgjivnygArU0DXdQ0G9S5024eGRWD4B4JBrMxinxRvNKqRIWdjgKByaAPtz4QfHvSfFFpBYa6ws9YACnP3ZPcV7XHNbX8DCN4p4nXDAEMCD2NfmTp+m6r5xmsradZYB5m4Lggetez/BT4rajpt2ILq63Z4bzDwRQB73a6+Ph54iufD90B/ZczGexLHhVPVB9K7ga7a6zo85tJFEpQ7QT3rxP4jXkfjrTPt1qw+12J3jb3HcV5pp3ji7t92nw3DwyxDhietAGX8QPCYu/F+q3etXYtpOqRqOZODg1zvwjufssmquc/dj6fVqp694rv38TPeamouygKqrnjkU74ZOANUQ4+dY+v1agD0i+1Mz2rRRMqzPwgY4G48Ak9hk19T6Z4h8J+HdCsdPbxHosMFlbpAC97EvCqF7t7V8h3TRxfMwyQOTXPT3lskpjjjQZ5JCgUAfUnxQ1P4QeOdJ+zeJPEeivLGD5F3bXaGeAn+6Vzx6qQQfTgV8eeKtM07Q9aNlpet2muWKgNFeWyMgYEnhlYfKwxyASORzUes6m91vhijConQr1rEYSSMoAJYnANAHrCTlPCSFBtDrgYqPwZAzBYJjtVm3E+1dhFoEN18OLC3Q7b5QHYVxFterHcSRJkLbDDEUAVfidr3m6iljp6gRxYXK9zXIyqtvGzz5Fyw4zT7K5SbVrq8uHACksA1Q6teLfzeYF56cdKAILKJ3uBI43etSXM/n7hgqq9AKXTdQ+zThZUxHggmltomfz5tp2McigAjxHbxpIoKk0XMUKTYTjIyKS8bakceDk8gVNFJFMYElGGGATQBkqp88bhks1dBpWlvKS6EDPaqZRLbXI4nGY2IINeleGtJhmmXyTk4BxQB3/w28E2D6Cn2yHzZpuvGarfEX4P7bGSSwAQEZwe1e1/Ce3to9MVpVUOowN1XfiJZzNYXDp9yRSBj1oA/PfVtMm0y7e3nIMinBxTbMkXEaknLcV1vj7TJ7HVZHuQcsxwT3rCgt8OkwXB7ZNAFXVAVkeM/eqEoYLRWHDuec+lW583F+WAJA6027YylfLUlxwAKAKlnbmW4QdD1roPFN1PcadawzNny+FzTHij0yzRpAftb9vQVFrp+1WNqyfeH3qAMOCVo3A49KdK5bIkx7Gnsibh2bFMmjyoxknmgAhiy4Unk81Yu/lt/lBGD1q74eto59Xg+0tti7muj8UtY3Ns9pp8a5QZ3DvQBi+FtV8m4VJOR0PvXReIAIYI5F5jk5HqK86hd45Ay5yDzXcW+oLc6ascpBX+VADj4nv20d7SRvORR8pPJFcrFdJ5VwxI3OjgrjuQalvpRDqIihPymqN7GsbtsOTnmgClRRRQB6L8DZGj8V3pQAk2Ljn/AK6R17RqWtjT4QgKvKe3pXzn4LuZLTUbmSGZoSbcgsvUjcvFdRd6xdkxMzbgTguT1oAb8SfEDNqQh0xjC0q4nCdGNef3DzSN+/dnI4G45xXaeE9FfX/Ft6rkSLDE0p/pXN65B9kvr2JxsYSHauO1AHuX7ITNaa1qszwiWO4iECAnoe5pPifo9v4L8QvbI6G5vrjIA5Cg88Vz37OT3Tatcx2zFBGRIWzgAY/+tW54nsbrxx8Q5JkJkWz4VuoJHXFAHnnxGvit5awhcvEm6ucu9ZMtq0WS+5RuBOBmu18SwxReK7lrmPf9njzJn+ECuV8PaBL4j1e6i0y0kaJs7Mj7mfWgDEF/KoUwqsZC7cqK0tKv7qZSgBdoyX3/AKAV3eu/BfXNI0J71vn2xmVsD07VxnhvUbTTdM1FZ1H2tyoQfSgCnc293cXv70kSBd7E9KrRRNBewSl9qBlLOP4cnn9K00m+0XDySyeXG4P/AOqqpIbRJyfuiU7T60Abk2l2jaheRT4dJYw0MwHGcdDVTwJciy1NmcYlhbfn26EVH4a1yS1PlzKJoAMFWGSBVrVLE2F5HqFkhMEpyQPQ9RQB9zfDLUEm+Hcd9YlJGKs4GeM44zXdRMXiRiMFlBI9K+U/gt43g0TT/wCzZ52WCX5lVjxzX0HbeONJFskl1OkKEABt2RQBe8Yox0kun3lbH4EYr4R+MXhp9L8TSyhSFnYsT2r7d13xTo8mnKyXkUkTMOhryL4lQ6FqmkSXR2PMn3QcZoA+UZIRaxwq+1WBDFe5FZ0kby3DuEIBJbnsK1dQtne6lkYtw5HPpVK+kVm8uPdkgDgdaAK8cMt3dpBbqZJGO1cd63tSVNEghtIwpvNp81x2z2qKCOPRo47jcTcMvBXtWRdSPLMZDlmbuaAN7VbmS48KWQUEbMLJj+ICuXxlSfeuo0x0itzayMJEeMhh/drmWG1nXk4OKAECkjNdV8Mljfxvp8kirtjYybT0OB0rl2jYLkkD2rpfBDJbXNxqE2QtuhwfegD0/wAW+O9Nn163tNGtIowI2guCFxyf/r14jciSyv5URirxuQCD71NJqGL+S6jX940hcE9wexqx4hhXFpdxqdtzHuJ96APpv9mBrTWtIuYbht77SJM8mvO/2hvDA8L39vc2MLLFLIVEo/kaxPgH4xHg/wAXWrzTYtbptsqHoPQ19DfGSTTvH3hK90+zVBcwp58Rx1I9KAPkWS5tZNNkN0v79kOw/wC1VrwKSrXrDPAQ8fjXNTRyQytFMGV4yVKnsa6LwVIsaajvOMooH60Abmq6pK7lVOFxjiudluSwkVThgDUvnhVmVslz0NZzSIxO0ncfvUAbOnaY0vhO9v2BMgbA4rDmcww2jp/rFbJPvXf+EbiGTw3cWM3Q5OO+a5DWLSO2RuejZAoA9t07Ung8Hi6nwC0Py/lXlOlrONN1e7lPEjYFT3uuTXPh6zR5CsajbgU/yymlxw5ysh3Ng0AYV3ZWkWjxMCftMhztq1pPha+uwskcZCAbjmrmlxQah4mt1Zf3MWMjtXsl79m0+xBhVcOMfhigD551G0kgeUTJja2M4q9bzB7KKOIDgc8V0PjNLa4jzGRknLYrmoJI4p8I3AWgB9uA+tDzBlFWq8iI80oHBByBTreYLMzg/M2cGoIz8zZ+9QA7UicQOP8AWoetdTourXWnQx30RJAwGFcvfsYriIqd0bDmrmmah5cj2snMMg6Z6UAfTnhD4i6Q+gwNcXSwSEYIzjmuvvPGWn32kRRR38UsYHI3DNfE2oZjlKQyNtB4Gajs7+7gkIhuZVI7bqAPoD4g22jatB5quvnxngZ614hqys986xfKi8ADpVmPxBc3Ee2Rirr1PrTLm5DxGQfeoAokIqHB/edCcVHau0EglADEc03zAzcqSD6Uluq72DEigBZ5Zp52mufm9Kv6W0UtpcRXAySMqcdKz5X5aMH8qt6U0fkzbx8y9OaAMlIzvIxkg8GrAjdc5H6U8z4zhBmlL71yWwx96AFQFLfcchieoqWyuVivItx+R/lbNV53IgUKckVRkkIAyeQcigC5q1sLfU3hQgI3IJqeEJbfJ5gZT1xTbm8hvFhaVWEirjdWfeldw2H260AaOsW6o1tPCuUb+KsqYYnkGex/lXTafLHdeHWiB/eR+tc07BpX3cYBGaAK1FFFAFvTbz7FO0mzflduM47g/wBK0m8QM8Wx7cEY4+fp+lYVFAHW+CPGP/CL6jc3RsftXnxmMr53lkA++01B4t8SWviC4S4XSxazgAOwn3buPTaK5migDovC/iu88OzXMlkMefH5ZAOMe9db8O/ivJ4R1Brq50r+02IwFNz5X/sjV5hRQB2Hi3xmuv69f6jHp32VLsgmHzt4XHvtGfyroPhx8UrbwUkuzw/9tll5d2vNmT6geWa8vooA+jJv2mDPpk9lceEUkjmQoSdQ6A/9sq8Dvry2n1SW6htDFC7lhCZN23J6ZwP5Vn0UAXLq886PYI9o3ZHOaRrvNkLcIQAd2d39MVUooAnt5xC4YITxg89a6G08WNBYi1ezSVAMAs//ANauXooA3v8AhICVZTbkDqu2TBU/XFMuPFGrT26wvdy7FPHzViUUAbQ8S6qHiP2uXEeMLuODV+58Z39wqiQtkdf3nB/DFctRQBq3ertcZ/dbQeo3Zz+lS22r2sFq0f8AZweVv+WjS9Pw21i0UAWJLkyHLgn8aaJiH3YBqGigDU0jVFsGmaS289nGAd+3H6GqRuDvdgqjcc1BRQBI8m/kg5+tWY79o9PktUXCyHLNnrVKigBe9Xf7QY6aLOSNXRW3Ix6rVGigCZpUMahY9rqfvBq6/RvH99p8cKypJO0alNwm2Fh2zwa4qigDR1zUV1O+a6EHku/3gG3ZPr0FRWF59lEoKFw4AOGx0/CqdFAGj/aK5z5B/wC+/wD61VjcYYlF2k9TnNV6KANbStak0+6EuwyL0KbsZ/SotU1M3908pjKKeibs4/Ss6igDSh1PbZi3li8xQcg7sY/SrUWvMhG6JmUDAHmf/WrDooA3NP182Vw0ottxJz9/B/PFdJcfEeSeIRvp52gY/wCPj/7GvP6KAN6TXxJ5m62JDdMydP0rMF3yx2dfeqlFAFv7YQykLjHvTEuCsjMQSD2zVeigCy10zJtYZ9DnpSJclWVgOR71XooAuTXplbcUw3rmq5k5yBg+tR0UAWIrkoQWUt+OM1a/tMYwYcr6b/8A61ZtFAF9r5M5jhZfq+f6VGbw/wAK4PrmqlFAE4uG37mANSwXrRMxI3A9s4qnRQBN558wtjj0zStcO2f09qgooAnSdlDZ5LDrnpUOaSigCQyMRjPAoL5GCKjooAu2V+bWKWPZuEg65xiqm45J9abRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MR neurography coronal images show increased caliber and T2 signal (A, B) and abnormal T1 contrast enhancement (C, D) of the right L3 nerve (short thin arrow), L4 nerve (long thin arrow), proximal portion of the femoral nerve (short thick arrow), and right obturator nerve (arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cianfoni A, Luigetti M, Media F, et al. Teaching NeuroImage: MRI of diabetic lumbar plexopathy treated with local steroid injection. Neurology 2009; 72:e32. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30760=[""].join("\n");
var outline_f30_2_30760=null;
var title_f30_2_30761="Diagnosis of brain death";
var content_f30_2_30761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of brain death",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     G Bryan Young, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30761/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/2/30761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death is an irreversible, biological event that consists of permanent cessation of the critical functions of the organism as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/1\">",
"     1",
"    </a>",
"    ]. This concept allows for survival of tissues in isolation, but it requires the loss of integrated function of various organ systems. Death of the brain therefore qualifies as death, as the brain is essential for integrating critical functions of the body. The equivalence of brain death with death is largely, although not universally, accepted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain death implies the permanent absence of cerebral and brainstem functions. Although the term \"brain dead\" is often used colloquially and to extend to all those with severe brain damage and those in vegetative states, in medical-legal terms, its meaning is very specific. Persistent vegetative state is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The concept of irreversible coma or brain death was first described in 1959, predating widespread organ donation; although the latter made its codification critically necessary. Although specific details of diagnostic criteria differ, the fundamental definition of brain death has substantively remained constant over time and across countries (",
"    <a class=\"graphic graphic_table graphicRef62251 graphicRef70736 \" href=\"mobipreview.htm?8/32/8704\">",
"     table 1A-B",
"    </a>",
"    ). One exception is that whereas some countries (eg, the United States) understand brain death as \"whole brain death\" others (eg, the United Kingdom) use the concept of brainstem death.",
"   </p>",
"   <p>",
"    While US law equates brain death with cardiopulmonary death, specific criteria are not mandated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/3\">",
"     3",
"    </a>",
"    ]. Some states and institutions have specific diagnostic mandates, especially when applied to organ donor candidates. Most clinicians rely on published guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, a 2007 survey of prominent neurologic institutions in the United States found that there was considerable variability in adherence to published guidelines and clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/6\">",
"     6",
"    </a>",
"    ]. Variable documentation of brain death criteria was also observed in a series of 142 children referred for organ donation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most adult series, trauma and subarachnoid hemorrhage are the most common event leading to brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Others include intracerebral hemorrhage, hypoxic ischemic encephalopathy, and ischemic stroke. Any condition causing permanent widespread brain injury can lead to brain death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of brain death can usually be made clinically, at the bed side. The criteria for brain death require certain conditions regarding the clinical setting as well as evidence of absence of brain function on neurologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of prerequisites before one can begin considering a patient \"brain dead\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,5,11\">",
"     4,5,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical or neuroimaging evidence of an acute CNS catastrophe that is compatible with the clinical diagnosis of brain death, ie, the cause of brain death should be known.",
"     </li>",
"     <li>",
"      Exclusion of complicating medical conditions that may confound clinical assessment (no severe electrolyte, acid-base, endocrine, or circulatory (ie, shock) disturbance).",
"     </li>",
"     <li>",
"      No drug intoxication or poisoning, which may confound the clinical assessment.",
"     </li>",
"     <li>",
"      Core temperature &gt;36&ordm;C (97&ordm;F). Hypothermia may also confound the diagnostic assessment of brain death and can also delay the increase in PaCO2 necessary to complete the apnea test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5,12-14\">",
"       5,12-14",
"      </a>",
"      ]. A warming blanket is required to achieve normothermia in many patients with brain death. There is little evidence base for a choice of threshold temperature. Canadian forum recommendations published in 2006 use 34&ordm;C as a standard [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal systolic blood pressure &gt;100 mg Hg. Vasopressors may be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination must demonstrate absent cerebral or brainstem function with all of the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coma",
"     </li>",
"     <li>",
"      Absent brain-originating motor response, including response to pain stimulus above the neck or other",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    brain-originating movements, eg, seizures, decerebrate or decorticate posturing.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absent pupillary light reflex; pupils are midposition or dilated (4 to 9 mm)",
"     </li>",
"     <li>",
"      Absent corneal reflexes",
"     </li>",
"     <li>",
"      Absent oculovestibular reflexes (caloric responses)",
"     </li>",
"     <li>",
"      Absent jaw jerk",
"     </li>",
"     <li>",
"      Absent gag, sucking, or rooting reflex",
"     </li>",
"     <li>",
"      Absent cough with tracheal suctioning",
"     </li>",
"     <li>",
"      Absent sucking or rooting reflexes",
"     </li>",
"     <li>",
"      Apnea as demonstrated by apnea test, described below",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique for examination of the cranial nerve reflexes is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link&amp;anchor=H8#H8\">",
"     \"Stupor and coma in adults\", section on 'Cranial nerves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The depth of coma must be assessed by documenting absent alerting and absent movements arising from the brain, either spontaneous or stimulus-induced. Brain-originating movements include cortically originating complex, purposeful movements, and also decerebrate or decorticate posturing, facial grimacing, and seizures.",
"   </p>",
"   <p>",
"    Movements originating from the spinal cord or peripheral nerve may occur in brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ]. These are common (33 to 75 percent) and may be triggered by tactile stimuli or occur spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/8,16,17\">",
"     8,16,17",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subtle, semi-rhythmic movements of facial nerve-innervated muscles can arise from the denervated facial nerve.",
"     </li>",
"     <li>",
"      Finger flexor movements.",
"     </li>",
"     <li>",
"      Tonic neck reflexes &mdash; Passive neck displacements, especially flexion, may be accompanied by complex truncal and extremity movements, including adduction at the shoulders, flexion at the elbows, supination or pronation at the wrists, flexion of the trunk (\"sitting up\" type movements), and neck-abdominal muscle contraction or head turning to one side. These might be quite dramatic, often called a \"Lazarus sign.\"",
"     </li>",
"     <li>",
"      Triple flexion response with flexion at the hip, knee, and ankle with foot stimulation, eg, testing for a Babinski sign.",
"     </li>",
"     <li>",
"      Other truncal movements including asymmetrical opisthotonic posturing of the trunk and preservation of superficial and deep abdominal reflexes.",
"     </li>",
"     <li>",
"      Alternating flexion-extension of the toes with passive displacement of the foot (undulating toe sign), or flexion of the toes after foot percussion, or a Babinski sign.",
"     </li>",
"     <li>",
"      Upper limb pronation extension reflex.",
"     </li>",
"     <li>",
"      Widespread fasciculations of trunk and extremities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Apnea test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apnea test is performed after all other criteria for brain death have been met. Core temperature &ge;36&ordm;C or 97&ordm;F, systolic blood pressure &ge;100 mmHg, eucapnia (PaCO2 35 to 45 mmHg), absence of hypoxia, and euvolemic status are prerequisites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The test is not valid in patients who chronically have high PaCO2 values (CO2 retainers) and in cases of neuromuscular paralysis or high cervical spinal cord lesions. In a positive apnea test there is no respiratory response to a PaCO2 &gt;60 mmHg or 20 mmHg greater than baseline values and a final arterial pH of &lt;7.28.",
"   </p>",
"   <p>",
"    Disconnecting the ventilator is often associated with profound hypoxemia and hemodynamic instability. This can be obviated by increasing inspired oxygen before and during the test. Preoxygenation eliminates stores of respiratory nitrogen and accelerates oxygen transport through the tracheal cannula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The fraction of inspired oxygen should be 1.0 for 10 minutes, up to a maximum PaO2 of 200 mmHg or until the PaCO2 exceeds 40 mmHg. Ventilation frequency is reduced to eucapnia; positive end-expiratory pressure is reduced to 5 cm H2O. If SaO2 &gt; 95 percent, then an arterial blood gas (ABG) is obtained. The patient is then disconnected from the ventilator. Oxygen is provided by a tracheal cannula at 6",
"    <span class=\"nowrap\">",
"     L/minute;",
"    </span>",
"    the tip should lie at the carina. Alternatives include using a T-piece system with oxygen flow at 12",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and using continuous positive airway pressure (CPAP) 10 cm H2O, with oxygen flow at 12",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual observation is the standard method for detecting respiratory movement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ]. Eight to ten minutes with no observable respiratory effort is a standard observation period. PaCO2 is measured just prior to reconnection to the ventilator to confirm that the target level (&gt;60 mmHg or 20 mmHg greater than baseline values) was achieved.",
"   </p>",
"   <p>",
"    The test may need to be aborted because of hypotension (systolic BP &lt; 90 mmHg), hypoxemia (SaO2 &lt;85 percent for &gt;30 seconds), or cardiac arrhythmia. This may suggest inadequate oxygenation or preoxygenation, or baseline cardiopulmonary disease. Complications precluding the completion of the apnea test occur in 10 to 26 percent of individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one series, complications were more frequent (39 versus 15 percent) in the 48 percent of patients in whom conditions were unfavorable (eg, inadequate preoxygenation, acid-base or electrolyte abnormalities, hypotension, and prior cardiac arrhythmia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/9\">",
"     9",
"    </a>",
"    ]. The test can be reattempted using CPAP as described above; in one series this method allowed completion of the apnea test in 2 of 20 patients who could not complete it using tracheal cannula oxygen supply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/19\">",
"     19",
"    </a>",
"    ]. Ancillary tests are necessary if the apnea test cannot be completed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Ancillary tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An innovation in the apnea test involves introducing 3 to 5 percent CO2 along with oxygen and providing about four breaths per minute using a ventilator that is capable of detecting respiratory effort, while monitoring the end-tidal CO2 concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/20\">",
"     20",
"    </a>",
"    ]. However, other authors have criticized CO2 supplementation techniques because rates of PaCO2 accumulations may be unpredictable, excessive hypercarbia can cause complications, and more gradual increases in PaCO2 may not effectively stimulate respiratory centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/9\">",
"     9",
"    </a>",
"    ]. PaCO2 increases at a rate of 2.5 to 3 mmHg per minute in traditional testing.",
"   </p>",
"   <p>",
"    Case reports have drawn attention to potential diagnostic confusion that may arise in the setting of spurious ventilator triggering by patients with apnea-test confirmed brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Sensitive flow trigger settings on new generation ventilators lead to ventilator self-cycling, which may be misinterpreted as respiratory effort. Increasing the trigger flow sensitivity threshold or changing to a pressure trigger mechanism eliminates this phenomenon. However, determination of apnea can only be assessed reliably by disconnecting the ventilator as described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False evidence of spontaneous breathing has also been reported, even before apnea testing is performed, on patients on pressure support ventilation in which the threshold for triggering the ventilator is set so low that a hyperdynamic precordium can lead to pressure changes to cause the ventilator provide &ldquo;breaths&rdquo; with low threshold settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/24\">",
"     24",
"    </a>",
"    ]. Formal apnea testing should be performed if this phenomenon seems likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Observation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of observation required to determine brain death varies extensively. A follow-up evaluation after 24 hours was an early requirement for brain death diagnosis in the United States. Later, requirements in this regard were made age dependent: a 48-hour evaluation interval for infants age seven days to two months, 24 hours for those greater than two months to one year, and 12 hours for those between 1 and 18 years. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Brain death in children'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    An observation period for adults is considered optional; six hours is often recommended with longer periods, up to 24 hours, recommended in cases of hypoxic ischemic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4\">",
"     4",
"    </a>",
"    ]. Guidelines in other countries recommend longer observation periods (",
"    <a class=\"graphic graphic_table graphicRef62251 graphicRef70736 \" href=\"mobipreview.htm?8/32/8704\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/25\">",
"     25",
"    </a>",
"    ]. The American Academy of Neurology guideline update published in 2010 found insufficient evidence to determine a minimally acceptable observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ]. In patients who have been resuscitated after cardiac arrest, we recommend observation for at least 24 hours from the time of the arrest, as spontaneous improvement in brainstem reflexes can occur hours after cardiac arrest. In such patients who have received induced hypothermia, the recovery time may be further extended, as some motor and brainstem reflexes may recover after being absent for three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/26\">",
"     26",
"    </a>",
"    ]. It may be advisable to perform an ancillary test of brain blood flow with such patients; electrophysiologic parameters may also be affected by induced hypothermia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited studies of serial examinations in this setting upon which to base recommendations for a required length of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ]. One case series reviewed data from 1229 adult and 82 pediatric (greater than one year of age) cases of brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/27\">",
"     27",
"    </a>",
"    ]. The interval between first and second examinations ranged from 3 to over 50 hours (mean 19.2 hours). None of the patients with an initial examination consistent with brain death regained brainstem function on repeat examination. However, rates of organ donation decreased with longer intervals between examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Examiner(s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number and the expertise of the examiners required to make a brain death varies by state and country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Some states (eg, Virginia) specifically require the physician to be a specialist in the neurosciences, while others (Alaska, Georgia) give authority to nurses with subsequent certification by a physician. States and countries also differ as to whether more than one physician is required to certify a patient as brain dead (",
"    <a class=\"graphic graphic_table graphicRef62251 graphicRef70736 \" href=\"mobipreview.htm?8/32/8704\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The examiner making the diagnosis of brain death should be familiar with the clinical criteria and comfortable in performing all aspects of the examination. A systematic review of the literature found that the precision of the neurologic examination in comatose patients is moderate to substantial; only one study found diminished precision in less experienced examiners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/28\">",
"     28",
"    </a>",
"    ]. Another common requirement or recommendation is that the brain death examiner be someone other than the treating physician and someone other than the physician involved in the recovery of organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/15,25,29\">",
"     15,25,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANCILLARY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A valid, complete clinical examination is sufficient and superior to diagnostic testing in the diagnosis of brain death in adults. However, sometimes the clinical criteria cannot be applied. Such situations include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the cranial nerves cannot be adequately examined",
"     </li>",
"     <li>",
"      When neuromuscular paralysis is present",
"     </li>",
"     <li>",
"      When heavy sedation is present",
"     </li>",
"     <li>",
"      When the apnea test is not valid (high carbon dioxide retainers) or cannot be completed",
"     </li>",
"     <li>",
"      When confounders render the clinical examination unreliable, eg, multiple organ failure and the presence of a sedating or paralyzing drug that may be very slow to clear",
"     </li>",
"     <li>",
"      To shorten the duration of the observation period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these situations, ancillary tests are necessary. Ancillary testing is also required for infants less than one year; two positive tests are required for those less than two months of age. Other countries mandate the use of confirmatory tests to supplement the clinical examination (",
"    <a class=\"graphic graphic_table graphicRef62251 graphicRef70736 \" href=\"mobipreview.htm?8/32/8704\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ideal ancillary test for brain death should meet all of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There should be no \"false positives,\" ie, when the test confirms \"brain death\" there should be none that recover or have the potential to recover.",
"     </li>",
"     <li>",
"      The test should be sufficient on its own to establish that brain death is or is not present, ie, whether there is total and irreversible destruction of the brainstem or the entire brain.",
"     </li>",
"     <li>",
"      The test should not be susceptible to \"confounders\" such as drug effects or metabolic disturbances.",
"     </li>",
"     <li>",
"      The test should be standardized in technology, technique, and classification of results.",
"     </li>",
"     <li>",
"      The test should be available, safe, and readily applied in all medical centers with ICUs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, no currently available test for brain death meets all of these criteria. Studies examining their utility are limited; they are generally quite small and often examine only clinically brain dead individuals, not allowing for detection of false-positive errors. Individual tests have different strengths and weaknesses in different clinical situations, which may guide their selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519888\">",
"    <span class=\"h2\">",
"     Brain blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests demonstrating absent blood flow to the brain are generally accepted as establishing whole brain death; it is axiomatic that the brain without a blood supply is dead. It does not always follow that the presence of some arterial blood flow in the intracranial compartment precludes the diagnosis of brain death.",
"   </p>",
"   <p>",
"    Brain death is usually accompanied by elevated intracranial pressure from tissue edema or other mass effect. When this exceeds systemic arterial pressure, there is no cerebral blood flow.",
"   </p>",
"   <p>",
"    Some intracranial arterial filling at the base of the brain without tissue perfusion can be seen in brain death, producing a \"false negative\" test result for brain death. More refined techniques that examine brain perfusion are likely to be more accurate. Such tests include: computed tomography perfusion studies (not widely available) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/30\">",
"     30",
"    </a>",
"    ], radionuclide studies (see",
"    <a class=\"local\" href=\"#H112519923\">",
"     'Nuclear medicine'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/31\">",
"     31",
"    </a>",
"    ], and magnetic resonance perfusion studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Absent opacification of deep cerebral veins on conventional or CT angiography may be more sensitive for brain death than filling of cerebral arteries (see",
"    <a class=\"local\" href=\"#H112519916\">",
"     'Computed tomographic angiography'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tests of blood flow may also be subject to false-negative error early on when trauma, surgery, ventricular drain, and open cranial sutures lower intracranial pressure.",
"   </p>",
"   <p>",
"    Widely available tests of cerebral blood flow include cerebral angiography, transcranial Doppler, magnetic resonance angiography, computed tomographic angiography, and nuclear medicine radionuclide scanning. These tests are not confounded by drugs, metabolic disorders, or hypothermia. A caveat is that the systemic blood pressure should be adequate, ie, the patient should not be in shock, when these tests are applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519895\">",
"    <span class=\"h3\">",
"     Cerebral angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four-vessel cerebral angiography is the traditional \"gold standard\" among cerebral blood flow tests for brain death. The test is invasive and requires transportation to the radiology department. Blood pressure must be monitored during the procedure, as patients are often hemodynamically unstable. In addition, a severely damaged brain may have lost autoregulation causing blood flow to vary with changes in perfusion pressure.",
"   </p>",
"   <p>",
"    In cases of brain death, cerebral angiography usually demonstrates absent blood flow at or beyond the carotid bifurcation or Circle of Willis. The external carotid system should be patent. In a minority of cases, angiography may demonstrate contrast stasis or delayed filling in intracranial arteries, perhaps as an evolutionary stage preceding absent filling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. False-negative cerebral angiograms showing normal appearing blood flow in at least some intracranial blood vessels are reported to occur when intracranial pressure is lowered by surgery, trauma, and ventricular shunts or in infants with pliable skulls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519902\">",
"    <span class=\"h3\">",
"     Transcranial Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial Doppler (TCD) is safe, noninvasive, and inexpensive, and it can be done at the bedside. The test requires expertise; both anterior and posterior circulations should be evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/40\">",
"     40",
"    </a>",
"    ]. Findings of small systolic peaks without diastolic flow or a reverberating flow pattern suggest high vascular resistance and support the diagnosis of brain death. Limitations include a 10 to 25 percent prevalence of temporal bone thickening that precludes evaluation of 6 of the usual 11 insonated intracranial arteries. Because of these and other technical limitations, absence of arterial signals on TCD (a finding in 9 percent of brain dead patients) is considered nondiagnostic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. False-positive tests (compared with cerebral angiography) are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with cerebral angiography, patients with external ventricular drains or large craniotomies may have false-negative testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. Caution should be exercised with very young children, at least until further studies are done in this population.",
"   </p>",
"   <p>",
"    In one study comparing 61 patients with clinical brain death with 39 control patients in coma but not brain dead, the sensitivity of TCD was 70.5 percent, and the specificity was 97.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar results were observed in a case-control study of 101 comatose patients in which it was also observed that both sensitivity and specificity improved over time to 100 percent for examinations performed 24 hours or more after clinical diagnosis of brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519909\">",
"    <span class=\"h3\">",
"     Magnetic resonance angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence of arterial blood flow on MRA supports the diagnosis of brain death. In addition, MRI also shows variable degrees of cerebral edema and mass effect. Small case series and one case control study suggest that it is a sensitive test for brain death, but has uncertain specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5,46-48\">",
"     5,46-48",
"    </a>",
"    ]. Disadvantages include that patients are required to lie flat and that there may be short periods of time in which clinical monitoring is impossible, making this somewhat problematic in unstable patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519916\">",
"    <span class=\"h3\">",
"     Computed tomographic angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic angiography (CTA) and computed tomographic perfusion are slightly more invasive than MRA, in that contrast injection is required. Case reports document findings of absent cerebral circulation perfusion on CTA in patients with brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, one case series found that 10 of 21 patients with clinical brain death and a flat EEG had apparent cerebral arterial perfusion on CTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/36\">",
"     36",
"    </a>",
"    ]. Only three of these patients had venous opacification, suggesting that absent deep venous opacification on CTA is a more sensitive CTA finding and is more specific for brain death. In another case series, 25 patients were evaluated by CTA and nuclear medicine; the tests results agreed in 22 patients (19 positive, 3 negative); three patients without flow on nuclear medicine had flow on CTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/52\">",
"     52",
"    </a>",
"    ]. All patients progressed to clinical brain death. The absence of studies examining CTA findings in patients who are comatose but not brain dead preclude an assessment of this test&rsquo;s specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112519923\">",
"    <span class=\"h3\">",
"     Nuclear medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common radionuclide modality for brain imaging uses the tracer, 99mTc-labeled hexamethylpropyleneamineoxime (HMPAO), and subsequent imaging with single photon emission computed tomographic (SPECT) brain scintigraphy. The tracer penetrates into the brain parenchyma in proportion to regional blood flow and shows no significant redistribution for several hours, making it easy to perform and interpret imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/53\">",
"     53",
"    </a>",
"    ]. The absence of isotope uptake (\"hollow skull phenomenon\") indicates no brain perfusion and supports the diagnosis of brain death (",
"    <a class=\"graphic graphic_figure graphicRef76427 \" href=\"mobipreview.htm?25/61/26576\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies find that HMPAO-SPECT is useful in the diagnosis of brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. The sensitivity improves on follow-up examination in 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In studies with small \"control\" groups of brain injured, but not brain dead individuals, there were no false-positive studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. HMPAO-SPECT also appears to be useful in pediatric patients, although the examination in very young infants with open cranial sutures also appears to be subject to false-negative error, at least on initial examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/58\">",
"     58",
"    </a>",
"    ]. A false-positive appearance of absent brain blood flow was described in an infant in whom brain blood flow was assessed by SPECT in a single imaging plane; this emphasizes the importance of imaging in both anterior and lateral views [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic tests used in the diagnosis of brain death include EEG and evoked potentials. These tests are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocerebral silence or a flat electroencephalogram (EEG) was a component of brain death declaration with the first guidelines published. Electrocerebral silence is present if no nonartifactual electrical potential &gt;2 mV is found during a 30-minute recording at increased sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/60\">",
"     60",
"    </a>",
"    ]. EEG remains strongly recommended in the United States and is an essential part of the American criteria for the diagnosis of brain death in very young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/61\">",
"     61",
"    </a>",
"    ]. However, although the flat or suppressed recording prompts clinicians to consider brain death, EEG is anatomically and physiologically limited for this purpose.",
"   </p>",
"   <p>",
"    The EEG records summated synaptic potentials from the cerebral neocortex and does not reveal potentials from subcortical structures, such as the brainstem or thalamus. Hence, the EEG may be flat or isoelectric in the presence of viable neurons in the brainstem and elsewhere. The EEG is also vulnerable to confounders, and it may be flat or isoelectric in cases of sedation from medication or toxic ingestion, hypothermia, or metabolic factors &ndash; conditions that do not necessarily imply complete and irreversible brain injury. A number of false-positive cases of flat EEG recordings in these situations have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In addition, especially in the intensive care unit (ICU), some electrical signals are recorded for which the source cannot be identified, even though they probably do not arise from the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/64\">",
"     64",
"    </a>",
"    ]. Such artifacts may be mistaken for residual cortical activity, producing a false-negative error.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory evoked potentials (SSEPs) and brainstem auditory evoked potentials (BAEPs) also have limited utility as ancillary tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. In SSEPs, the bilateral absence of the parietal sensory cortex responses (N19-P22) in response to median nerve stimulation is supportive of brain death. The absence of brainstem responses to an auditory stimulus (Waves III to V) in the presence of preserved cochlear response (Wave I) is required for a BAEP result to support the diagnosis of brain death.",
"   </p>",
"   <p>",
"    Each test activates a discrete sensory pathway and extends the electrophysiologic interrogation beyond the EEG to areas of interest in the brainstem. However, these are highly specific, restricted pathways; EPs do not test the functional integrity of other CNS structures. For both SSEP and BAEP, restricted proximal lesions, including those outside the central nervous system, may eliminate cortical response. Cases of preserved EEG integrity in the face of absent evoked potentials have been described in individuals with primary brainstem pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike EEG signals, the early components of SSEPs and BAEPs are minimally affected by sedative drugs and anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/69\">",
"     69",
"    </a>",
"    ]. However, hypothermia, drugs, and metabolic derangements can affect middle and late somatosensory and auditory potentials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/70\">",
"     70",
"    </a>",
"    ]. Some have argued that the combination of BAEPs and SSEPs with EEG offers greater assurance of an accurate diagnosis of brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the requirement for an intact Wave I in the BAEP limits its broad applicability, as the cochlear end organ is frequently damaged in trauma.",
"   </p>",
"   <p>",
"    One series of EP testing in 130 clinically brain dead patients (ages 8 to 77 years) showed that BAEPs provided information in 29.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/68\">",
"     68",
"    </a>",
"    ]. In these patients, BAEP excluded brain death in 4.6 percent, while confirming the diagnosis in 24.6 percent. In the same 130 patients, SSEPs were useful in 97 percent, confirmed brain death in 94 percent, and excluded the diagnosis in 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/68\">",
"     68",
"    </a>",
"    ]. A cohort study of 181 comatose patients found that the P14 responses on SSEP were uniformly absent in all 108 brain dead patients and uniformly present in the remaining non brain dead patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/71\">",
"     71",
"    </a>",
"    ]. Similar results have been shown in a primary pediatric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    test examines the heart rate response to intravenous injection of 3 mg atropine. An increase in heart rate of &lt;3 percent supports the diagnosis of brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. As the dorsal motor vagal nucleus is in the medulla, the test provides a limited assessment of caudal medullary function. Although this is probably one of the last functions to be lost in brain death, the test provides a very restricted assessment and has not been widely validated.",
"   </p>",
"   <p>",
"    In a study of 118 brain dead patients and 152 survivors of severe brain injury, the ratio of venous oxygen concentration in the right atrium compared with the jugular bulb was shown to have 96.6 percent sensitivity and 99.3 percent specificity for brain death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/75\">",
"     75",
"    </a>",
"    ]. The test is not available in many centers, carries a small risk, and requires special training for catheter insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Choice of test",
"    </span>",
"    &nbsp;&mdash;&nbsp;All ancillary tests for brain death have limitations. Cerebral angiography best approximates a \"gold standard\" but is invasive, risky, and may be inaccurate (as are other tests of blood flow) in profound hypotension and when the cranial vault is breached by trauma, surgery, ventricular drain, or open cranial sutures. Under these circumstances an electrophysiologic test (EEG or SSEP) may be superior. However, tests of cerebral blood flow are less subject to confounding by hypothermia, drugs, and metabolic factors than are electrophysiologic tests. For this reason, tests of cerebral blood flow are the most useful in those clinical setting in which the clinical criteria cannot be applied. SSEPs should not be used if the primary pathology is in the brainstem or in the setting of underlying neuropathy. EEG, EPs, and TCD may be done at the bedside. The availability of different testing modalities and the requisite experience and expertise differ among institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     BRAIN DEATH MIMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misdiagnosis of brain death has been reported in the following clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Locked-in syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/76\">",
"       76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuromuscular paralysis, as found in severe, acute polyneuropathies (some may also have autonomic dysfunction, including pupillary areflexia) or with neuromuscular blocking agents",
"     </li>",
"     <li>",
"      Hypothermia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drug intoxication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The locked-in syndrome is a consequence of a focal injury to the base of the pons, usually by embolic occlusion of the basilar artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/76\">",
"     76",
"    </a>",
"    ]. Consciousness is preserved; however, the patient cannot move muscles in the limbs, trunk, or face, except that voluntary blinking and vertical eye movements remain intact. Patients with this syndrome have been mistakenly believed to be unconscious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients with primary brainstem pathology who are believed to be brain dead should be carefully examined to ensure that they are not instead locked-in. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/63/34807?source=see_link\">",
"     \"Locked-in syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other entities listed, as well as other potential brain death mimics (eg, metabolic encephalopathy) may produce a neurologic examination consistent with brain death, but they should not be mistaken for brain death if the other criteria are applied. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical setting'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BRAIN DEATH IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death in children most commonly occurs as a result of trauma and anoxic encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/82\">",
"     82",
"    </a>",
"    ]. Infections and cerebral neoplasms are other causes. United States guidelines for criteria for brain death in children were updated in 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/83\">",
"     83",
"    </a>",
"    ]. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of brain death cannot be made in preterm infants less than 37 weeks gestational age.",
"     </li>",
"     <li>",
"      Hypotension, hypothermia, and metabolic disturbances should be treated and corrected and medications that can interfere with the neurologic examination and apnea testing should be discontinued with time allowed for adequate clearance before proceeding with the evaluation.",
"     </li>",
"     <li>",
"      Two examinations including apnea testing with each examination separated by an observation period are required. Examinations should be performed by different attending physicians. Apnea testing may be performed by the same physician. An observation period of 24 hours for term newborns to 30 days of age, and 12 hours for infants and children (30 days to 18 years) is recommended. Assessments in neonates and infants should be performed by pediatric specialists with critical care training.",
"      <br/>",
"      <br/>",
"      The first examination determines the child has met the accepted neurologic examination criteria for brain death. The second examination confirms brain death based on an unchanged and irreversible condition. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neurologic examination'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Assessment of neurologic function following cardiopulmonary resuscitation or other severe acute brain injuries should be deferred for 24 hours or longer if there are concerns or inconsistencies in the examination.",
"     </li>",
"     <li>",
"      Apnea testing to support the diagnosis of brain death requires documentation of an arterial PaCO2 20mm Hg above the baseline and &ge;60mm Hg with no respiratory effort during the testing period. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Apnea test'",
"      </a>",
"      above.) If the apnea test cannot be safely completed, an ancillary study should be performed.",
"     </li>",
"     <li>",
"      Ancillary studies (EEG and radionuclide cerebral blood flow) are not required to establish brain death and are not a substitute for the neurologic examination. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ancillary tests'",
"      </a>",
"      above.) Ancillary studies may be used to assist in making the diagnosis of brain death:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      when components of the examination or apnea testing cannot be completed safely due to the underlying medical condition of the patient;",
"     </li>",
"     <li>",
"      if there is uncertainty about the results of the neurologic examination;",
"     </li>",
"     <li>",
"      if a medication effect may be present; or",
"     </li>",
"     <li>",
"      to reduce the inter-examination observation period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When ancillary studies are used, a second clinical examination and apnea test should be performed and components that can be completed must remain consistent with brain death. In this instance the observation interval may be shortened and the second neurologic examination and apnea test (or all components that are able to be completed safely) can be performed at any time thereafter.",
"   </p>",
"   <p>",
"    These guidelines are based in large part on consensus opinion as evidence is limited. As a result, they are somewhat controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/84\">",
"     84",
"    </a>",
"    ]. Some believe that a diagnosis of brain death cannot be made reliably in very young infants. Committees in the United Kingdom, Australia, and New Zealand decided to declare brain death only in children &ge;2 months in age.",
"   </p>",
"   <p>",
"    Recommendations from a Canadian forum published in 2006 had somewhat different qualifications regarding the brain death criteria for children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full-term newborns &gt;48 hours and &lt;30 days old must have serial determinations separated by 24 hours. Clinical criteria should additionally include absent oculocephalic and suck reflexes. The minimum body temperature must be &ge;36&ordm;C. Ancillary tests are required for presence of confounders or inability to establish clinical criteria.",
"     </li>",
"     <li>",
"      For infants 30 days to one year, clinical criteria should use oculocephalic rather than the oculovestibular reflex. A second examiner should confirm the diagnosis, but no time interval is specifically required. Ancillary tests are required only for clinical uncertainty or confounding factors.",
"     </li>",
"     <li>",
"      For children greater than one year, a second examiner should confirm the diagnosis if organ donation is planned as required by law. No time interval is required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, there are no published reports of recovery of neurologic recovery after a diagnosis of brain death as outlined above (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical criteria'",
"    </a>",
"    above.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, brain death rarely lasts for more than a few days before it is followed by somatic death. Brain ischemia leads to sympathetic nervous system collapse leading to vasodilation and cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/85\">",
"     85",
"    </a>",
"    ]. In most patients, blood pressure rapidly declines even with the use of intravenous vasopressor therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/86\">",
"     86",
"    </a>",
"    ]. Pulmonary edema and diabetes insipidus are frequent early consequences of brain death and may also precipitate cardiopulmonary failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/87\">",
"     87",
"    </a>",
"    ]. In one series, all 73 patients meeting the clinical criteria for brain death suffered cardiac asystole despite full cardiorespiratory support; 97 percent died within seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/88\">",
"     88",
"    </a>",
"    ]. Most clinicians feel that the diagnosis of brain death is doubtful in the face of prolonged clinical stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case series of 175 patients surviving longer than one week after diagnosis of brain death challenges this tenet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/90\">",
"     90",
"    </a>",
"    ]. In this series, 80 patients survived two weeks, 44 survived four weeks, 20 survived two months, and seven survived six months. Those with long survivals were very young (two newborns). The validity of the sources and brain death diagnoses in these patients has been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have religious beliefs that oppose the equivalence of brain death with death. The states of New Jersey and New York have dealt with this by passing laws that require cardiopulmonary death as the definition of death in these patients. There may be other sources of controversy. While there is legal precedent for discontinuing life support over the family's objection, many advocate delay, education, support, and negotiation in such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30761/abstract/2,3,92,93\">",
"     2,3,92,93",
"    </a>",
"    ]. The potential for organ donation offers comfort to the bereaved and should be offered to families, but it should not be the impetus for the diagnosis of brain death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death is the complete and irreversible loss of cerebral and brainstem function. In most countries and most situations, brain death is considered to be equivalent to cardiopulmonary death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of brain death is usually made by neurologic examination, provided certain prerequisites are met: the underlying cause is understood; the etiology is capable of producing neuronal death and confounding from drug intoxication or poisoning, metabolic derangements, and hypothermia have been ruled out. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurologic examination must demonstrate coma, no brain-generated response to external stimuli, and absent brainstem reflexes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neurologic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An apnea test is performed in all patients meeting all other brain death criteria who are stable enough to undergo the test. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Apnea test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ancillary tests are required when clinical criteria cannot be applied and to supplement the clinical examination in young children. Tests of brain blood flow, especially those of brain perfusion, are the most reliable &ldquo;stand alone&rdquo; laboratory examinations when the clinical criteria cannot be applied. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ancillary tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Brain death in children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wijdicks EFM. Brain Death, Lippincott Williams and Wilkins, Philadelphia 2001. p.175.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/2\">",
"      Bernat JL. Ethical issues in the perioperative management of neurologic patients. Neurol Clin 2004; 22:viii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/3\">",
"      Burkle CM, Schipper AM, Wijdicks EF. Brain death and the courts. Neurology 2011; 76:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/4\">",
"      Practice parameters for determining brain death in adults (summary statement). The Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1995; 45:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/5\">",
"      Wijdicks EF, Varelas PN, Gronseth GS, et al. Evidence-based guideline update: determining brain death in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/6\">",
"      Greer DM, Varelas PN, Haque S, Wijdicks EF. Variability of brain death determination guidelines in leading US neurologic institutions. Neurology 2008; 70:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/7\">",
"      Mathur M, Petersen L, Stadtler M, et al. Variability in pediatric brain death determination and documentation in southern California. Pediatrics 2008; 121:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/8\">",
"      Saposnik G, Bueri JA, Mauri&ntilde;o J, et al. Spontaneous and reflex movements in brain death. Neurology 2000; 54:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/9\">",
"      Goudreau JL, Wijdicks EF, Emery SF. Complications during apnea testing in the determination of brain death: predisposing factors. Neurology 2000; 55:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/10\">",
"      Wijdicks EF, Rabinstein AA, Manno EM, Atkinson JD. Pronouncing brain death: Contemporary practice and safety of the apnea test. Neurology 2008; 71:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/11\">",
"      Gardiner D, Shemie S, Manara A, Opdam H. International perspective on the diagnosis of death. Br J Anaesth 2012; 108 Suppl 1:i14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/12\">",
"      Joffe AR, Kolski H, Duff J, deCaen AR. A 10-month-old infant with reversible findings of brain death. Pediatr Neurol 2009; 41:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/13\">",
"      Shemie SD, Langevin S, Farrell C. Therapeutic hypothermia after cardiac arrest: another confounding factor in brain-death testing. Pediatr Neurol 2010; 42:304; author reply 304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/14\">",
"      Machado C. Are brain death findings reversible? Pediatr Neurol 2010; 42:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/15\">",
"      Shemie SD, Doig C, Dickens B, et al. Severe brain injury to neurological determination of death: Canadian forum recommendations. CMAJ 2006; 174:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/16\">",
"      Saposnik G, Mauri&ntilde;o J, Saizar R, Bueri JA. Undulating toe movements in brain death. Eur J Neurol 2004; 11:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/17\">",
"      Saposnik G, Maurino J, Saizar R, Bueri JA. Spontaneous and reflex movements in 107 patients with brain death. Am J Med 2005; 118:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/18\">",
"      Beckmann YY, Cift&ccedil;i Y, Se&ccedil;il Y, Eren S. Fasciculations in brain death. Crit Care Med 2010; 38:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/19\">",
"      L&eacute;vesque S, Lessard MR, Nicole PC, et al. Efficacy of a T-piece system and a continuous positive airway pressure system for apnea testing in the diagnosis of brain death. Crit Care Med 2006; 34:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/20\">",
"      Sharpe MD, Young GB, Harris C. The apnea test for brain death determination: an alternative approach. Neurocrit Care 2004; 1:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/21\">",
"      Wijdicks EF, Manno EM, Holets SR. Ventilator self-cycling may falsely suggest patient effort during brain death determination. Neurology 2005; 65:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/22\">",
"      Kannan S, Sinclair S. Spurious ventilator triggering in a dead patient. Anaesthesia 2002; 57:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/23\">",
"      Willatts SM, Drummond G. Brainstem death and ventilator trigger settings. Anaesthesia 2000; 55:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/24\">",
"      McGee WT, Mailloux P. Ventilator autocycling and delayed recognition of brain death. Neurocrit Care 2011; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/25\">",
"      Wijdicks EF. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. Neurology 2002; 58:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/26\">",
"      Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. Ann Neurol 2010; 67:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/27\">",
"      Lustbader D, O'Hara D, Wijdicks EF, et al. Second brain death examination may negatively affect organ donation. Neurology 2011; 76:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/28\">",
"      Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004; 291:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/29\">",
"      Baumgartner H, Gerstenbrand F. Diagnosing brain death without a neurologist. BMJ 2002; 324:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/30\">",
"      Roberts HC, Roberts TP, Smith WS, et al. Multisection dynamic CT perfusion for acute cerebral ischemia: the \"toggling-table\" technique. AJNR Am J Neuroradiol 2001; 22:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/31\">",
"      Spieth ME, Ansari AN, Kawada TK, et al. Direct comparison of Tc-99m DTPA and Tc-99m HMPAO for evaluating brain death. Clin Nucl Med 1994; 19:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/32\">",
"      Barbier EL, Lamalle L, D&eacute;corps M. Methodology of brain perfusion imaging. J Magn Reson Imaging 2001; 13:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/33\">",
"      Wu O, Ostergaard L, Sorensen AG. Technical aspects of perfusion-weighted imaging. Neuroimaging Clin N Am 2005; 15:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/34\">",
"      Duyn JH, van Gelderen P, Talagala L, et al. Technological advances in MRI measurement of brain perfusion. J Magn Reson Imaging 2005; 22:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/35\">",
"      Ala TA, Kuhn MJ, Johnson AJ. A case meeting clinical brain death criteria with residual cerebral perfusion. AJNR Am J Neuroradiol 2006; 27:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/36\">",
"      Quesnel C, Fulgencio JP, Adrie C, et al. Limitations of computed tomographic angiography in the diagnosis of brain death. Intensive Care Med 2007; 33:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/37\">",
"      Savard M, Turgeon AF, Gari&eacute;py JL, et al. Selective 4 vessels angiography in brain death: a retrospective study. Can J Neurol Sci 2010; 37:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/38\">",
"      Flowers WM Jr, Patel BR. Persistence of cerebral blood flow after brain death. South Med J 2000; 93:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/39\">",
"      Braum M, Ducrocq X, Huot JC, et al. Intravenous angiography in brain death: report of 140 patients. Neuroradiology 1997; 39:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/40\">",
"      Kuo JR, Chen CF, Chio CC, et al. Time dependent validity in the diagnosis of brain death using transcranial Doppler sonography. J Neurol Neurosurg Psychiatry 2006; 77:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/41\">",
"      Lampl Y, Gilad R, Eschel Y, et al. Diagnosing brain death using the transcranial Doppler with a transorbital approach. Arch Neurol 2002; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/42\">",
"      Ducrocq X, Braun M, Debouverie M, et al. Brain death and transcranial Doppler: experience in 130 cases of brain dead patients. J Neurol Sci 1998; 160:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/43\">",
"      Paolin A, Manuali A, Di Paola F, et al. Reliability in diagnosis of brain death. Intensive Care Med 1995; 21:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/44\">",
"      Cabrer C, Dom&iacute;nguez-Roldan JM, Manyalich M, et al. Persistence of intracranial diastolic flow in transcranial Doppler sonography exploration of patients in brain death. Transplant Proc 2003; 35:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/45\">",
"      Dosemeci L, Dora B, Yilmaz M, et al. Utility of transcranial doppler ultrasonography for confirmatory diagnosis of brain death: two sides of the coin. Transplantation 2004; 77:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/46\">",
"      Karantanas AH, Hadjigeorgiou GM, Paterakis K, et al. Contribution of MRI and MR angiography in early diagnosis of brain death. Eur Radiol 2002; 12:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/47\">",
"      Ishii K, Onuma T, Kinoshita T, et al. Brain death: MR and MR angiography. AJNR Am J Neuroradiol 1996; 17:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/48\">",
"      Matsumura A, Meguro K, Tsurushima H, et al. Magnetic resonance imaging of brain death. Neurol Med Chir (Tokyo) 1996; 36:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/49\">",
"      Yu SL, Lo YK, Lin SL, et al. Computed tomographic angiography for determination of brain death. J Comput Assist Tomogr 2005; 29:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/50\">",
"      Qureshi AI, Kirmani JF, Xavier AR, Siddiqui AM. Computed tomographic angiography for diagnosis of brain death. Neurology 2004; 62:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/51\">",
"      Dupas B, Gayet-Delacroix M, Villers D, et al. Diagnosis of brain death using two-phase spiral CT. AJNR Am J Neuroradiol 1998; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/52\">",
"      Berenguer CM, Davis FE, Howington JU. Brain death confirmation: comparison of computed tomographic angiography with nuclear medicine perfusion scan. J Trauma 2010; 68:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/53\">",
"      Wieler H, Marohl K, Kaiser KP, et al. Tc-99m HMPAO cerebral scintigraphy. A reliable, noninvasive method for determination of brain death. Clin Nucl Med 1993; 18:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/54\">",
"      Bonetti MG, Ciritella P, Valle G, Perrone E. 99mTc HM-PAO brain perfusion SPECT in brain death. Neuroradiology 1995; 37:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/55\">",
"      de la Riva A, Gonz&aacute;lez FM, Llamas-Elvira JM, et al. Diagnosis of brain death: superiority of perfusion studies with 99Tcm-HMPAO over conventional radionuclide cerebral angiography. Br J Radiol 1992; 65:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/56\">",
"      Facco E, Zucchetta P, Munari M, et al. 99mTc-HMPAO SPECT in the diagnosis of brain death. Intensive Care Med 1998; 24:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/57\">",
"      Munari M, Zucchetta P, Carollo C, et al. Confirmatory tests in the diagnosis of brain death: comparison between SPECT and contrast angiography. Crit Care Med 2005; 33:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/58\">",
"      Okuyaz C, G&uuml;c&uuml;yener K, Karabacak NI, et al. Tc-99m-HMPAO SPECT in the diagnosis of brain death in children. Pediatr Int 2004; 46:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/59\">",
"      Joffe AR, Lequier L, Cave D. Specificity of radionuclide brain blood flow testing in brain death: case report and review. J Intensive Care Med 2010; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/60\">",
"      Guideline three: minimum technical standards for EEG recording in suspected cerebral death. American Electroencephalographic Society. J Clin Neurophysiol 1994; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/61\">",
"      Report of special Task Force. Guidelines for the determination of brain death in children. American Academy of Pediatrics Task Force on Brain Death in Children. Pediatrics 1987; 80:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/62\">",
"      Rothstein TL. Recovery from near death following cerebral anoxia: A case report demonstrating superiority of median somatosensory evoked potentials over EEG in predicting a favorable outcome after cardiopulmonary resuscitation. Resuscitation 2004; 60:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/63\">",
"      Heckmann JG, Lang CJ, Pfau M, Neund&ouml;rfer B. Electrocerebral silence with preserved but reduced cortical brain perfusion. Eur J Emerg Med 2003; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/64\">",
"      Ashwal S, Schneider S. Failure of electroencephalography to diagnose brain death in comatose children. Ann Neurol 1979; 6:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/65\">",
"      Machado C. An early approach to brain death diagnosis using multimodality evoked potentials and electroretinography. Minerva Anestesiol 1994; 60:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/66\">",
"      Orzirgin ON, Ozcelik T, Sevimli NK. Auditory brain stem responses in the detection of brain death. Lulak Burun Bogaz Ihtis Derg 2003; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/67\">",
"      Firsching R, Frowein RA, Wilhelms S, Buchholz F. Brain death: practicability of evoked potentials. Neurosurg Rev 1992; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/68\">",
"      Facco E, Munari M, Gallo F, et al. Role of short latency evoked potentials in the diagnosis of brain death. Clin Neurophysiol 2002; 113:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/69\">",
"      Saito T, Takeichi S, Tokunaga I, et al. Experimental studies on effects of barbiturate on electroencephalogram and auditory brain-stem responses. Nihon Hoigaku Zasshi 1997; 51:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/70\">",
"      Gu&eacute;rit JM. Medical technology assessment EEG and evoked potentials in the intensive care unit. Neurophysiol Clin 1999; 29:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/71\">",
"      Wagner W. Scalp, earlobe and nasopharyngeal recordings of the median nerve somatosensory evoked P14 potential in coma and brain death. Detailed latency and amplitude analysis in 181 patients. Brain 1996; 119 ( Pt 5):1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/72\">",
"      Ruiz-L&oacute;pez MJ, Mart&iacute;nez de Azagra A, Serrano A, Casado-Flores J. Brain death and evoked potentials in pediatric patients. Crit Care Med 1999; 27:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/73\">",
"      Siemens P, Hilger HH, Frowein RA. Heart rate variability and the reaction of heart rate to atropine in brain dead patients. Neurosurg Rev 1989; 12 Suppl 1:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/74\">",
"      H&uuml;ttemann E, Schelenz C, Sakka SG, Reinhart K. Atropine test and circulatory arrest in the fossa posterior assessed by transcranial Doppler. Intensive Care Med 2000; 26:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/75\">",
"      D&iacute;az-Rega&ntilde;&oacute;n G, Mi&ntilde;ambres E, Holanda M, et al. Usefulness of venous oxygen saturation in the jugular bulb for the diagnosis of brain death: report of 118 patients. Intensive Care Med 2002; 28:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/76\">",
"      Patterson JR, Grabois M. Locked-in syndrome: a review of 139 cases. Stroke 1986; 17:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/77\">",
"      Danzl DF, Pozos RS. Accidental hypothermia. N Engl J Med 1994; 331:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/78\">",
"      Peters FT, Jung J, Kraemer T, Maurer HH. Fast, simple, and validated gas chromatographic-mass spectrometric assay for quantification of drugs relevant to diagnosis of brain death in human blood plasma samples. Ther Drug Monit 2005; 27:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/79\">",
"      Stojkovic T, Verdin M, Hurtevent JF, et al. Guillain-Barr&eacute; syndrome resembling brainstem death in a patient with brain injury. J Neurol 2001; 248:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/80\">",
"      Friedman Y, Lee L, Wherrett JR, et al. Simulation of brain death from fulminant de-efferentation. Can J Neurol Sci 2003; 30:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/81\">",
"      Chisholm N, Gillett G. The patient's journey: living with locked-in syndrome. BMJ 2005; 331:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/82\">",
"      Goh AY, Mok Q. Clinical course and determination of brainstem death in a children's hospital. Acta Paediatr 2004; 93:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/83\">",
"      Nakagawa TA, Ashwal S, Mathur M, et al. Clinical report&mdash;Guidelines for the determination of brain death in infants and children: an update of the 1987 task force recommendations. Pediatrics 2011; 128:e720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/84\">",
"      Wijdicks EF, Smith WS. Brain death in children: why does it have to be so complicated? Ann Neurol 2012; 71:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/85\">",
"      Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/86\">",
"      Fugate JE, Rabinstein AA, Wijdicks EF. Blood pressure patterns after brain death. Neurology 2011; 77:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/87\">",
"      Wijdicks EF. Determining brain death in adults. Neurology 1995; 45:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/88\">",
"      Hung TP, Chen ST. Prognosis of deeply comatose patients on ventilators. J Neurol Neurosurg Psychiatry 1995; 58:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/89\">",
"      Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001; 344:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/90\">",
"      Shewmon DA. Chronic \"brain death\": meta-analysis and conceptual consequences. Neurology 1998; 51:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/91\">",
"      Wijdicks EF, Bernat JL. Chronic \"brain death\": meta-analysis and conceptual consequences. Neurology 1999; 53:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/92\">",
"      Cranford RE. Discontinuation of ventilation after brain death. Policy should be balanced with concern for the family. BMJ 1999; 318:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30761/abstract/93\">",
"      Inwald D, Jakobovits I, Petros A. Brain stem death: managing care when accepted medical guidelines and religious beliefs are in conflict. Consideration and compromise are possible. BMJ 2000; 320:1266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4831 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30761=[""].join("\n");
var outline_f30_2_30761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Apnea test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Observation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Examiner(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANCILLARY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112519888\">",
"      Brain blood flow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112519895\">",
"      - Cerebral angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112519902\">",
"      - Transcranial Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112519909\">",
"      - Magnetic resonance angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112519916\">",
"      - Computed tomographic angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112519923\">",
"      - Nuclear medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Choice of test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BRAIN DEATH MIMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BRAIN DEATH IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4831|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/61/26576\" title=\"figure 1\">",
"      SPECT scan in brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/5/24670\" title=\"table 1A\">",
"      Brain death criteria by country A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/14/16622\" title=\"table 1B\">",
"      Brain death criteria by country B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/63/34807?source=related_link\">",
"      Locked-in syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30762="Cervical intraepithelial neoplasia: Management";
var content_f30_2_30762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical intraepithelial neoplasia: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/2/30762/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/2/30762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical intraepithelial neoplasia (CIN) is a premalignant cervical disease that is also called cervical dysplasia or cervical squamous intraepithelial lesions (CSIL). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link&amp;anchor=H1#H1\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical intraepithelial neoplasia (CIN) encompasses a range of histological diagnoses. Women with low-grade CIN have minimal potential for developing cervical malignancy, while those with high grade lesions are at high risk of progression to malignancy. In managing women with CIN, the goal is to prevent possible progression to invasive cancer while avoiding overtreatment of lesions that are likely to regress.",
"   </p>",
"   <p>",
"    Consensus guidelines for management of women with CIN have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. These are discussed below and can be found in algorithmic form online at",
"    <a class=\"external\" href=\"file://www.asccp.org/\">",
"     www.ASCCP.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Management of CIN is reviewed here. Diagnosis of CIN, techniques for CIN treatment, and reproductive effects of CIN treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general management approaches to CIN: expectant versus immediate treatment. Management of CIN is based upon correlation of the cervical cytology findings, colposcopic impression, cervical biopsy results, and individual patient characteristics, such as age, pregnancy, and the likelihood of compliance with treatment recommendations. Since treatment can adversely affect future pregnancy outcome, this risk also needs to be considered when deciding upon an interventional or expectant approach.",
"   </p>",
"   <p>",
"    Treatment is never performed based upon a cytologic diagnosis alone, but is sometimes initiated at the time of",
"    <span class=\"nowrap\">",
"     colposcopy/biopsy",
"    </span>",
"    in women who are at high risk of loss to follow-up (see",
"    <a class=\"local\" href=\"#H4\">",
"     'See-and-treat protocols'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ablation and excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general approaches to treatment of CIN: ablative methods (eg, cryotherapy or laser ablation) and excisional methods (eg, cold knife [scalpel] or laser conization, loop electrosurgical excision [LEEP, LLETZ]). A systematic review of 28 randomized and controlled trials showed that, in general, these techniques were equally effective, averaging approximately 90 percent cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of ablation versus excision is based on many factors, such as severity of disease, morbidity, adverse effects, and cost-effectiveness. Most importantly, excisional treatment is required if there is suspected glandular or invasive squamous disease or if there is uncertainty whether the colposcopy and biopsy accurately diagnosed the intraepithelial neoplasia. A full discussion of the choice between ablation versus excision can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     See-and-treat protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;See-and-treat protocols are performed in an office excisional procedure in at-risk populations based upon findings at colposcopy, rather than having the patient await biopsy results and make a return visit. This approach is an attempt to lower the 20 to 40 percent loss-to-follow-up rate with the traditional multi-visit management of CIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/3\">",
"     3",
"    </a>",
"    ]. Some investigators have cautioned against the use of this practice, citing high false positive colposcopy rates resulting in over-treatment. However, new techniques are emerging, such as fluorescence spectroscopy, which may improve the specificity of visual assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The see-and-treat approach appears to be most valuable in women with high grade lesions in whom reliable follow-up is compromised and overtreatment is least likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Data from the",
"    <span class=\"nowrap\">",
"     ASCUS/LSIL",
"    </span>",
"    Triage Study (ALTS) showed that women with high grade cytologic lesions were at high risk of CIN 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/7\">",
"     7",
"    </a>",
"    ]. In patients positive for high oncogenic risk human papillomavirus (HPV), the risk of CIN 3 by cytologic and colposcopic findings was: normal cytology (7 percent), atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) (11 percent), high grade squamous intraepithelial lesions (HSIL) (45 percent), and HSIL plus colposcopic impression of high grade",
"    <span class=\"nowrap\">",
"     disease/cancer",
"    </span>",
"    (67 percent). Based on these findings, immediate treatment may be a reasonable approach in women with HSIL plus colposcopic impression of high grade disease, both for patient convenience and to avoid loss of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alternative methods for treatment of CIN have been developed, all of which are currently investigational. Such techniques include photodynamic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], cyclooxygenase-2 inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/10\">",
"     10",
"    </a>",
"    ], vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/11\">",
"     11",
"    </a>",
"    ], environmental alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/12\">",
"     12",
"    </a>",
"    ], use of topical agents (eg, difluoromethylornithine, all-trans retinoic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]), and oral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical treatment of CIN with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , a nucleotide analogue, is under investigation. A randomized trial found that women with CIN 2 or 3 treated with 2 percent topical cidofovir versus placebo were more likely to show regression of the lesion upon conization (61 versus 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this treatment does not appear to be as effective as excision or ablation and its clinical role remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LOW GRADE LESIONS: CIN 1",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical intraepithelial lesion (CIN) 1 is a low-grade lesion caused by human papillomavirus (HPV) subtypes of both low and high oncogenic risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, CIN 1 lesions will regress in most women. As an example, a retrospective study of 680 women with CIN 1 followed for one year found the following: 49 percent regressed to negative cytology or histology; 18 percent had persistent low grade cytology or histology; and 10 were subsequently diagnosed with CIN 2,3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of women with CIN 1 depends upon the preceding cytology. When CIN 1 is preceded by low-grade cytologic findings (atypical squamous cells of undetermined significance [ASC-US], atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion [ASC-H], and low-grade squamous intraepithelial lesion [LSIL]), treatment with excisional biopsy is not advised for most women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. The exceptions to this are women with CIN 1 that persists for at least two years, for whom either continued surveillance or treatment is acceptable. However, for women with persistent CIN 1 in the setting of an unsatisfactory colposcopy, treatment is preferred (",
"    <a class=\"graphic graphic_algorithm graphicRef56061 \" href=\"mobipreview.htm?29/10/29859\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The majority of CIN 1 preceded by low-grade cervical cytology will not progress to high-grade disease. Studies have reported that 4 to 13 percent of women with CIN 1 preceded by low-grade histology will be diagnosed with CIN 2,3 within 6 to 24 months of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. No studies have reported invasive cervical cancer in this patient population within this follow-up period.",
"   </p>",
"   <p>",
"    Women with CIN on biopsy preceded by a cytologic finding of high-grade SIL (HSIL) or atypical glandular cells-not otherwise specified (AGC-NOS) have a high risk of high-grade preinvasive disease or invasive cancer. Management options for these women include: diagnostic excisional procedure; review of previous cytology, colposcopic findings, and histology; or observation with colposcopy and cytology, provided colposcopy is satisfactory and endocervical sampling is negative (",
"    <a class=\"graphic graphic_algorithm graphicRef80684 \" href=\"mobipreview.htm?23/27/23989\">",
"     algorithm 2",
"    </a>",
"    ). The evaluation of women with glandular abnormalities on cervical cytology is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, women with HSIL cytology have a greater than 70 percent prevalence of underlying CIN 2,3 or worse. Similarly, women with AGC have a high prevalence of underlying CIN 2,3, adenocarcinoma in situ, or cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link&amp;anchor=H16564920#H16564920\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Risk of premalignant or malignant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data regarding how many women with a CIN 1 biopsy preceded by HSIL or AGC cytology will develop high grade preinvasive disease or cancer. However, based upon the higher prevalence of clinically significant disease in these women, the likelihood of missing a high grade lesion upon initial colposcopy is higher in women with HSIL or AGC cytology compared with those with low grade cytology.",
"   </p>",
"   <p>",
"    Several investigators have attempted to predict the risk of progression or regression on the basis of HLA genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/21\">",
"     21",
"    </a>",
"    ], PTEN expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/22\">",
"     22",
"    </a>",
"    ], and many other biomarkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. With the exception of follow-up HPV testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/25\">",
"     25",
"    </a>",
"    ], no reliable and reproducible paradigm has been established to triage patients with CIN 1 on the basis of such predictors.",
"   </p>",
"   <p>",
"    Use of HPV testing for cervical cancer screening is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CIN 1 preceded by low grade cytological abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since spontaneous regression is observed in most women in this setting (ASC-US, ASC-H, LSIL), expectant management is generally preferred for the reliable patient with biopsy-confirmed CIN 1, in whom the entire lesion and limits of the transformation zone are completely visualized (ie, satisfactory colposcopic examination).",
"   </p>",
"   <p>",
"    Approximately 80 to 85 percent of women referred for initial colposcopy because of LSIL or HPV DNA positive ASC-US have CIN 1 or less detected on biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. Overall, 9 to 16 percent of these women will have histologically confirmed CIN 2 or 3 within two years of follow-up. Fewer women with ASC-H have only CIN 1 or less detected at initial biopsy, but for those who do, the risk of subsequent progression to CIN 2,3 is 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/27\">",
"     27",
"    </a>",
"    ]. Therefore, an effective method for monitoring patients managed expectantly is important.",
"   </p>",
"   <p>",
"    The only randomized trial evaluating approaches to postcolposcopy monitoring of these patients concluded that HPV testing after 12 months with repeat colposcopic referral if the HPV results are positive for high risk types was more efficient than semiannual cytology or combined cytology and high risk HPV DNA testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/26\">",
"     26",
"    </a>",
"    ]. Sensitivity to detect subsequent CIN 2,3 for a single HPV DNA test at 12 months was 92 percent, with a 55 percent rate of colposcopy referral. To achieve comparable sensitivity with the other follow-up methods, more visits would be required and with a higher rate of colposcopy referral, 64 to 70 percent.",
"   </p>",
"   <p>",
"    Based on these data, the American Society for Colposcopy and Cervical Pathology (ASCCP) consensus guidelines recommend expectant management of women with biopsy confirmed CIN 1 using follow-up with HPV testing at 12 months or repeat cytology at 6 and 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colposcopy should be repeated if repeat cytology shows ASC or greater or HPV DNA testing is positive for a high risk type.",
"     </li>",
"     <li>",
"      After two negative smears or a negative HPV DNA test, routine screening may be resumed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up of women with CIN 1 beyond 24 months has shown that spontaneous regression or progression can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/28\">",
"     28",
"    </a>",
"    ]. There are no data to suggest that it is unsafe to continue close clinical follow-up of a compliant patient with persistent CIN 1, with treatment planned if there is evidence of disease progression or if the women chooses to be treated.",
"   </p>",
"   <p>",
"    CIN 2,3 are managed as described below (see",
"    <a class=\"local\" href=\"#H16\">",
"     'High grade lesions: CIN 2,3'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8063015\">",
"    <span class=\"h4\">",
"     Unsatisfactory colposcopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIN 1 is easiest to follow in the patient with a satisfactory colposcopy and negative ECC. In women in whom CIN was preceded by low-grade cytology (ASC-US, ASC-H, LSIL), if the colposcopy is unsatisfactory (transformation zone could not be fully visualized), in our practice we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative ECC &ndash; Follow with cytology at 6 and 12 months; colposcopy is repeated for abnormal cytologic results (ASC or greater). High-risk HPV testing may also be performed, but its impact on clinical decision making is uncertain in this setting since approximately 80 to 85 percent of CIN I lesions test HPV positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive ECC &ndash; We consider women with the following characteristics candidates for follow-up with cytology: low-grade ECC in a patient of childbearing age who desires future pregnancy and is reliable to comply with follow-up. For all other patients, we prefer an excisional procedure. Frequently, the grade of the ECC is unknown, since many pathologists will not grade a positive ECC. For an ungraded ECC, we perform an excision. Excision does not preclude future pregnancy, but has been associated with obstetric complications, the likelihood and severity of which appear to be less for loop electrosurgical excision procedures than cold knife conization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ablation or excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;If CIN 1 persists for more than 24 months, treatment becomes an acceptable option. In addition, an occasional patient may elect to have treatment of the CIN 1 lesion to relieve her anxiety. Immediate therapy may also be warranted in a patient at very high risk for loss to follow-up. The provider must keep in mind that a significant number of such patients would have spontaneously resolved their lesion without treatment, but therapy may occasionally be indicated for the reasons stated above.",
"   </p>",
"   <p>",
"    Treatment of the reproductive age patient desirous of future fertility in this setting requires careful consideration and counseling of the patient regarding the treatment-associated risk of subsequent preterm delivery (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If treatment is planned, ablative or excisional modalities are appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. Ablative treatment is reasonable if colposcopy is satisfactory, endocervical sampling (ECC) is negative for glandular or squamous lesions, and treatment is primary. If treatment is planned and colposcopy is unsatisfactory or there are abnormalities on ECC, or there is recurrent disease after ablation, an excisional procedure is recommended to exclude the presence of an underlying high grade or invasive lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     CIN 1 preceded by high grade cytological abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management decisions of a patient with CIN 1 preceded by cytologic abnormalities that are associated with a high risk of malignancy (HSIL, AGC) should take into account colposcopic findings, patient age, and her desire for future fertility. When HSIL or AGC-NOS is followed by a histologic diagnosis of CIN 1, there is a general concern that an underlying high-grade lesion has been missed by colposcopy and biopsy. For that reason, an excisional diagnostic procedure has traditionally been recommended for these situations. Owing to recent data highlighting the concern over the morbidity associated with excisional procedures for future pregnancies, ASCCP guidelines now offer expectant management as an alternative approach, as long as colposcopy was satisfactory and ECC was negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H14\">",
"     'Pregnant women'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In most cases, an excisional procedure provides both definitive diagnosis and treatment. This approach is universally recommended if colposcopy is unsatisfactory or ECC is positive, except in special populations, such as pregnant or adolescent patients. An immediate excisional procedure should also be the preferred management for those patients with a high-grade cytologic abnormality and CIN 1 on biopsy who are beyond childbearing. In the latter scenario, the risk of missed CIN 2,3 or worse outweighs procedure-related morbidities.",
"   </p>",
"   <p>",
"    When managed expectantly, women with CIN 1 preceded by high grade cervical cytology are at higher risk of progression to CIN 2,3 or having a missed underlying CIN 2,3 lesion than CIN 1 preceded by low-grade cytologic abnormalities; therefore, monitoring during expectant management is more intensive. Both cytology and colposcopy are performed at 6 and 12 months. After two negative cytology smears with confirmatory colposcopy, routine screening may be resumed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. If HSIL or AGC-NOS or worse is detected on follow-up, a diagnostic excisional procedure is recommended to exclude the presence of an underlying high grade histologic lesion.",
"   </p>",
"   <p>",
"    An alternative to expectant management or a diagnostic excisional procedure is to review the cytology and histology slides and the colposcopy findings. If this review results in a revised interpretation, then the revised diagnosis should guide further management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exceptions for special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adolescent women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines from professional societies advise against starting cervical cancer screening before age 21, as it may lead to unnecessary and harmful evaluation and treatment in women at extremely low risk for cancer. Thus, adherence to this recommendation provided, management discussions of the adolescent with CIN should no longer be needed. &nbsp;",
"   </p>",
"   <p>",
"    ASCCP guidelines, developed prior to the change in screening recommendations, indicated that for adolescents (age 13 to 20 according to the ASCCP guidelines) who have had cervical cytology, expectant management of confirmed CIN 1 is preferred, irrespective of the index cytologic diagnosis or a satisfactory or unsatisfactory colposcopic examination, because undetected high grade disease is uncommon in this setting, invasive cancer is rare, and regression to normal is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1,31-34\">",
"     1,31-34",
"    </a>",
"    ]. In one series, only 0.4 percent of women less than 20 years of age with CIN 1 or less diagnosed by colposcopy with directed and random biopsies were subsequently diagnosed with CIN 3 or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/35\">",
"     35",
"    </a>",
"    ]. Recent Neisseria gonorrhoeae infection and use of depot medroxyprogesterone were associated with lesion regression. Management of these lesions must be approached in the context of the known risk of treatment of CIN on future pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H33#H33\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Starting age'",
"    </a>",
"    .) In this setting, ASCCP recommends to repeat cytology after 12 months, with further management based on the cytologic findings. Adolescents with HSIL or greater would be referred to colposcopy; all others are followed with another cytology 12 months later. At 24 months, anyone with ASC or greater would undergo colposcopy. Follow-up of adolescents with HPV DNA testing is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up of pregnant women with CIN 1 is deferred until at least six weeks postpartum, at which time the cervix has returned to its pregravid state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. This approach is based upon the low risk of CIN 2,3 or invasive cancer being missed or developing during pregnancy, the high rate of postpartum regression of CIN 1 to normal, and the risk of disturbing the pregnancy if invasive procedures are performed antepartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Coexistent HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of low-grade cervical lesions in the HIV positive patient is a complex issue that is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HIGH GRADE LESIONS: CIN 2,3",
"    </span>",
"    &nbsp;&mdash;&nbsp;CIN 2 and 3 are high grade lesions. They are managed in the same way because histological distinction between the two grades of CIN is poorly reproducible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1,39-41\">",
"     1,39-41",
"    </a>",
"    ]. Given the overall high risk of progression of both CIN 2 and 3, prompt treatment is recommended, with the exception of pregnant women and adolescents.",
"   </p>",
"   <p>",
"    Since most patients with CIN 2 or CIN 3 have some intervention rather than expectant management, data on outcome of untreated high-grade disease are lacking. For CIN 2 lesions, it appears that 40 to 58 percent of lesions will regress if left untreated, while 22 percent progress to CIN 3 and 5 percent progress to invasive cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In data from the ALTS trial, regression of CIN 2 was less likely in women with HPV-16 subtype than other subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For CIN 3, the estimated spontaneous regression rate is 32 to 47 percent, with 12 to 40 percent progressing to invasive cancer if untreated (",
"    <a class=\"graphic graphic_figure graphicRef60116 \" href=\"mobipreview.htm?4/20/4423\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/43,45-49\">",
"     43,45-49",
"    </a>",
"    ]. The best data on the natural history of histologically confirmed CIN 3 is derived from a study that evaluated the incidence of invasive cancer over time in two groups of women with this lesion: 143 women who received close follow-up but no treatment and 593 women who received adequate or probably adequate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/49\">",
"     49",
"    </a>",
"    ]. The cumulative incidence of invasive cancer of the",
"    <span class=\"nowrap\">",
"     cervix/vaginal",
"    </span>",
"    vault was significantly higher in untreated women at 10 years (20 versus 0.3 percent) and 30 years (31 versus 0.7 percent). Ninety-two of the 143 women who received close follow-up, but no treatment, had cytologic evidence of persistent disease 6 to 24 months after initial diagnosis of CIN 3. In this subgroup, the cumulative incidence of invasive cancer of the",
"    <span class=\"nowrap\">",
"     cervix/vaginal",
"    </span>",
"    vault at 10 and 30 years was 31 and 50 percent, respectively.",
"   </p>",
"   <p>",
"    One explanation for the lower rate of progression of CIN 2 than CIN 3 is that CIN 2 is more likely to be caused by oncogenic HPV subtypes 31,33,35,39,45,51,52, and 58, which have a weaker association with development of cancer than the more highly oncogenic subtypes HPV 16 and 18, which are commonly found with CIN 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options fall into one of two main categories: procedures that ablate the abnormal tissue; these do not produce a specimen for additional histologic evaluation, and procedures that excise the area of abnormality; these allow further histologic study. Clinical trials comparing the different treatment modalities have not found that any treatment is significantly more successful than another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/2,51-53\">",
"     2,51-53",
"    </a>",
"    ]. Regardless of the modality used, the entire transformation zone should be eliminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to any therapeutic intervention, an assessment needs to be made as to whether a patient qualifies for ablative therapy or if she requires a more invasive excisional procedure for further diagnostic work-up.",
"   </p>",
"   <p>",
"    A full discussion of ablative therapy can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ablative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are candidates for ablative therapy if they have no suspected glandular or invasive squamous disease and are compliant with follow-up.",
"   </p>",
"   <p>",
"    A full discussion of can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Excisional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for excisional therapy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected microinvasion",
"     </li>",
"     <li>",
"      Unsatisfactory colposcopy (the transformation zone is not fully visualized)",
"     </li>",
"     <li>",
"      Lesion extending into the endocervical canal (including CIN 1)",
"     </li>",
"     <li>",
"      Endocervical curettage showing CIN or a glandular abnormality",
"     </li>",
"     <li>",
"      Lack of correlation between the cytology and",
"      <span class=\"nowrap\">",
"       colposcopy/biopsies",
"      </span>",
"     </li>",
"     <li>",
"      Suspected adenocarcinoma in situ",
"     </li>",
"     <li>",
"      Colposcopist unable to rule out invasive disease",
"     </li>",
"     <li>",
"      Recurrence after an ablative or previous excisional procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excisional treatment can be performed by cold knife conization, laser conization, or the loop electrosurgical excision procedure (LEEP), also called large loop excision of the transformation zone (LLETZ). In general, with suspected microinvasion or adenocarcinoma in situ (AIS), cold knife conization is often recommended so that margins can be evaluated without cautery artifact. Operator experience may be a consideration in choosing between LEEP and cold knife conization. The depth of conization should be limited to the minimum necessary in reproductive age women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link&amp;anchor=H11#H11\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\", section on 'Depth of excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytologically and colposcopically unsuspected AIS and microinvasive squamous carcinomas have been reported in approximately 0.5 percent of cervical specimens obtained through excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/55\">",
"     55",
"    </a>",
"    ]. In one report of 1189 patients who underwent LEEP, 15 patients (1.3 percent) had adenocarcinoma in situ and six (0.5 percent) had microinvasive squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/56\">",
"     56",
"    </a>",
"    ]. Ten (67 percent) of the adenocarcinomas in situ and two (33 percent) of the microinvasive carcinomas were not recognized by cytology and colposcopy. Another series of 3738 women who underwent laser ablation for CIN reported nine invasive or microinvasive cancers of the cervix (0.24 percent) during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/57\">",
"     57",
"    </a>",
"    ]. These observations, in combination with the development of LEEP as an effective and well tolerated outpatient procedure, have been a catalyst for the increasing use of excisional methods in the treatment of CIN, especially for high grade lesions.",
"   </p>",
"   <p>",
"    A diagnostic, excisional procedure and sampling of the endocervical canal in women in whom the complete transformation zone is not visualized is important to exclude cancer. This was illustrated in studies showing that as many as 7 percent of women with CIN 2,3 and an unsatisfactory colposcopic examination had occult invasive cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/52,58\">",
"     52,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy should not be performed as an initial treatment of CIN 2,3. The incidence of significant morbidity with hysterectomy is higher than with the less invasive modalities discussed above.",
"   </p>",
"   <p>",
"    There are, however, some indications for which hysterectomy remains a valid treatment option for CIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conization specimen margins that are positive for CIN 2,3, especially in the setting of completed childbearing and expected poor compliance with follow-up. In most cases, however, the treatment of choice is close clinical follow-up or, in select cases, reexcision to exclude an invasive cancer instead of hysterectomy. Hysterectomy should generally be reserved for those in whom a repeat excisional procedure is not technically feasible or where the cervix and vagina are scarred in a way that severely compromises the reliability of cervical cytology and close clinical follow-up.",
"      <br/>",
"      <br/>",
"      If hysterectomy is contemplated in the setting of cone margins and endocervical sampling that are positive for CIN 3 carcinoma in situ, consideration should be given to performing a frozen cone at the time of hysterectomy in order to avoid performing an inappropriate simple hysterectomy in a patient with occult invasive carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Presence of coexistent gynecologic conditions requiring hysterectomy",
"     </li>",
"     <li>",
"      Patient request and persistent or recurrent CIN 2,3",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines from professional societies advise against commencing cervical cancer screening before age 21. ASCCP guidelines, developed prior to the change in screening recommendations, indicated that in adolescents (age 13 to 20 according to the ASCCP guidelines) with CIN 2,3, the rate of regression is high and progression to invasive cancer is extremely small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1,31-33\">",
"     1,31-33",
"    </a>",
"    ]. Therefore, observation with colposcopy and cytology at six-month intervals for up to two years is preferable to excisional or ablative therapy for reliable adolescents with biopsy-confirmed CIN 2,3 as long as colposcopy is satisfactory, endocervical curettage is negative, and the possibility of occult disease is acknowledged by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. Repeat biopsy is indicated if high grade disease persists at 12 months and treatment is indicated if it persists for 24 months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a specific histological diagnosis of CIN 2 (rather than CIN 2,3), observation is preferable to treatment, while ablation or excision has traditionally been recommended for adolescents with CIN 3 or with unsatisfactory colposcopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the latter recommendation should be modified is a matter of debate, given current screening guidelines and the above discussed natural history and",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    data.",
"   </p>",
"   <p>",
"    After two consecutive negative results, the patient can return to a routine screening interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of CIN 2,3 is not indicated during pregnancy because high grade lesions discovered during pregnancy have a high rate of regression in the postpartum period. In one study, 70 percent of 153 women with CIN 3 had regression and none progressed to invasive carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/36\">",
"     36",
"    </a>",
"    ]. This underscores the role for conservative antepartum management followed by careful postpartum evaluation. Furthermore, the morbidity associated with cervical conization during pregnancy is substantial.",
"   </p>",
"   <p>",
"    CIN 2,3 should be monitored during pregnancy with colposcopy (without endocervical curettage); there are no data on which to base a recommendation for the optimal interval, but once each trimester is a reasonable approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. Colposcopy and cervical cytology should be performed 6 to 12 weeks postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/45\">",
"     45",
"    </a>",
"    ]. Repeat biopsies are indicated only if worsening disease is suspected by cytology or colposcopic appearance, with a diagnostic excisional procedure if invasive disease is suspected and knowledge of the diagnosis will alter management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/59\">",
"     59",
"    </a>",
"    ]. Issues regarding diagnosis and management of cervical cancer in pregnant women are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=see_link\">",
"     \"Cervical cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Coexistent HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of high grade cervical lesions in the HIV positive patient is a complex issue that is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Delayed follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women do not follow-up promptly after abnormal cervical cytology. In a retrospective study of over 8000 women with abnormal cervical cytology, 19 percent were lost to follow-up, including 8 percent of those with HSIL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a patient who had HSIL cervical cytology in the past, but got lost to follow-up for six or more months, evaluation should include repeat collection of cervical cytology and colposcopy with biopsy and ECC with management based on those results.",
"   </p>",
"   <p>",
"    For a non-adolescent, non-pregnant patient with biopsy-proven CIN 2,3 who has a latency prior to her scheduled treatment, it appears reasonable to proceed with the planned treatment without re-evaluation despite delay for up to 6 to 12 months. Once the treatment delay has been more than 12 months, the patient should be reassessed with cervical cytology, colposcopy, biopsy and ECC for several reasons prior to proceeding with the planned treatment to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclude the development of a lesion suspicious for microinvasive or invasive carcinoma. In the case of a suspected microinvasive carcinoma, a conization would be indicated. In the case of a gross lesion suspicious for cancer, all that may be needed is a cervical biopsy to confirm the diagnosis and conization through cancer would and should be avoided.",
"     </li>",
"     <li>",
"      Assess the patient for potential resolution of her high grade lesion. As discussed above, regression is particularly likely in the postpartum patient and particularly important for any young patient who is desirous of future fertility for whom the treatment-associated risk of preterm delivery has to be considered in the context of higher spontaneous regression rates of CIN 2,3 (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Adolescents'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative (excisional or ablative) outpatient therapy of women with CIN can reduce the risk of invasive cancer of the cervix by 95 percent in the first eight years after therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/61\">",
"     61",
"    </a>",
"    ]. However, even with careful long-term follow-up, the risk of invasive cervical cancer among these women remains greater than that among the general population of women, and the increased risk persists for as long as 20 to 25 years (56 per 100,000 woman years versus 5.6 per 100,000 woman years in the general population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/62-67\">",
"     62-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, the rate of recurrent or persistent CIN is 5 to 17 percent despite therapy with any of the excisional or ablative techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/2\">",
"     2",
"    </a>",
"    ]. Higher rates of persistent disease are associated with large lesion size (eg, greater than two thirds of the surface of the cervix) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/51\">",
"     51",
"    </a>",
"    ], endocervical gland involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/68\">",
"     68",
"    </a>",
"    ], positive margin status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], and continuing HPV DNA positivity (especially with HPV 16 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/71\">",
"     71",
"    </a>",
"    ]) six months or more post-treatment, while the risk is much lower in the absence of these characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/69,72-76\">",
"     69,72-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of margin status was demonstrated in a meta-analysis of 66 studies involving over 35,000 women who underwent an excisional procedure for any grade of CIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/69\">",
"     69",
"    </a>",
"    ]. Follow-up was less than two years in most studies. Compared to women with clear or uncertain margins, women with positive margins were at significantly increased risk of any grade posttreatment CIN (RR 5.47, 95% CI 4.37-6.83). If posttreatment CIN 2,3 was used as the endpoint, the relative risk was 6.09 (95% CI 3.87-9.60; pooled prevalence 18 percent versus 3 percent with",
"    <span class=\"nowrap\">",
"     clear/uncertain",
"    </span>",
"    margins).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920343\">",
"    <span class=\"h3\">",
"     Negative margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high rate of cure when the entire lesion has been excised. This was illustrated in one of the few studies with long-term follow-up. In this study, 4417 women with clear margins after cold knife conization for histologically confirmed CIN 3 were followed with colposcopy, cytology, and pelvic examination for a mean of 18 years (range 5 to 30 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New high-grade squamous intraepithelial lesions (HSIL, CIN 2 or 3) developed in 15 (0.35 percent) patients after a median of 107 (range 40 to 201) months. In two of these women, high-grade glandular intraepithelial lesions developed 14 and 17 years after conization.",
"     </li>",
"     <li>",
"      The remaining 4402 (99.65 percent) patients remained free of HSIL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various approaches have been proposed for follow-up when the entire lesion appears to have been removed. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HPV testing at 6 to 12 months",
"     </li>",
"     <li>",
"      HPV testing and cervical cytology at 6 to 12 months",
"     </li>",
"     <li>",
"      Cervical cytology at 6 and 12 months",
"     </li>",
"     <li>",
"      A combination of cytology and colposcopy with endocervical curettage at 6 and 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat colposcopy and an ECC are indicated if ASC or greater is diagnosed on cytology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a positive HPV test is detected. After two negative results for cervical cytology (or one negative HPV test) have been obtained, annual follow-up screening is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]. A negative HPV test essentially eliminates the risk of persistent CIN after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with uncertain margin status after LEEP, and those who were treated with ablative therapy, can also be followed according to the above guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920351\">",
"    <span class=\"h3\">",
"     Positive margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that patients with positive margins after an excisional procedure are at significantly higher risk for residual disease as determined at subsequent hysterectomy or with repeat excision than patients with clear margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/69,77,79-90\">",
"     69,77,79-90",
"    </a>",
"    ]. Women who have positive margins on the excised specimens or in the concomitant endocervical curettage specimen should be counseled about the risks and benefits of observation versus further treatment, taking into account age, pregnancy plans, and management preferences.",
"   </p>",
"   <p>",
"    Clinical follow-up with HPV testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cytology and endocervical sampling at six months, instead of immediate retreatment, is appropriate in patients who are compliant with frequent monitoring and may be preferred for patients desiring future fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. Alternatively, and especially for women post childbearing, a repeat excisional procedure can be offered to patients with positive margins with CIN 3 who prefer to assume the risk of potential treatment-associated complications rather than the risk of progression or underdiagnosis of residual disease.",
"   </p>",
"   <p>",
"    The risk of residual disease is highest if both the excised specimen and the endocervical curettage show high grade histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/80,83,94\">",
"     80,83,94",
"    </a>",
"    ]. The risk of residual disease is also increased if both the ecto- and endocervical margins are positive. A study of 390 patients with involved margins after cold-knife conization for CIN 3 reported that the combined risk of persistent, recurrent, or progressive disease when ectocervical, endocervical, or both margins were positive was 17, 21, and 52 percent, respectively, after 6 to 30 years follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/94\">",
"     94",
"    </a>",
"    ]. Five patients developed microinvasive disease and one patient developed stage 1B carcinoma.",
"   </p>",
"   <p>",
"    Recurrences in women with positive margins can occur years after treatment. In a retrospective study of women after LEEP, mean time to recurrence in women with positive margins was almost four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920359\">",
"    <span class=\"h3\">",
"     Negative excisional specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A completely negative",
"    <span class=\"nowrap\">",
"     LEEP/cone",
"    </span>",
"    biopsy performed for high grade lesions is also of concern. The clinical significance of this situation was illustrated by a study in which 14 percent of 674 LEEP specimens performed for biopsy proven high grade cervical intraepithelial neoplasia had no evidence of dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/95\">",
"     95",
"    </a>",
"    ]. The recurrence rate after a negative LEEP was similar to that after a LEEP with a positive margin (24 versus 27 percent), and 24 percent of these patients had subsequent neoplastic findings, including two carcinomas and eight high-grade lesions, after a median follow-up of two years. These patients should be followed similarly to those with positive margins, with cytology and endocervical curettage every six months for at least the first three visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with CIN 2,3 are managed with ablative or excisional therapy, exceptions are discussed above (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Special populations'",
"    </a>",
"    above). Following treatment, a number of follow-up protocols have been advocated, such as use of HPV DNA testing, cytology, and various combinations of cytology, endocervical sampling, and colposcopy at various intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. None of these have been compared in randomized controlled trials, and comparisons between studies have often been limited by differences in study design and follow-up. However, observational studies have consistently reported that posttreatment HPV testing at 6 to 12 months post-therapy is highly sensitive (sensitivity 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/96\">",
"     96",
"    </a>",
"    ]) in identifying",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    CIN and more sensitive than cytology (sensitivity 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/96\">",
"     96",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1,45,72-75,96,98-103\">",
"     1,45,72-75,96,98-103",
"    </a>",
"    ]. Whether combined cytology plus HPV testing is superior remains to be proven.",
"   </p>",
"   <p>",
"    A long-term multi-cohort study of 435 women treated for CIN",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    demonstrated the value of combined cervical cytology and high-risk HPV testing at 6 and 24 months postprocedure at a referral threshold for further evaluation and treatment if either the cytology test showed ASC or worse or the HPV test was positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/104\">",
"     104",
"    </a>",
"    ]. If both tests were negative at six months, the risk of persistent or recurrent CIN",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    was 4.6 percent; if both tests were negative at 6 and 24 months, the risk was 1.8 percent. In contrast, if either test was positive at six months, the risk of persistent CIN",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    or worse was 45 to 60 percent, indicating the need for immediate evaluation and treatment for these patients.",
"   </p>",
"   <p>",
"    Use of HPV testing for cervical cancer screening is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1920793\">",
"    <span class=\"h3\">",
"     Clinical protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Colposcopy and Cervical Pathology advises a choice of two follow-up protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytology or cytology and colposcopy every six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      After two negative results, annual screening may be resumed and should be continued at least 20 years.",
"     </li>",
"     <li>",
"      If cytology shows atypical squamous cells or a more severe abnormality, colposcopy with endocervical sampling should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HPV testing for high-risk subtypes at 6 to 12 months after treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      HPV negative &ndash; annual screening may be resumed and should be continued for at least 20 years.",
"     </li>",
"     <li>",
"      HPV positive &ndash; colposcopy with endocervical sampling should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of colposcopy should be followed as appropriate for the histologic result. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Low grade lesions: CIN 1'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'High grade lesions: CIN 2,3'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Post-hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of vaginal intraepithelial neoplasia (VAIN) or vaginal cancer is extremely low in women who have undergone total hysterectomy (removal of the uterus and cervix) for benign disease (excluding CIN 2,3) and for this reason, screening guidelines in the United States (US) from the US Preventive Services Task Force (USPSTF), the American Cancer Society (ACS), and the American College of Obstetricians and Gynecologists (ACOG) concur that most women do not need post-hysterectomy vaginal cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/105-108\">",
"     105-108",
"    </a>",
"    ]. Vaginal cytology for vaginal cancer screening is advisable in women with CIN 2,3 prior to, or diagnosed at the time of, total hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/105-109\">",
"     105-109",
"    </a>",
"    ]. ACOG recommends ongoing screening of these women for at least 20 years after treatment of CIN2,3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H26#H26\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Prior hysterectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H36#H36\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Women who have undergone hysterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interpretation of vaginal cytology results is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link&amp;anchor=H9531352#H9531352\">",
"     \"Cervical cytology: Interpretation of results\", section on 'Vaginal cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HPV VACCINATION IN WOMEN WITH CIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women and girls who are candidates for HPV vaccination, the United States Centers for Disease Control and Prevention recommends vaccination regardless of a history of genital warts, abnormal Papanicolaou test, or positive HPV DNA test, because these conditions are not evidence of prior infection with all vaccine HPV types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2809883\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SEXUAL PARTNERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2809903\">",
"    <span class=\"h2\">",
"     Male partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV testing in men is not commercially available. Studies of women with CIN have found the following prevalences of associated conditions in their male sexual partners: high risk HPV infection (58 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/112\">",
"     112",
"    </a>",
"    ]) and penile intraepithelial neoplasia (9 to 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]). Randomized trial data shows that condom use promotes regression of HPV-associated lesions in women with CIN and their male sexual partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. As an example, in a randomized trial, women with CIN and their male sexual partners who did versus did not use condoms had higher rates of regression of CIN lesions (53 versus 35 percent) and clearance of high risk HPV infection (23 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of penile premalignant lesions and penile cancer can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42328?source=see_link&amp;anchor=H282022481#H282022481\">",
"     \"Carcinoma of the penis: Clinical presentation and diagnosis\", section on 'Differential Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2809910\">",
"    <span class=\"h2\">",
"     Female partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV infection occurs in women who have sex with women, including those who have had not sexual contact with men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/2/30762/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Strategies to prevent persistence and reinfection of HPV have not been identified for women with CIN who have sex with women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25113?source=see_link\">",
"     \"Medical care of women who have sex with women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515103\">",
"    <span class=\"h1\">",
"     SUBSEQUENT FERTILITY AND PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cervical intraepithelial neoplasia with ablation or excision may affect subsequent fertility or pregnancy. There are few studies regarding how long women should wait to conceive after treatment. We suggest an interval of three months or longer from an excisional procedure to conception of a pregnancy. Reproductive effects of CIN treatment are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Reproductive effects of treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CIN 1 &mdash; Given the high rate of spontaneous regression, we suggest expectant management rather than treatment of most patients with CIN 1 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Low grade lesions: CIN 1'",
"      </a>",
"      above.) Expectant management is strongly preferred in adolescents and young women. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adolescent women'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Aggressive intervention is not warranted when CIN 1 is preceded by cervical cytology showing low-grade cytologic lesions (ASC-US, LSIL). A significant number of these lesions spontaneously regress, and progression to CIN 2,3 or invasive cancer is uncommon. A reasonable approach to follow-up is HPV testing at 12 months or repeat cytology at 6 and 12 months. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'CIN 1 preceded by low grade cytological abnormalities'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Women with cytologic evidence of HSIL or atypical glandular cells (AGC) have a relatively high prevalence of underlying CIN 2,3 or worse. When colposcopically-directed biopsy reveals only CIN 1 in this setting, there is a higher likelihood that a small high grade lesion was missed. Therefore, CIN 1 preceded by HSIL or AGC is managed more aggressively than CIN 1 preceded by ASC-US or LSIL; either an immediate diagnostic excisional procedure or close clinical follow-up is reasonable. For women who are past childbearing, we suggest a diagnostic excisional procedure rather than an ablative procedure or close monitoring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For young women planning future pregnancy, we suggest close clinical follow-up rather than an invasive procedure, given the potential risk of these procedures on future childbearing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We follow these women with both cytology and colposcopy at 6 and 12 months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CIN 1 preceded by high grade cytological abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CIN 2,3 &mdash; Given the low rate of spontaneous regression and high rate of progression, we suggest treatment rather than expectant management of patients with CIN 2,3 (except for adolescents and pregnant women) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'High grade lesions: CIN 2,3'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Ablative and excisional procedures have equally effective cure rates. We suggest a loop electrosurgical excisional procedure (LEEP) over an ablative or other excisional procedures (cold knife cone) in patients who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). LEEP is an office procedure with ease of use, providing a histologic specimen at low cost and morbidity, and high rate of success. Ablative procedures are an acceptable alternative in properly selected patients (biopsy confirmed CIN 2,3, satisfactory colposcopy, and negative endocervical curettage) and may be the preferable treatment strategy for women with CIN 2,3 desirous of future fertility who meet these treatment criteria.",
"     </li>",
"     <li>",
"      We suggest cold knife conization for women with suspected microinvasion, and suspected adenocarcinoma in situ (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Cold knife conization results in a specimen devoid of marginal artifacts and thus permits accurate histologic assessment of the transformation zone, endocervical canal, and margins. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Excisional therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, the rate of recurrent or persistent disease is 5 to 17 percent despite therapy with any of the excisional or ablative techniques. Large lesion size (eg, greater than two thirds of the surface of the cervix), endocervical gland involvement, positive margin status, and continuing HPV DNA positivity are associated with higher rates of persistent disease, while the risk is much lower in the absence of these characteristics. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following ablation or excision of biopsy confirmed CIN 2,3, options for follow-up include: HPV testing at 6 to 12 months, or cervical cytology at 6 and 12 months, or HPV testing and cervical cytology at six months or a combination of cytology and colposcopy with endocervical curettage at 6 and 12 months. For patients with negative conization margins and for those who underwent ablative therapy, we suggest a single post-treatment cervical cytology and HPV test at 6 to 12 months post-therapy, given its excellent sensitivity and negative predictive value. Repeat colposcopy is indicated if ASC or greater or a positive HPV test are detected. Patients with a negative cervical cytology and HPV test or two consecutive negative cervical cytology tests can return to annual screening. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with positive conization margins after an excisional procedure are at increased risk for residual disease. Women who have positive margins on the excised specimens or in the concomitant endocervical curettage specimen should be counseled about the risks and benefits of observation with frequent monitoring versus another excisional procedure. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/1\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/2\">",
"      Martin-Hirsch PL, Paraskevaidis E, Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000; :CD001318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/3\">",
"      Holschneider CH, Ghosh K, Montz FJ. See-and-treat in the management of high-grade squamous intraepithelial lesions of the cervix: a resource utilization analysis. Obstet Gynecol 1999; 94:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/4\">",
"      Mitchell MF, Cantor SB, Ramanujam N, et al. Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1999; 93:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/5\">",
"      Irvin WP Jr, Andersen WA, Taylor PT Jr, et al. \"See-and-treat\" loop electrosurgical excision. Has the time come for a reassessment? J Reprod Med 2002; 47:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/6\">",
"      Charoenkwan K, Srisomboon J, Siriaunkgul S, et al. A \"See and Treat\" approach for high grade squamous intraepithelial lesion on cervical cytology. J Med Assoc Thai 2004; 87:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/7\">",
"      Walker JL, Wang SS, Schiffman M, et al. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol 2006; 195:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/8\">",
"      Yamaguchi S, Tsuda H, Takemori M, et al. Photodynamic therapy for cervical intraepithelial neoplasia. Oncology 2005; 69:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/9\">",
"      Bodner K, Bodner-Adler B, Wierrani F, et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. Anticancer Res 2003; 23:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/10\">",
"      Hefler LA, Grimm C, Speiser P, et al. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol 2006; 125:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/11\">",
"      Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/12\">",
"      Velema JP, Ferrera A, Figueroa M, et al. Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in Honduras. Int J Cancer 2002; 97:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/13\">",
"      Vlastos AT, West LA, Atkinson EN, et al. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 2005; 11:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/14\">",
"      Ruffin MT, Bailey JM, Normolle DP, et al. Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev 2004; 13:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/15\">",
"      Del Priore G, Gudipudi DK, Montemarano N, et al. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol 2010; 116:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/16\">",
"      Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 2009; 115:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/17\">",
"      Bansal N, Wright JD, Cohen CJ, Herzog TJ. Natural history of established low grade cervical intraepithelial (CIN 1) lesions. Anticancer Res 2008; 28:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/18\">",
"      Cox JT, Schiffman M, Solomon D, ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/19\">",
"      Castle PE, Gage JC, Wheeler CM, Schiffman M. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 2011; 118:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/20\">",
"      Elit L, Levine MN, Julian JA, et al. Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia : a randomized trial in Canada and Brazil. Cancer 2011; 117:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/21\">",
"      Sastre-Garau X, Cartier I, Jourdan-Da Silva N, et al. Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol 2004; 104:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/22\">",
"      Lee JS, Choi YD, Lee JH, et al. Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma. J Surg Oncol 2006; 93:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/23\">",
"      Lee JW, Lee SJ, Seo J, et al. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol Oncol 2005; 97:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/24\">",
"      Baak JP, Kruse AJ, Janssen E, van Diermen B. Predictive testing of early CIN behaviour by molecular biomarkers. Cell Oncol 2005; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/25\">",
"      Santos AL, Derchain SF, Sarian LO, et al. Performance of Pap smear and human papilloma virus testing in the follow-up of women with cervical intraepithelial neoplasia grade 1 managed conservatively. Acta Obstet Gynecol Scand 2006; 85:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/26\">",
"      Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/27\">",
"      Bonvicino A, Huitron S, Fadare O. Papanicolaou test interpretations of \"atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion\" : an investigation of requisite duration and number of colposcopic procedures to a definitive diagnosis of high-grade dysplasia in routine practice. Cancer 2007; 111:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/28\">",
"      Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/29\">",
"      Coutl&eacute;e F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/30\">",
"      Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/31\">",
"      Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/32\">",
"      Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/33\">",
"      Moore K, Cofer A, Elliot L, et al. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 2007; 197:141.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/34\">",
"      Committee on Adolescent Health Care. ACOG Committee Opinion No. 436: evaluation and management of abnormal cervical cytology and histology in adolescents. Obstet Gynecol 2009; 113:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/35\">",
"      Pretorius RG, Peterson P, Azizi F, Burchette RJ. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. Am J Obstet Gynecol 2006; 195:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/36\">",
"      Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999; 93:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/37\">",
"      Economos K, Perez Veridiano N, Delke I, et al. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 1993; 81:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/38\">",
"      Connor JP. Noninvasive cervical cancer complicating pregnancy. Obstet Gynecol Clin North Am 1998; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/39\">",
"      Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/40\">",
"      Robertson AJ, Anderson JM, Beck JS, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol 1989; 42:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/41\">",
"      Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr 1996; :17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/42\">",
"      Ost&ouml;r AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/43\">",
"      Chan JK, Monk BJ, Brewer C, et al. HPV infection and number of lifetime sexual partners are strong predictors for 'natural' regression of CIN 2 and 3. Br J Cancer 2003; 89:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/44\">",
"      Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/45\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 66, September 2005. Management of abnormal cervical cytology and histology. Obstet Gynecol 2005; 106:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/46\">",
"      McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984; 64:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/47\">",
"      Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989; 60:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/48\">",
"      Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/49\">",
"      McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/50\">",
"      Nucci MR, Crum CP. Redefining early cervical neoplasia: recent progress. Adv Anat Pathol 2007; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/51\">",
"      Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998; 92:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/52\">",
"      Duggan BD, Felix JC, Muderspach LI, et al. Cold-knife conization versus conization by the loop electrosurgical excision procedure: a randomized, prospective study. Am J Obstet Gynecol 1999; 180:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/53\">",
"      Cox JT. Management of cervical intraepithelial neoplasia. Lancet 1999; 353:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/54\">",
"      Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003; 189:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/55\">",
"      Bigrigg MA, Codling BW, Pearson P, et al. Colposcopic diagnosis and treatment of cervical dysplasia at a single clinic visit. Experience of low-voltage diathermy loop in 1000 patients. Lancet 1990; 336:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/56\">",
"      Ferenczy A, Choukroun D, Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet Gynecol 1996; 87:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/57\">",
"      Pearson SE, Whittaker J, Ireland D, Monaghan JM. Invasive cancer of the cervix after laser treatment. Br J Obstet Gynaecol 1989; 96:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/58\">",
"      Fine BA, Feinstein GI, Sabella V. The pre- and postoperative value of endocervical curettage in the detection of cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol 1998; 71:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/59\">",
"      Goldberg GL, Altaras MM, Block B. Cone cerclage in pregnancy. Obstet Gynecol 1991; 77:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/60\">",
"      Singhal R, Rubenstein LV, Wang M, et al. Variations in practice guideline adherence for abnormal cervical cytology in a county healthcare system. J Gen Intern Med 2008; 23:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/61\">",
"      Soutter WP, de Barros Lopes A, Fletcher A, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997; 349:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/62\">",
"      Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005; 331:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/63\">",
"      Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006; 118:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/64\">",
"      Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/65\">",
"      Strander B, Andersson-Ellstr&ouml;m A, Milsom I, Spar&eacute;n P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007; 335:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/66\">",
"      Melnikow J, McGahan C, Sawaya GF, et al. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009; 101:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/67\">",
"      Rebolj M, Helmerhorst T, Habbema D, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012; 345:e6855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/68\">",
"      Demopoulos RI, Horowitz LF, Vamvakas EC. Endocervical gland involvement by cervical intraepithelial neoplasia grade III. Predictive value for residual and/or recurrent disease. Cancer 1991; 68:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/69\">",
"      Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007; 8:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/70\">",
"      Manchanda R, Baldwin P, Crawford R, et al. Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years. BJOG 2008; 115:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/71\">",
"      G&ouml;k M, Coup&eacute; VM, Berkhof J, et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007; 104:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/72\">",
"      Paraskevaidis E, Koliopoulos G, Alamanos Y, et al. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001; 98:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/73\">",
"      Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000; 79:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/74\">",
"      Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997; 66:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/75\">",
"      Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/76\">",
"      Kaufman RH. Is there a role for human papillomavirus testing in clinical practice? Obstet Gynecol 2001; 98:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/77\">",
"      Reich O, Pickel H, Lahousen M, et al. Cervical intraepithelial neoplasia III: long-term outcome after cold-knife conization with clear margins. Obstet Gynecol 2001; 97:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/78\">",
"      Hern&aacute;di Z, Szoke K, S&aacute;py T, et al. Role of human papillomavirus (HPV) testing in the follow-up of patients after treatment for cervical precancerous lesions. Eur J Obstet Gynecol Reprod Biol 2005; 118:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/79\">",
"      Paterson-Brown S, Chappatte OA, Clark SK, et al. The significance of cone biopsy resection margins. Gynecol Oncol 1992; 46:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/80\">",
"      Felix JC, Muderspach LI, Duggan BD, Roman LD. The significance of positive margins in loop electrosurgical cone biopsies. Obstet Gynecol 1994; 84:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/81\">",
"      Park JY, Lee SM, Yoo CW, et al. Risk factors predicting residual disease in subsequent hysterectomy following conization for cervical intraepithelial neoplasia (CIN) III and microinvasive cervical cancer. Gynecol Oncol 2007; 107:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/82\">",
"      Mohamed-Noor K, Quinn MA, Tan J. Outcomes after cervical cold knife conization with complete and incomplete excision of abnormal epithelium: a review of 699 cases. Gynecol Oncol 1997; 67:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/83\">",
"      Husseinzadeh N, Shbaro I, Wesseler T. Predictive value of cone margins and post-cone endocervical curettage with residual disease in subsequent hysterectomy. Gynecol Oncol 1989; 33:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/84\">",
"      Lapaquette TK, Dinh TV, Hannigan EV, et al. Management of patients with positive margins after cervical conization. Obstet Gynecol 1993; 82:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/85\">",
"      Livasy CA, Maygarden SJ, Rajaratnam CT, Novotny DB. Predictors of recurrent dysplasia after a cervical loop electrocautery excision procedure for CIN-3: a study of margin, endocervical gland, and quadrant involvement. Mod Pathol 1999; 12:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/86\">",
"      Phelps JY 3rd, Ward JA, Szigeti J 2nd, et al. Cervical cone margins as a predictor for residual dysplasia in post-cone hysterectomy specimens. Obstet Gynecol 1994; 84:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/87\">",
"      Lopes A, Morgan P, Murdoch J, et al. The case for conservative management of \"incomplete excision\" of CIN after laser conization. Gynecol Oncol 1993; 49:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/88\">",
"      Maluf PJ, Adad SJ, Murta EF. Outcome after conization for cervical intraepithelial neoplasia grade III: relation with surgical margins, extension to the crypts and mitoses. Tumori 2004; 90:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/89\">",
"      Moore BC, Higgins RV, Laurent SL, et al. Predictive factors from cold knife conization for residual cervical intraepithelial neoplasia in subsequent hysterectomy. Am J Obstet Gynecol 1995; 173:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/90\">",
"      Kalogirou D, Antoniou G, Karakitsos P, et al. Predictive factors used to justify hysterectomy after loop conization: increasing age and severity of disease. Eur J Gynaecol Oncol 1997; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/91\">",
"      Murdoch JB, Morgan PR, Lopes A, Monaghan JM. Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment. Br J Obstet Gynaecol 1992; 99:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/92\">",
"      Monk A, Pushkin SF, Nelson AL, Gunning JE. Conservative management of options for patients with dysplasia involving endocervical margins of cervical cone biopsy specimens. Am J Obstet Gynecol 1996; 174:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/93\">",
"      Buxton EJ, Luesley DM, Wade-Evans T, Jordan JA. Residual disease after cone biopsy: completeness of excision and follow-up cytology as predictive factors. Obstet Gynecol 1987; 70:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/94\">",
"      Reich O, Lahousen M, Pickel H, et al. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet Gynecol 2002; 99:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/95\">",
"      Livasy CA, Moore DT, Van Le L. The clinical significance of a negative loop electrosurgical cone biopsy for high-grade dysplasia. Obstet Gynecol 2004; 104:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/96\">",
"      Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004; 30:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/97\">",
"      Bornstein J, Schwartz J, Perri A, et al. Tools for post LEEP surveillance. Obstet Gynecol Surv 2004; 59:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/98\">",
"      Zielinski GD, Bais AG, Helmerhorst TJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004; 59:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/99\">",
"      Zielinski GD, Rozendaal L, Voorhorst FJ, et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol 2003; 91:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/100\">",
"      Chao A, Lin CT, Hsueh S, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 2004; 190:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/101\">",
"      Houfflin Debarge V, Collinet P, Vinatier D, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 2003; 90:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/102\">",
"      Coup&eacute; VM, Berkhof J, Verheijen RH, Meijer CJ. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007; 114:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/103\">",
"      Park JY, Kim DY, Kim JH, et al. Human papillomavirus test after conization in predicting residual disease in subsequent hysterectomy specimens. Obstet Gynecol 2009; 114:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/104\">",
"      Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/105\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/106\">",
"      Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52:342.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Agency for Healthcare Research and Quality, Rockville, MD 2003. www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/108\">",
"      Stokes-Lampard H, Wilson S, Waddell C, et al. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 2006; 113:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/109\">",
"      Schockaert S, Poppe W, Arbyn M, et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 2008; 199:113.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule --- United States, 2010. MMWR. file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/112\">",
"      Bleeker MC, Hogewoning CJ, Berkhof J, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005; 41:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/113\">",
"      Aynaud O, Ionesco M, Barrasso R. Penile intraepithelial neoplasia. Specific clinical features correlate with histologic and virologic findings. Cancer 1994; 74:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/114\">",
"      Barrasso R, De Brux J, Croissant O, Orth G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N Engl J Med 1987; 317:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/115\">",
"      Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/116\">",
"      Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/117\">",
"      Marrazzo JM, Koutsky LA, Kiviat NB, et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001; 91:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/2/30762/abstract/118\">",
"      Marrazzo JM, Koutsky LA, Stine KL, et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis 1998; 178:1604.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3215 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30762=[""].join("\n");
var outline_f30_2_30762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ablation and excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      See-and-treat protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LOW GRADE LESIONS: CIN 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CIN 1 preceded by low grade cytological abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8063015\">",
"      Unsatisfactory colposcopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ablation or excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CIN 1 preceded by high grade cytological abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exceptions for special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adolescent women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Coexistent HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HIGH GRADE LESIONS: CIN 2,3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ablative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Excisional therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Coexistent HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Delayed follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1920343\">",
"      - Negative margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1920351\">",
"      - Positive margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1920359\">",
"      - Negative excisional specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1920793\">",
"      - Clinical protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Post-hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HPV VACCINATION IN WOMEN WITH CIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2809883\">",
"      MANAGEMENT OF SEXUAL PARTNERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2809903\">",
"      Male partners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2809910\">",
"      Female partners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515103\">",
"      SUBSEQUENT FERTILITY AND PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3215|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?29/10/29859\" title=\"algorithm 1\">",
"      ASCCP guidelines CIN 1 after low grade cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?23/27/23989\" title=\"algorithm 2\">",
"      ASCCP guidelines CIN 1 after high grade cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3215|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/20/4423\" title=\"figure 1\">",
"      CIN terminology and histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42328?source=related_link\">",
"      Carcinoma of the penis: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44343?source=related_link\">",
"      Cervical intraepithelial neoplasia: Ablative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/52/16200?source=related_link\">",
"      Cervical intraepithelial neoplasia: Reproductive effects of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25113?source=related_link\">",
"      Medical care of women who have sex with women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_2_30763="Amos amp all given ceph";
var content_f30_2_30763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cross reactivity between penicillins and cephalosporins with identical side chains",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selective allergy to",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cephalosporin with identical side chain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reaction rate",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Audicana (1994)",
"       </td>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        Cephalexin",
"       </td>",
"       <td class=\"centered\">",
"        1 of 10 (10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sastre J (1996)",
"       </td>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        Cefadroxil",
"       </td>",
"       <td class=\"centered\">",
"        2 of 16 (12)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Miranda A (1996)",
"       </td>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        Cefadroxil",
"       </td>",
"       <td class=\"centered\">",
"        8 of 21 (38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         11 of 47 (23)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of patients proven to be selectively allergic to amoxicillin or ampicillin challenged with cephalosporins that contain identical R1 side chains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30763=[""].join("\n");
var outline_f30_2_30763=null;
var title_f30_2_30764="Guidelines cGVHD";
var content_f30_2_30764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for screening, prevention, and management of late complications in patients with oral cGVHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Late complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Screening",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Oral squamous cell carcinoma",
"       </td>",
"       <td>",
"        <p>",
"         Smoking cessation",
"        </p>",
"        Moderate alcohol consumption",
"       </td>",
"       <td>",
"        <p>",
"         Annual clinical examination",
"        </p>",
"        Biopsy of atypical/suspicious lesions",
"       </td>",
"       <td>",
"        Referral to multidisciplinary head and neck oncology center",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Rampant dental caries",
"       </td>",
"       <td>",
"        <p>",
"         Minimize intake of refined carbohydrates (especially sugar-containing soft drinks)",
"        </p>",
"        <p>",
"         Brush at least twice daily, after eating when possible",
"        </p>",
"        <p>",
"         Floss daily",
"        </p>",
"        <p>",
"         Fluoride 1.1 percent gel paint on or in custom trays, daily",
"        </p>",
"        <p>",
"         Remineralizing agent, apply with fluoride",
"        </p>",
"        Professional fluoride varnish application",
"       </td>",
"       <td>",
"        <p>",
"         Increased risk in patients with significant salivary gland cGVHD",
"        </p>",
"        <p>",
"         Increased risk in patients with orofacial sclerotic cGVHD",
"        </p>",
"        <p>",
"         Increased risk in patients were severe mucosal disease and avoidance of oral hygiene",
"        </p>",
"        <p>",
"         Examine teeth for evidence of cervical demineralization/decay",
"        </p>",
"        Twice annual dental visits",
"        <br/>",
"        <ul>",
"         <li>",
"          Soft and hard tissue examination",
"         </li>",
"         <li>",
"          Bitewing radiographs (annual)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Treat dental caries as soon as diagnosed",
"        </p>",
"        <p>",
"         Careful follow-up for new or recurrent caries",
"        </p>",
"        <p>",
"         Reinforce oral hygiene and dietary habits",
"        </p>",
"        Reinforce daily preventive measures",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Fibrosis",
"       </td>",
"       <td>",
"        No known preventive measures",
"       </td>",
"       <td>",
"        <p>",
"         Ask patient if aware of tightness/limited opening",
"        </p>",
"        <p>",
"         Extensive sclerotic skin disease, especially with neck involved",
"        </p>",
"        Examine for intraoral buccal fibrotic bands by palpation",
"       </td>",
"       <td>",
"        <p>",
"         Physical therapy",
"        </p>",
"        <p>",
"         Intralesional steroid therapy",
"        </p>",
"        <p>",
"         Surgery",
"        </p>",
"        Systemic therapy for systemic involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     cGVHD: chronic graft versus host disease.",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood 2012; 120:3407. Copyright &copy; 2012 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30764=[""].join("\n");
var outline_f30_2_30764=null;
var title_f30_2_30765="Selected high-risk drugs";
var content_f30_2_30765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected high-risk drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential harm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        May often be appropriate; however, aggressive glycemic control may often yield greater harms than benefits in older adults.",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonylureas",
"       </td>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        Older hospitalized patients at significant risk for hypogylcemia; avoid or use with great caution.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin",
"       </td>",
"       <td>",
"        Gastrointestinal, intracranial bleeding",
"       </td>",
"       <td>",
"        Although a high-risk drug, benefits of warfarin therapy often outweigh harms; maintenance of prothrombin time/international normalized ratio in therapeutic range tightly linked to risk/benefit ratio.",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digoxin",
"       </td>",
"       <td>",
"        Impairment of cognition, heart block",
"       </td>",
"       <td>",
"        May have a third-line role in management of systolic heart failure; suboptimal choice for rate control in atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Falls",
"       </td>",
"       <td>",
"        Associated with as much as a 60 percent increase in fall risk.",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphenhydramine, other first-generation antihistamines",
"       </td>",
"       <td>",
"        Impaired cognition, urinary retention in men",
"       </td>",
"       <td>",
"        Poor choice as sleep aid due to anticholinergic effects, next-day sedation, impact on performance including driving; close medication reconciliation important because patients may also obtain over-the-counter drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioid analgesics",
"       </td>",
"       <td>",
"        Constipation, sedation, confusion, cardiorespiratory depression, seizures",
"       </td>",
"       <td>",
"        Codeine, meperidine, pentazocine, butorphanol and nalbuphine are poor choices for analgesia. Fentanyl, morphine, or oxycodone are often appropriate with careful dose adjustment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"       <td>",
"        Death, pneumonia",
"       </td>",
"       <td>",
"        Elevated risk of death when used to treat behavioral complications of dementia, although in selected cases, benefits may exceed risks if consistent with patient goals of care.",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapeutic agents",
"       </td>",
"       <td>",
"        Myelosuppression (neutropenia, anemia), hepatotoxicity, cardiotoxicity",
"       </td>",
"       <td>",
"        Comprehensive assessment is required for determining goals of treatment, particularly in light of comorbidities. When indicated, chemotherapy dose and schedule should be carefully individualized for organ function and anticipated toxicities of treatment. In general, greater treatment-related toxicity is accepted when the expected outcome of treatment is cure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Selected antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoroquinolones",
"       </td>",
"       <td>",
"        Tendon inflammation and rupture, hypoglycemia, cardiac arrhythmias,",
"        <em>",
"         C. difficile",
"        </em>",
"        -associated diarrhea, exacerbation of myasthenia gravis",
"       </td>",
"       <td>",
"        Elevated risk of tendon rupture in combination with glucocorticoids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitrofurantoin",
"       </td>",
"       <td>",
"        Pulmonary toxicity, hepatotoxicity",
"       </td>",
"       <td>",
"        Therapeutic concentrations are not attained in urine of patients with renal insufficiency (CrCl &lt;60 mL/minute).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole (co-trimoxazole)",
"       </td>",
"       <td>",
"        Hyperkalemia, hypoglycemia (with sulfonylurea), severe dermatologic reaction (rare)",
"       </td>",
"       <td>",
"        Drug interactions include warfarin (&uarr; INR), agents that increase serum potassium, and sulfonylureas (&uarr; hypoglycemic effect).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51:S265.",
"       </li>",
"       <li>",
"        Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med 2009; 151:854.",
"       </li>",
"       <li>",
"        Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545.",
"       </li>",
"       <li>",
"        Deusenberry CM, Coley KC, Korytkowski MT, et al; Hypoglycemia in hospitalized patients treated with sulfonylureas.&nbsp; Pharmacotherapy 2012; doi: 10.1002/j. 1875-9114.2011.01088.x&nbsp;(ePublished ahead of print May 8, 2012)",
"       </li>",
"       <li>",
"        Mant J, Hobbs FD, Fletcher K, et al; BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA). Lancet. 2007; 370 (9586):493-503.",
"       </li>",
"       <li>",
"        Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169:1952.",
"       </li>",
"       <li>",
"        Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005; 294:1934.",
"       </li>",
"      </ol>",
"      <br>",
"       Revisions and additional information included with data from: Steinman MA, Hanlon JT. Managing medications in clinically complex elders: \"There's got to be a happy medium.\" JAMA 2010; 304:1592.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30765=[""].join("\n");
var outline_f30_2_30765=null;
var title_f30_2_30766="Protocol adenosine stress";
var content_f30_2_30766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Adenosine infusion protocol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Muthu Velusamy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30766=[""].join("\n");
var outline_f30_2_30766=null;
var title_f30_2_30767="Paracardiac mass on MRI";
var content_f30_2_30767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choriocarcinoma with mediastinal invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial section on MRI demonstrates a paracardiac mass due to metastatic choriocarcinoma with severe narrowing of the main pulmonary artery (long arrow). A right pleural metastasis is also present (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_2_30767=[""].join("\n");
var outline_f30_2_30767=null;
